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Ammonia plays a central role in the pathogenesis of cerebral oedema in paracetamol-
induced acute liver failure (PALF). Infection and inflammation play an important 
synergistic role in its development. Toll-like receptors (TLRs) sense pathogens and 
induce inflammation but whether this contributes to the development of cerebral 
oedema in PALF remains unknown. I postulated that ammonia-induced cerebral oedema 
and immune dysfunction are mediated by TLR9 and aimed to determine whether this 
could be prevented in a hyperammonemic TLR9 knockout mouse model. 
TLR9 expression on circulating neutrophils and their function in PALF was assessed. To 
examine the influence of PALF plasma and endogenous DNA on TLR9 expression, 
healthy neutrophils were incubated with PALF plasma with/without DNase. Ammonium 
acetate (NH4-Ac) was injected intraperitoneally in wild type Black6 (WT-B6), TLR9-/- B6 
mice and TLR9fl/fl LysCre B6 mice with TLR9 deleted from neutrophils and macrophages. 
The TLR9 antagonist ODN2088 was also evaluated. 
Neutrophil TLR9 correlated with plasma IL-8 and ammonia concentration and increased 
with severity of hepatic encephalopathy and systemic inflammation. Healthy neutrophil 
TLR9 expression increased upon stimulation with PALF plasma which was abrogated by 
pre-incubation with DNase. Following NH4-Ac stimulation, intracellular cytokine (IFN-γ, 
TNF-α and IL-6) production of lymphocytes and macrophages were increased in WT-B6 
mice compared to controls. This was accompanied by increased brain water however in 
TLR9-/-, cytokine production and brain water content were decreased. This was seen 
similarly in WT-B6 administered the TLR9 antagonist ODN2088 in conjunction with 
NH4-Ac. TLR9fl/fl LysCre mice had decreased cytokine production and brain water 
compared to the TLR9fl/fl group following NH4-Ac injection. Total DNA levels were 
increased in the circulation after NH4-Ac injection. 
In summary, ammonia-induced cerebral oedema and immune dysfunction are mediated 
through TLR9 and DNA dependent. The amelioration of brain oedema and lymphocyte 
cytokine production by ODN2088 supports exploration of TLR9 antagonism in early 
PALF to prevent progression to cerebral oedema. 
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1.1.1. Anatomy and physiology of the liver 
The liver is one of the largest internal organs in the human body situated on the right 
side of the abdominal cavity beneath the diaphragm. It weighs about 1.2 to 1.5 kg, and 
consists of two lobes, the right and left lobes, and is further divided into eight segments. 
Each segment is made up of many smaller units called lobules that comprise a central 
vein, liver cells (hepatocytes) separated by the sinusoids and portal tracts. The 
functional unit of the liver is called a hepatic acinus [Figure 1.1]. The liver receives a dual 
blood supply through the portal vein and hepatic artery carrying nutrient rich blood 
from the gut and spleen. Among the liver cells, hepatocytes constitute 80% of the 
population, while the remaining is made up of hepatic stellate cells (1%), endothelial 
cells (10%) and cells of the immune system (9%). Among the 9% of the immune cells in 
the liver, Kupffer cells derived from liver macrophages, form the majority and are 
responsible for 80% of phagocytosis in the system. They are responsible for removal of 
aged red cells, viruses, bacteria and endotoxin, and can produce inflammatory cytokines 
that are released into the systemic circulation 1 [Figure 1.2]. 
1.1.2. Functions of the liver 
The liver is a versatile organ and plays a central role in metabolism, synthesis, 
biotransformation, detoxification and storage of a number of metabolites; it also has a 
protective function 1 [Figure 1.3]. Since most of the metabolic enzymes are present only 
in the liver, it plays a vital role in the metabolism of carbohydrates, amino acids and 
lipids 2. Metabolism of vitamin-K, an essential factor necessary for the initiation of 
clotting and excretion of bilirubin, an end product of haeme catabolism, takes places in 
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the liver. Bilirubin mostly in its unconjugated form requires the liver enzymes for its 
excretion as stercobilin and urobilin in faeces and urine. An increase in the bilirubin, 
either conjugated or unconjugated, causes jaundice 1, 3. Synthesis of proteins including 
albumin, globulin and fibrinogen and clotting factors – II, VII, IX and X involved in the 
coagulation cascade also takes place mainly in the liver 1. Detoxification of certain drugs 
(e.g. paracetamol) and ammonia into urea and glutamine takes place mainly in the liver. 
Accumulation of toxic substances may lead to severe liver injury and result in acute 
hepatitis 1, 4. Serum bilirubin, albumin and prothrombin time are the most commonly 
assessed liver function tests and they are robust measures of excretion and liver 
synthetic function. Abnormalities in the liver function tests may be indicative  of hepatic 
dysfunction 5. 
1.1.3. Diseases of the liver 
An insult to the liver leads to abnormal liver function and results in acute liver injury or 
chronic liver disease. Chronic liver disease is the fifth commonest causes of death in 
United Kingdom (UK) and the mortality rate has increased exponentially over recent 
years. The three commonest causes of chronic liver disease in the UK include alcohol-
related cirrhosis caused by excessive alcohol consumption, non-alcoholic fatty liver 
disease caused by fat deposition in the liver cells and chronic hepatitis C infection. In 
acute liver failure, hepatitis or inflammation of the liver occurs within 24 to 72 hours 
following a liver insult and is most commonly caused by toxicity resulting from drugs 
e.g. paracetamol or exposure to harmful substances and acute viral infection such as 



























1.1.3.1. Acute liver failure 
Acute liver failure (ALF), or fulminant hepatic failure, as described by Trey and 
Davidson, is a rare but frequent consequence of severe liver injury and is defined as the 
onset of hepatic dysfunction with additional complications of coagulopathy and 
encephalopathy in a patient with no pre-existing liver disease 10. Subsequently, O’Grady 
and colleagues at King’s College Hospital classified ALF with the prefixes hyper- and sub-
acute liver failure, based on the time to the development of encephalopathy from the 
onset of jaundice. Patients who develop encephalopathy within 7 days are termed as 
‘hyperacute’, patients developing encephalopathy between 5 to 12 weeks are termed as 
‘subacute’, while patients developing encephalopathy between 8 days and 28 days are 
termed as acute liver failure [Table – 1.1] 11. ALF is very rare (1 – 6 cases per million) 
and its presentation is severe and heterogeneous in nature. .  
1.1.3.1.1. Causes of acute liver failure 
ALF is less common in developed countries compared to the developing countries where 
it is predominantly caused by viral infections (hepatitis A, B and E) 12. Although less 
common in developed countries, ALF occurs more frequently among young adults and 
middle-aged people and is mainly caused by drug-induced hepatotoxicity. The mortality 
rate of ALF is high and is the most common cause for an emergency liver transplantation 
13. Paracetamol-induced acute liver injury is the commonest cause of ALF in the western 
world and culminates in the development of coagulopathy, hepatic encephalopathy (HE) 
and multiple organ failure (MOF) in less than 7 days. Other causes of ALF include other 
drug-induced liver injury e.g. ecstasy and cocaine, acute hepatitis B, Wilson’s disease and 
seronegative hepatitis 13 [Table – 1.2]. 
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There was a drastic increase in the number of paracetamol-induced acute liver failure 
(PALF) cases until a few years ago in the developed western countries, especially in the 
United Kingdom (UK) and United States of America (USA) but not in the developing 
countries 13. In tertiary care centres across USA, approximately 40% of the ALF cases 
were accounted for paracetamol overdose and one-third of those cases necessitated 
emergency liver transplantation (LT) 14, 15. At King’s College Hospital in London, one of 
seven transplant centres in the UK specialising in managing ALF patients, paracetamol 
toxicity contributed to 57% of all the ALF cases and almost one-third of those patients 
died or underwent LT 16. Paracetamol overdose was found to be commonest in people 
between the ages of 32 and 38, especially in women, and almost half of those cases were 
intentional (suicidal)14-16. Following the legalisation of restriction of paracetamol sales 
in UK, there has been a decline in the number of cases, mortality and the need for 
emergency LT following intentional paracetamol overdose 17-19. 
1.1.3.1.1.1. Paracetamol and liver injury 
Paracetamol is an efficacious analgesic and antipyretic drug, available over the counter 
at retail stores worldwide 20. It is safe when paracetamol is taken in recommended doses 
(4G/day in adults) whilst overdose results in liver and kidney injury in all cases 14. 
However it has been shown that aminotransferase levels are elevated after therapeutic 
doses of paracetamol 21 and factors such as fasting and alcohol have been shown to 
induce ALF after an unintentional overdose of paracetamol 22-24. Paracetamol is mainly 
metabolised by the liver with <5% being excreted in unchanged form 4.  The majority of 
the paracetamol consumed is excreted through the bile or urine by conjugation of its 
hydroxyl group with glucuronic acid and sulphate 25. A small portion of paracetamol is 
removed along with glutathione to form non-toxic cysteine and mercapturic acid. During 
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this process an intermediary product N-acetyl-p-benzoquinoneimine, a reactive 
metabolite, is formed by the activity of cytochrome P-450s 1A2, 2E1 and 3A426-28. When 
excessive doses are consumed, more benzoquinoneimine is formed by cytochrome P-
450, which depletes the hepatic glutathione stores, since other pathways of 
detoxification get saturated. An excessive dose of paracetamol causes depletion of 
protein thiols, and damages the mitochondria by increasing cellular calcium. 
Furthermore, it increases the formation of peroxynitrite and activates c-Jun N-terminal 
kinase which leads to mitochondrial permeability transition and necrosis of the liver cell 
27, 29, 30 [Figure 1.4]. 
1.1.3.1.2. Consequences of acute liver failure 
In hepatocellular necrosis, the metabolism, synthesis, detoxification and protective 
functions of the liver are significantly impaired. As a consequence of hepatic dysfunction 
there is decreased production of essential blood clotting factors causing prolonged 
bleeding time or prothrombin time, decreased albumin production and increased 
transaminase levels in the blood. Since the liver is a vital organ, ALF causes dysfunction 
in the extra hepatic organs too. Acute kidney injury and pancreatitis may be associated 
with ALF caused by paracetamol toxicity 31. Some paracetamol overdoses are staggered 
or inadvertent and may not all be secondary to intentional overdose. ALF also induces 
cardiovascular, respiratory and adrenal dysfunction 12.  It also induces a sterile systemic 
inflammatory response syndrome (SIRS) within the body. It also affects the circulating 
leucocytes causing impaired function and immunoparesis leading to a high risk of sepsis 
in these patients 12, 13. Liver dysfunction also leads to decreased ammonia detoxification 
resulting in hyperammonemia and this may lead to HE  [Figure 1.5]. 
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ALF patients may succumb to brain herniation due to brain oedema and intracranial 
hypertension 32, 33. Cerebral oedema is mainly caused by increased water content in the 
brain that results in swelling. The rigid skull bone that protects the brain restricts the 
swelling of the brain and as a consequence a small increase in fluid can cause a 
significant increase in intracranial pressure or ICH which in turn leads to decreased 
cerebral perfusion pressure and capillary blood flow, resulting in ischaemia 34.  
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Table 1.1: Classification, clinical features and prognosis of the subtypes of ALF 13. 
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Figure 1.5: Consequences of ALF 35. 
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1.1.3.1.2.1. Systemic inflammatory response syndrome 
Sepsis is defined as the systemic or clinical response arising from an infection. There is 
an increased risk of morbidity and mortality especially among immunocompromised 
and critically ill patients who develop sepsis. Sepsis was also reported to be the most 
common cause for death in non-coronary intensive care units. The term sepsis 
syndrome was applied to an identical clinical response, which was observed in the non-
infectious state. However both these terms, sepsis and sepsis syndrome, led to confusion 
and a standardisation of terminology was required to eliminate the communication 
concerning sepsis and its sequelae, especially with the treatment. In 1991, during the 
American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference, a set of guidelines were introduced to define these terms along with 
detailed physiological parameters to categorise them. The term sepsis was used to 
describe the clinical manifestation arising from an infection. A new term ‘systemic 
inflammatory response syndrome (SIRS)’ was used to describe the inflammatory 
process occurring in the absence of an infection, independent of its cause [Figure 1.6] 36. 
The term SIRS is used in the presence of 2 or more of the following manifestations, 
namely body temperature > 38°C or < 36°C; heart rate > 90 beats per minute; tachypnea, 
respiratory rate > 20 breaths per minute or hyperventilation, as indicated by a PaCO2 of 
< 32 mm Hg; and alteration in the white blood cell count, > 12000/mm3 or < 
4000/mm3, or the presence of more than 10 immature neutrophils. Besides infection, a 
systemic inflammatory response is also caused by non-infectious pathological causes 
such as pancreatitis, ischaemia, multiple trauma and tissue injury, immune-mediated 
organ injury, and the exogenous administration of inflammatory mediators that induce 
cytokine production. The development of MOF is a frequent complication of SIRS and 
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this contributes to the mortality of those patients who get admitted to an intensive care 
unit (ICU) and thereby require the life-support therapy 36.  
There is a marked propensity for patients with PALF to develop sepsis which may not 
only hasten the development of brain oedema, but may further progress to MOF and 
death 37. SIRS with or without infection, contributed to the progression of HE in ALF 38. 
In addition, SIRS with and without infection, worsened the severity of HE in PALF 39 






Figure 1.6: The inter-relationship between SIRS, sepsis and infection 36. 
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1.1.3.1.2.2. Hepatic encephalopathy 
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that is mainly associated 
with hepatic dysfunction in both acute and chronic liver failure 40. Symptoms of HE have 
quantitatively and qualitatively distinct features related to the severity of the acute liver 
injury. This varies from mild or moderate confusion to coma and seizures. In severe 
cases of ALF, HE is typically associated with the development of cerebral oedema and in 
hyperacute cases such as PALF, patients have the highest risk of developing cerebral 
oedema 41. Based on the various neurological manifestations that occur in patients with 
liver disease, HE is quantitatively graded on a scale of 0 to 4 using the West Haven 
criteria 42 [Table 1.3]. 
Ammonia has been thought to play an important role in the pathogenesis of HE for the 
past 125 years 43-45 and when present in high concentrations, has a potential to affect the 
central nervous system (CNS) by modulating inhibitory and excitatory 
neurotransmission 46. In patients with ALF, elevated brain ammonia levels induce 
swelling of astrocytes leading to cytotoxic brain oedema 47. There was a significant 
increase in swelling in cultured astrocytes after they were exposed to high 
concentrations of ammonia 48. Ammonia is taken up by astrocytes in the brain and 
converted to glutamine where it exerts an osmotic effect and induces astrocyte swelling 
and brain oedema 49. Therefore it is clear that astrocytes are the main cells involved in 
the pathogenesis of HE as they have been found to be the cells that are most commonly 
affected by ammonia [Figure 1.7]. 
Hyperammonemia plays a definitive role in the development of HE and brain oedema, 
with up to 25% of patients developing intracranial hypertension (ICH) 33. In fact arterial 
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ammonia was found to be at its highest level in patients with ICH [Figure 1.8] 50. 
Furthermore, Clemmesen and colleagues showed that mortality was increased in those 
patients with arterial ammonia >150 µmol/L [Figure 1.9]. Cerebral oedema and 
increased intracranial pressure may be fatal without access to emergency liver 




Table 1.3: Clinical features of hepatic encephalopathy classified using the 
West Haven criteria 
Grade using West Haven criteria Clinical Features 
0 No abnormality apparent on clinical examination 
1 Short term memory loss, difficulty in 
concentrating and reverse of sleep wake cycle 
2 Lethargy, apathy, confusion, drowsiness, 
disorientation, inappropriate behaviour 
3 Stuporose but rousable, marked confusion, 
incoherent speech 


















Figure 1.9: Increased arterial ammonia in ALF patients with cerebral 
herniation 51. 
The mortality was increased in patients with cerebral herniation compared to those 




1.1.3.1.2.2.1. Ammonia and hepatic encephalopathy 
The relationship between ammonia, liver and the brain was discovered in 1890’s when 
Pavlov and his colleagues conducted experiment in dogs and showed the surgical 
shunting of blood from the portal vein into the vena cava caused increased ammonia in 
the circulation as the liver was not able to metabolise ammonia into urea 43. They also 
observed that the arterial ammonia was increased fourfold and was associated with 
behavioural disturbances in dogs following a meat protein meal. The researchers 
concluded that this phenomenon could be due to ammonia following the failure of its 
conversion to urea in the liver 45. The similarity between this syndrome and coma 
induced by hepatic failure stimulated researchers to study the toxicity of ammonia in 
humans. Measurement of blood and tissue ammonia has become reliable after the 
development of non-invasive techniques such as 13NH3 positron emission tomography 
and 1H magnetic resonance spectroscopy 52. In ALF, the concentration of arterial 
ammonia may go up to 0.45 mM and the magnitude of this increase predicts brain 
herniation in these patients 51. The brain to blood ammonia concentration ratios has 
been shown to be four times greater in ALF 53. 
1.1.3.1.2.2.1.1. Ammonia 
Ammonia is mainly produced in the gut. Dietary intake of proteins is essential as it is an 
important source of energy for the body 54. Proteins are metabolised to amino acids in 
the liver 54, 55 and they further breakdown into ammonia following deamination 56, 57. 
Ammonia is metabolised to less toxic urea so that it can be excreted in the urine. The key 
enzymes required for the conversion of ammonia to carbamoyl phosphate in the urea 
cycle is present mainly in the mitochondria of the liver 58, 59. In paracetamol-induced 
acute liver injury, the mitochondrial function is impaired 60 and this affects the ammonia 
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metabolism and results in hyperammonemia. Ammonia is found to have a definitive role 
in the development of encephalopathy in liver disease 61 and very high values are 
observed in the patients with coma 62. Hyperammonemia mainly causes toxicity to the 
brain and in the patients with acute liver injury it causes neurotransmitter inhibition 
and excitation 46 which impairs brain energy metabolism 63-66. It alters the gene 
expression of proteins involved in brain function 67, 68 and also causes impairment in the 
auto regulation of cerebral blood flow 69, 70.  
1.1.3.1.2.2.1.2. Ammonium salts and brain oedema 
Ammonia toxicity have been studied in animals by infusing different ammonium 
compounds through intravenous, oral, subcutaneous and intraperitoneal routes with an 
assumption that their toxicities were similar and they induce brain damage. A study on 
different ammonium compounds shows that the toxicity of those compounds was 
mainly dependent on their effect on blood pH 71. This change was related either to the 
effect of pH on the NH3/NH4+ ratio and the ability of ammonia to cross the blood brain 
barrier or to a direct effect of pH on the blood brain barrier 72. However, it has been 
ammonium acetate (NH4CH3C02) (NH4-Ac) that has been used in large doses to induce 
acute ammonia toxicity 71-73. Injection of a high dose of NH4-Ac (7 and 12 mM/kg of 
bodyweight) resulted in the death of mice and rats within a short span of time by 
depleting the brain ATP and this was mediated through the N-methyl D-aspartate 
(NMDA) receptors and glutamate binding sites 73, 74. Acute ammonia toxicity decreased 
the antioxidants and increased the production of superoxide radicals in liver and brain 
mitochondria thereby inducing oxidative stress in these animals 75, but by inhibiting the 




1.1.3.1.2.2.1.3. Alternative sources of ammonia 
The other alternative source of ammonia is mainly from the intestines. In the colon, 
bacterial urease produce ammonia by splitting urea and other amino acids [Figure 1.10] 
77, while in germ-free mice phosphate–activated glutaminase (PAG) present in the 
enterocytes breaks down glutamine to produce ammonia [Figure 1.11] 78. The ammonia 
produced in the intestine contributes to hyperammonemia-associated neurotoxicity in 
chronic liver disease or inborn errors of metabolism 79, 80. Engineering the gut microbes 
by depleting the pre-existing microbiota and inoculation of altered Schaedler flora, a 
consortium of bacteria with minimal urease gene content decreased the urease activity 
in murine models. Transplantation of altered Schaedlar flora decreased the morbidity 
and mortality in a murine model of hepatic injury 81. However, in portacaval shunted 
rats it has been demonstrated that intestinal glutamine uptake does not influence the 
arterial ammonia concentration 82. Furthermore, it has been demonstrated that renal 
glutaminase plays an important role in the excretion of ammonium ions in the urine. In 
chronic and acute hyperammonemic models there is a mild to marked depletion of renal 
glutamine uptake which impacts on the net renal ammonia disposal and indicates that 















Figure 1.11: Production of ammonia in the enterocytes in germ-free mice by 




1.1.3.1.2.2.2. Astrocytes and hepatic encephalopathy 
Astrocytes are part of the CNS that also consists of vascular endothelial cells, pericytes 
and neurons 84. Astrocytes are star-shaped cells in the brain present in the gray matter 
and approximately one-third of the brain volume is made up of these cells. They secrete 
cytokines and neurotrophic factors which activate the neurons and also have many 
biochemical, neurochemical and regulatory roles 85. Astrocytes along with endothelial 
cells help in the formation of the blood brain barrier and astrocyte swelling, a feature of 
advanced HE in ALF, also affects the function of the blood brain barrier. Astrocyte 
swelling is the most prominent neuropathological finding in the brain autopsies of ALF 
patients and animal models of cerebral oedema [Figure 1.12] 47.  
Impairment in the astrocyte function can be detrimental to the CNS as it leads to 
neuronal excitability and dysfunction. Although astrocyte swelling has been associated 
with increased cerebral blood flow, hyperthermia, by products from the necrotic liver, 
sepsis, pro-inflammatory cytokines, glutamate and vaso paralysis, the precise 
mechanism by which the swelling occurs still remains to be determined. Therefore it is 
assumed that all these factors synergistically induce cytotoxic cell swelling with 
ammonia playing a central role 85. 
In contrast to the concepts regarding the neurotoxic effects of ammonia, it has been 
recently demonstrated that the neurotoxic effects of ammonia are mainly dependent on 
the dysfunction of glial and neuronal cells rather than the astrocyte swelling per se. 
Ammonia impairs astrocyte potassium buffering and the increased extracellular 
potassium concentration is sufficient to induce neurological dysfunction and seizures in 
animals. Ammonia along with potassium then promotes the over activation of Na+-K+-
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2Cl− cotransporter isoform 1 (NKCC1) in neurones that plays an important role in 
inhibition of neurotransmission in the cortex 86. 
Cerebral oedema is often seen in patients with ALF, and can lead to increased 
intracranial pressure, brain herniation and death. The exact processes involved are not 
well defined, but it is a widely held opinion that a cytotoxic process due to the effects of 
ammonia plays a significant part 87. At the cellular level, neurones exposed to very high 
levels of ammonia quickly show extensive degeneration and undergo increased rates of 
apoptosis and necrosis.  
Astrocytes swell in the presence of high ammonia. This is traditionally ascribed to cell 
hypertonicity from an increase in cellular glutamine. This swelling may contribute to the 
intracranial hypertension seen in ALF. Arterial ammonia concentrations in ALF have 
been shown to correlate with the severity of cerebral herniation and death and with 
severe grades of HE 51. Patients with ALF who have not progressed to grade 3/4 HE are 
unlikely to progress to develop intracranial hypertension 33, 87. 
In patients with ALF, hyperammonemia increases the glutamine concentration in 
astrocytes which then produces osmotic stress and astrocyte swelling leading to the 
development of HE. This is caused by increased synthesis of glutamine and decreased 
clearance of glutamine from the astrocyte as a result of impaired transport 88, 89. The 
ability of the astrocytes to maintain osmotic equilibrium is caused by losing osmolytes 
such as myo-inositol in response to the increased glutamine, which then decreases the 
cell volume 90. However in cirrhotic patients, the buffering capacity of the brain mainly 
depends on the relative concentrations of myo-inositol and glutamine/glutamate ratio. 
The decreased concentrations of myo-inositol in cirrhotic patients helps maintain the 
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cellular osmotic equilibrium in cirrhotic patients caused by increased glutamine 91-93 
thereby preventing the osmotic stress and astrocyte swelling. 
The ability of the astrocytes to maintain osmotic equilibrium is caused by losing 
osmolytes such as myo-inositol in response to the increased glutamine, which then 
decreases the cell volume 90.In patients with chronic liver disease, the buffering capacity 
of the brain mainly depends on the relative concentrations of myo-inositol and 
glutamine/glutamate ratio. The decreased concentrations of myo-inositol in patients 
with cirrhosis helps maintain the cellular osmotic equilibrium caused by increased 
glutamine 91-93 thereby preventing the osmotic stress and astrocyte swelling. However in 
ALF, the rapid rise and accumulation of ammonia in the astrocyte overcomes any 
compensatory buffering mechanism and cerebral oedema is often inevitable. 
Taurine is an important amino acid mainly produced in the liver and transported to 
other organs such as the brain. Taurine mainly stored in the astrocyte plays an 
important role in the homeostasis of potassium and calcium in the CNS and is also 
involved in the excitability of neurons. Decreased concentrations of taurine have been 
reported in ALF and chronic liver disease suggesting that modification of brain taurine 
concentration could play an important role in the pathogenesis of neurological 
symptoms that characterise HE 94. The concentrations of other amino acids are also 
important as they may influence the outcome of HE in patients with ALF and cirrhosis. In 
cirrhosis, the concentration of some essential amino acids such as tryptophan, 
methionine, phenylalanine and non-essential amino acids such as aspartate, glutamate 
and tyrosine are increased. In ALF, the concentrations of both essential and non-
essential amino acids, except for the branched amino acids are markedly increased in 
the brain and cerebrospinal fluid after hepatic necrosis. Furthermore, the brain to 
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plasma ratio of the amino acids in patients is similar to those of normal subjects 
suggesting that the plasma concentration dictates the brain concentration 95, 96. This 










Figure 1.12: Astrocyte swelling in the brain tissue of a patient with PALF 70. 
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1.1.3.1.2.2.3. Systemic inflammation and hepatic encephalopathy 
Although it is very well known that ammonia plays a central role in the development of 
HE and astrocytes are the key cells involved in this process, there is additional 
information that inflammation plays a central role in the pathogenesis of HE. Activated 
microglial cells and astrocytes produce tumour necrosis factor α (TNF-α), a cytokine 
produced in response to brain injury or inflammation. TNF-α induces the production of 
cytokines such as interleukin (IL)-1 and IL-6, and they both have the potential to 
compromise the integrity of blood brain barrier 97-99. Microglia are bone marrow 
derived, CNS-resident macrophages that upon activation perform like antigen 
presenting cells and have proinflammatory effector functions 100. Brain lactate 
concentration usually increased following hyperammonemia is solely responsible for 
the activation of microglial and astroglial cells which in turn produce cytokines such as 
TNF-α, IL-1β and IL-6. Furthermore, the increased cytokine production in microglial-
enriched cultures rather than astroglial-enriched cultures suggest that microglia play an 
important role in the pathological consequences of hyperammonemia 101. 
During infection and inflammation, the peripheral immune system sends signals to the 
brain to elicit a response. This response involves the expression of pro-inflammatory 
cytokines such as TNF-α, IL-1β and IL-6, both in circulation and the brain. Cytokines gain 
a direct entry into the brain by crossing the blood brain barrier through a storable 
transport mechanism. In patients dying with septic shock, there was apoptosis of 
neuronal and glial cells within the brain autonomic centres, strongly associated with the 
iNOS expression in endothelial cells which in turn altered cellular osmotic homeostasis. 
Cytokines such as TNF-α and IL-6 increase fluid phase permeability and ammonia 
diffusion in brain endothelial cells which have receptors for TNF-α and IL-1β. Astrocytes 
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treated with lipopolysaccharide (LPS), ammonia or glutamine separately resulted in the 
production of free radicals such as nitric oxide and increase in the reactive oxygen 
species (ROS). In a pig model of ALF, LPS and amatoxin induced more intracranial 
hypertension than animals given amatoxin alone 49. Treatment with albumin dialysis 
reduced the severity of HE in pigs induced with ALF by reducing oxidative stress and 
restoring nitrogen metabolism 102. Glutamine synthetase, an enzyme found mainly in the 
astrocytes, converts ammonia and glutamate into glutamine. Increased glutamine in the 
brain exerts an osmotic effect, which leads the astrocytes to take in water and cause 
swelling. Mitochondrial phosphate-activated glutaminase metabolises the glutamine and 
releases ammonia within mitochondria, which increases the reactive oxygen species 49. 
These observations support the role of inflammation in the pathogenesis of HE. 
Systemic inflammation contributes to the development of HE in ALF, indicating a 
possible link between inflammation and HE 38. Infection and/or the resulting SIRS were 
shown to be an important factor in the development of HE in patients with PALF 37. 
Furthermore, the brain produces pro-inflammatory cytokines such as TNF-α, IL-1β and 
IL-6 in the advanced stages of HE in ALF 103. 
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1.1.3.1.3. Management and socio-economic burden of acute liver failure 
Intravenous administration of N-Acetylcysteine (NAC) is the most common treatment 
and initial care available for patients with paracetamol-induced hepatotoxicity and is 
highly efficacious when administered within the first 24 hours 14-16. NAC has complex 
antioxidant and immunologic effects that may also benefit other causes of ALF. However 
an excessive dose of paracetamol, and/or a delay or failure to give NAC therapy 
increases the risk of MOF developing and culminates in high mortality with the need for 
emergency LT 104, 105. A condition specific care is given to ALF patients based on the 
various organ(s) that fail to function [Table – 1.4]. 
Following hepatocyte death, necrotic by products such as DNA, ammonia and 
chemokines are released into the circulation, thereby activating the innate immunity 
and amplifying the liver injury 106-108. The SIRS plays an important role in the 
development of MOF in patients with PALF, thereby increasing the progression to 
encephalopathy and mortality and prevents them being listed for LT 38. Therefore in an 
attempt to remove the necrotic products from circulation, plasma replacement by fresh 
frozen plasma was considered as an option of treatment. High volume plasma exchange 
performed in ALF patients as part of a clinical trial reduced the mortality, thereby 
increasing the transplant free survival in those patients 109. Necrotic by products such as 
ammonia, DNA, the neutrophil associated chemokine IL-8 and other pro-inflammatory 
cytokine released by monocytes were decreased after plasma replacement therapy 109, 
110. 
Clinical and experimental studies show that hypothermia is beneficial in the treatment 
of uncontrolled increase of intracranial pressure. Mild hypothermia (33°C – 35°C) 
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reduced ammonia-induced brain swelling in rats and decreased the toxicity in mice 111, 
112, whilst moderate hypothermia (32°C – 33°C) reduced arterial ammonia and cerebral 
uptake of ammonia thereby decreasing cerebral blood flow in ALF patients 113. Mild 
hypothermia improved survival and attenuated liver injury by reducing hepatic 
congestion in a paracetamol-induced mouse model 114. In ALF patients, moderate 
hypothermia restored cerebrovascular autoregulation and vasodilatory response to 
carbon dioxide 115 and also prevented the cerebral hyperemia in LT 116. However in a 
recently concluded multicentre randomized controlled trial, it has been shown that this 
process is not beneficial, as re-warming has been detrimental to the patients and they 
cannot be cooled for longer periods 117. 
Hospitalisation of these cases causes a huge burden on the economy of the nation’s 
health care system and many cases in the western world are listed for a LT. Although 
administration of NAC helps to prevent ALF when treated early, there has not been any 
drug shown to prevent the development of MOF once ALF is established. 
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Table 1.4: Common management issues and condition-specific elements of 





In humans and vertebrates, the immune system plays an important role in fighting 
against infection. To protect the host against any infection, the immune system first 
detects the presence of an infection and this task is carried out by the white blood cells 
of the innate immune system. The immune system then contains the infection and 
eliminates any unwanted microorganisms from the body wherever possible 118. The 
immune system also has the ability to memorise the antigens it has previously 
encountered and activate the immune system quickly in cases of re-infection and this is 
undertaken by the white blood cells of the adaptive immune system 118, 119. The immune 
system consists of two different parts, an early and non-specific innate immunity that 
takes just a few hours to develop, and a delayed and specific adaptive immunity that 
takes days rather than hours to develop. The innate and adaptive immune responses 
depend on the activities of the white blood cells 118 [Figure 1.13]. 
1.2.1. Innate immunity 
Host innate immunity, an immediate and non-specific mechanism, mainly contributes in 
the initial protection during an infection against all microbes that invade the body. It is 
an intermediary system that allows the host to develop its specific adaptive immunity. 
When a microorganism invades the body, it gets detected by certain host receptors that 
trigger the innate immune system. This results in the activation of other cell types which 
leads to the release or synthesis of various factors known as ‘acute-phase reactants’. The 
acute-phase reactants are factors that initiate phagocytosis and microbial killing, and are 
produced mainly in the liver 120. There are many different types of cells and proteins that 
are involved in the innate immune system including the phagocytic cells such as 
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neutrophils, monocytes and macrophages; inflammatory cells such as eosinophils, 
basophils and mast cells; natural killer (NK) cells; complementary proteins; acute phase 
proteins and cytokines 121 122. 
1.2.2. Adaptive immunity 
Adaptive immunity, a delayed response from the host, involves mainly B and T 
lymphocytes, which constitute 30 to 40% of the white blood cells and contain unique 
receptors which are specific in the recognition of pathogens. The important event in 
adaptive immunity is recognition of pathogens (antigens) by antigen specific cell-surface 
receptors present on B and T lymphocytes. The lymphocytes also have the ability to 
memorise the antigens it has previously encountered and activate the immune system 
quickly in cases of re-infection 119. 
1.2.3. Cytokines 
Cytokines are soluble proteins that are important in cell signaling and modulate the 
immune system. They include interferons (IFNs), interleukins (ILs), chemokines (CXCR), 
tumour necrosis factors (TNF) and colony stimulating factors. They are produced by 
white blood cells such as neutrophils, lymphocytes, NK cells, macrophages, and other 
cells such as endothelial cells and fibroblasts. Some cytokines are produced 
predominantly by helper T cells and macrophages and are secreted by more than one 
type of cell 123. Cytokines are classified as either pro-inflammatory or anti-inflammatory, 
based on their role in inflammation. Pro-inflammatory cytokines promote systemic 
inflammation and excessive production causes detrimental effects on the body 124 
whereas anti-inflammatory cytokines promote healing and reduce inflammation. 125 
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Thus a balance between these two classes are required or an imbalance could lead to 
disease 123. 
1.2.4. Inflammasomes 
Inflammasomes are receptors expressed mainly in myeloid cells and part of the innate 
immune system. They are multimeric complexes that assemble in the cytosol after 
sensing the pathogen-associated molecular patterns (PAMPs) or damage-associated 
molecular patterns (DAMPs) and leads to the downstream signalling of cytokines. Upon 
activation, the relevant NOD-like receptors form a caspase-1-activating scaffold which 
then subsequently cleaves the pro-IL-1β and pro-IL-18 into their active forms and cause 






Figure 1.13: Cells of the immune system. 
The main cells involved in the innate immunity (rapid response) and in the adaptive 
immunity (slow response) 127. 
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1.2.5. White blood cells 
White blood cells (WBC) or leukocytes are one of the solid components in the blood 
along with red blood cells and platelets. Plasma is the liquid part of the blood that 
carries the solid components and nutrients to different parts of the body. Granulocytes 
are those white blood cells that contain granules in their cytoplasm such as neutrophils, 
basophils and eosinophils. Agranulocytes are white blood cells that do not contain any 
granules and they include lymphocytes and monocytes 118.  
1.2.5.1. Neutrophils 
Neutrophils form the majority (60 – 70%) of the white blood cells and play a major role 
in the innate immune system. They are also called polymorphonuclear neutrophils 
(PMNs) because of the segmentation seen in their nucleus 128. A normal neutrophil is 10 
to 12µM in size, round or spherical shaped and contains a single nucleus which is 
segmented into 2 to 5 lobes [Figure 1.14] 129. Under a light microscope, when stained 
with a Romanowsky stain neutrophils have a pink colour with a purple coloured nucleus 
and granules in the cytoplasm, and this appearance is due to their acidophilic and 
basophilic properties [Figure 1.15] 128. The average life span of a neutrophil is around 
5.4 days 130. 
1.2.5.1.1. Function of neutrophils 
The most important function of the neutrophil is its antimicrobial properties, and it is 
mainly involved in chemotaxis, phagocytosis and killing of bacteria. In infections and 
inflammation, neutrophils form the front line of defence and are the first immune cells 
to migrate to sites of infection or inflammation 118. The neutrophils are activated 
through CD16, an IgG molecule with low expression, FcγRIII seen on neutrophils 
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through a phosphotidylinositol linkage 131. Neutrophils migrate to the site of infection 
and adhere to the endothelial wall at the injury site by binding CD11b, the protein 
integrin alpha M subunit to the intercellular adhesion molecule - 1 (ICAM-1) 132. 
Neutrophils form a pseudo pod and slowly surround the bacteria to engulf them 
(Phagocytosis) [Figure 1.16]. The various antimicrobial substances present within the 
neutrophil granules such as myeloperoxidase get released upon activation and kill the 






Figure 1.14: Image of a neutrophil under a transmission electron microscope. 




Figure 1.15: Image of a neutrophil under a light microscope. 






Figure 1.16: Neutrophil engulfing bacteria. 
This is the image taken under a TEM (2900x) showing the engulfment of E. coli bacteria 




Figure 1.17: Function of neutrophils. 




1.2.5.1.2. Increase and decrease in neutrophil counts 
An increase in neutrophil count is termed ‘neutrophilia’ which is increased in sepsis and 
inflammatory conditions such as hepatitis. A decrease in neutrophil count is termed 
‘neutropenia’ and it occurs in conditions such as pancytopenia, certain leukaemias and 
infections. There may also be a decrease in the neutrophil count due to splenic 
sequestration or as a side effect of certain drugs and chemotherapy 134. 
1.2.5.1.3. Neutrophils and acute liver failure 
In response to paracetamol hepatotoxicity, neutrophils are rapidly recruited and 
infiltrated in the liver 135 where they become activated by chemokines such as 
CXCL8/interleukin-8 (IL-8) 136 and mitochondrial products such as formyl peptides and 
mitochondrial DNA amplifying hepatocellular damage by release of proteolytic enzymes 
and reactive oxygen species (ROS) [Figure 1.18] 106. Neutrophils alongside macrophages 
also participate in the removal of necrotic cell debris in preparation for tissue repair and 
resolution of the inflammatory response 137. Depletion of neutrophils reduced 
hepatocellular necrosis in paracetamol-induced mouse models indicating that 
neutrophils play a vital role in the development of acute liver injury 138. Circulating 
neutrophils have a decreased phagocytic capacity and increased spontaneous oxidative 
burst (SOB) in patients with ALF 139. Moreover, neutrophil function indices are 
important biomarkers of poor prognosis in ALF and can be implicated as important 
mediators in the development of cellular and organ dysfunction and the increased 
susceptibility to developing sepsis 139. Decreased neutrophil phagocytic activity (NPA) 
correlates with peak arterial ammonia concentration in patients with ALF and there is 
growing evidence to suggest that ammonia may be causally implicated in contributing to 
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neutrophil dysfunction 139, 140. In paracetamol overdose, neutrophils showed toxic 
granulation and vacuoles in the cytoplasm, as a result of increased granulocyte colony 




Figure 1.18: Neutrophil infiltration in the liver after paracetamol overdose 106. 
This is the image taken under a confocal microscope illustrating the infiltration of neutrophils in the liver after paracetamol overdose in mice 





Figure 1.19: Neutrophils in the circulation after paracetamol overdose 141.  
These are images taken using a light microscope (100x) and a TEM (4800x) showing 
toxic granulation, vacuoles and abnormal nucleus to cytoplasm ratio in circulatory 





Lymphocytes are the second most abundant (20 – 40%) among the white blood cells. A 
typical lymphocyte is 8 to 10µM in size, round or spherical shaped and contains a single 
nucleus with a thin rim of cytoplasm 128. The different types of lymphocytes include T 
lymphocytes, B lymphocytes and NK cells, where T cells and B cells are part of the 
adaptive immune system and NK cells are part of the innate immune system. Upon 
activation by an antigen or during an infection, lymphocytes become effector cells, that 
are short-lived, along with cytotoxic T cells participate in the host immune defence by 
producing cytokines and antibodies 118. 
1.2.5.2.1. T lymphocytes 
As with other immune cell subsets, T lymphocytes (T cells) also originate from 
haematopoietic stem cells in the bone marrow. However their progenitor cells migrate 
to the thymus via the blood, where they mature and are named as thymus-dependent 
lymphocytes or T cells 118. Initially they develop as immature CD4 and CD8 double-
positive cells and mature as single CD4 positive or CD8 positive T cells 142. 
CD4+ T cells, also known as T helper (TH) cells, activate other cell types such as cytotoxic 
T cells and help in the maturation of B lymphocytes 118. T helper cells are differentiated 
into several subsets of effector T cells including TH1, TH2, TH9, TH17 and regulatory T 
cells (T-regs) 118.  T helper cells secrete IFN-γ, TNF -α, IL-6, IL-4, IL-10, IL-17, 
tumorogenic growth factor (TGF) -β and various other cytokines to induce immune 
responses 123. 
CD8+ T cells, also known as cytotoxic T cells, kill target cells by inducing them to 
undergo apoptosis. The most important function of CD8+ T cells is to kill cancer cells 
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and virus infected cells. Upon activation, CD8+ T cells, like CD4+ T cells, have the ability 
to produce cytokines such as IFN-γ and TNF-α. IFN-γ activates the macrophages, recruits 
them to the site of injury and both act as effector cells and antigen-presenting cells 118. 
Memory cells are those T lymphocytes that have the ability to memorise the antigens on 
exposure to any infection and quickly produce cytokines in cases of re-infection, 
whereas naive T cells are those cells that have encountered any specific antigen 118. 
Memory and naive T cells are seen both in CD4+ and CD8+ T cells 143, 144. 
T regs are mainly identified by the transcription factor Fox-P3 and their main function is 
to suppress the excessive activity of effector T cells towards the end of an immune 
reaction 145.  
1.2.5.2.2. Natural killer cells 
Natural killer (NK) cells are a type of lymphocyte that develop in the bone marrow from 
the same progenitor cells as B and T lymphocytes. They do not contain any antigen-
specific receptors therefore they are identified as part of the innate immune system. 
They are larger than B and T lymphocytes and contain cytotoxic granules in the 
cytoplasm. NK cells are responsible for recognising and killing cells infected with 
tumour and viruses. NK cells are activated by cytokines produced by macrophages. Upon 
activation NK cells express killer cell lectin-like receptor subfamily G 1 (KLRG-1) and 
natural killer group 2D (NKG2D) family on their surface, and they also produce 






Macrophages are the mature form of monocytes that are present mainly in tissues. 
Macrophages along with neutrophils mainly participate in the initial defence mechanism 
and in the adaptive immune mechanism. During the innate immune phase, macrophages 
participate in microbial killing by phagocytising invading pathogens, whilst in the 
adaptive immune phase they are involved in clearing the dead cells targeted by effector 
cells and producing cytokines such as IFN-γ, TNF-α, and IL-6. They also induce 
inflammation and secrete cytokines that activate other immune cells and recruit them to 
the site of injury 118. 
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1.2.6. Toll-like receptors 
Toll like receptors (TLRs) or pattern-recognition receptors are type I transmembrane 
receptors that detect pathogens based on specific molecular patterns 146. In the year 
1989, Charles Alderson Janeway Jr, a famous immunobiologist at Yale University, 
predicted that innate immunity is responsible for the activation of the adaptive immune 
system. He also proposed the theory of innate pattern recognition and their links to 
adaptive immunity 147. This prediction paved the way for further research in this field 
and many researchers around the globe including him confirmed this theory in the 
subsequent years 148. 
Hoffmann observed that mutations in Drosophila melanogaster prevented them from 
making a protective immune response against Aspergillus fumigates. By analysing the 
genes that caused this mutation, Hoffmann showed that this was dependent on the 
activation of a particular factor called dorsal related immune factor 149. Following this, 
Charles Janeway Jr and Ruslan Medzhitov showed that a homologue of the dorsal related 
factor were present in humans, which are now termed as Toll like receptors (TLRs) 150. 
They also showed that activation of these receptors on certain white blood cells induced 
cytokine production and activated the adaptive immune system 150, 151. However, the 
importance of this TLR family was not fully accepted, until Bruce Beutler showed that 
activation of TLRs and the resultant cytokine production was based on a specific 
recognition pattern. He found that mice defective of a particular gene (TLR4) did not 
induce any inflammatory response and this receptor (TLR4) was essential for the 
identification of lipopolysaccharide (LPS) and subsequent cytokine production 152. 
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Later on a similar set of genes, in a large family consisting of 10 members (TLRs 1, 2, 3, 
4, 5, 6, 7, 8, 9 and 10) were identified in humans and other species 153. Among those, 
TLRs 1, 2, 4, 5 and 6 are present on the surface of cells and are specialized in the 
recognition of bacterial products, while TLRs 3, 7, 8 and 9 are intracellular and 




Figure 1.20: Position of TLRs and their ligands. 
This picture illustrates the position of the different human TLRs in a cell, whether they are present on the surface or intracellular organelle 
(endosomes). It also illustrates the ligands that bind to the different TLRs.  
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1.2.6.1. TLR signaling pathways 
When stimulated by microbial components, TLRs present on various cell types induce 
intracellular responses that result in the production of inflammatory cytokines, 
chemotactic factors and antiviral type I interferons. Cytokines are produced by 
activating the different transcription factors such as nuclear factor - κB (NF-κB), 
interferon regulatory factor (IRF) and activator protein 1 (AP-1) in different signaling 
pathways. NF-κB and AP-1 act to induce the production of pro-inflammatory cytokines 
and chemotactic factors, whereas IRF factors induce the production of antiviral type I 
interferons 118. 
1.2.6.1.1. Myeloid differentiation factor 88 dependent pathway 
The different signaling pathways are activated by the ligand-induced dimerization of 
two TLR ectodomains, which brings the Toll/interleukin-1 receptor (TIR) domains in 
the cytoplasm close together so that they can interact with the TIR domains of the 
adaptor molecules that initiate intracellular signaling. There are four different adaptors 
in mammalian TLRs and they are myeloid differentiation factor 88 (MyD88), MyD88 
adaptor-like (MAL), TIR domain-containing adaptor-inducing IFN-β (TRIF) and TRIF-
related adaptor molecule (TRAM). It is important that different TLRs interact with 
different combinations of these adaptors to induce cytokine production 118 [Figure 1.21]. 
To activate the signaling pathways, TLR5, -7 and -9 interact only with the MyD88 
molecule; TLR3 interacts only with TRIF; while the rest either use MyD88 paired with 
MAL, or TRIF paired with TRAM 118. The MyD88 is a protein that interacts with the TLR 
and IL-1R and it contains a TIR domain in its C-terminal protein and a death domain in 
its N-terminal portion. MyD88 upon stimulation recruits the IL-1R-associated kinase 
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(IRAK), which gets phosphorylated and associates itself with TRAF-6, leading to 
activation of two important signalling pathways, jun amino terminal kinases (JNK) and 




Figure 1.21: TLR signalling pathways, MyD88-dependent and MyD88-
independent. 
This picture shows the signalling pathways of TLR2, TLR4 and TLR9 which require the 
common adaptor MyD88 for cytokine activation by signalling the NF-κB pathway. It also 
shows the cytokine activation by TLR4 through the NF-κB pathway, without the 




1.2.6.2. TLRs role in phagocytosis and adaptive immunity 
There is impairment in bacterial phagocytosis including Escherichia coli, Salmonella 
typhimurium and Staphylococcus aureus due to the impaired maturation of the 
phagosome in the absence of MyD88. It has also been demonstrated that TLRs induce 
phagosome maturation through activation of p38 in the MyD88 pathway. Phagocytosis, 
an important process during the host defence against microbes, causes degradation of 
those microbes and its subsequent presentation of pathogen-derived peptide antigen. 
Recognition of pathogens by TLRs is also known to induce the production of genes 
coding for inflammatory cytokines and co-stimulatory molecules. The phagocytosis-
mediated antigen presentation and TLR-gene production causes the development of 
antigen specific adaptive immunity in the host 155. 
Among all TLRs, TLR2, 4 and 9 are the most common receptors on neutrophils and have 
been studied mostly in relation to liver disease. They can be easily detected using 
antibody detection methods, while the expression of other TLRs involves molecular 
techniques.  
1.2.6.3. TLR2 
TLR2 recognises a broad spectrum of microbial components like lipopeptides, 
peptidoglycan from gram-positive bacteria mainly 156, and also has high affinity towards 
some of the products from Mycobacterium, Trypanosoma cruzi, Staphylococcus 
epidermidis, Treponema maltophilum and fungi. TLR2 recognises a wide spectrum of 
microbial components, mainly because it forms heterophilic dimers with TLR1 and 
TLR6, and is also involved in the recognition of various components of fungi. TLR2 
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expressed on the cell surface can be identified by staining the cell surface using specific 
monoclonal antibodies 155, 157. 
1.2.6.4. TLR4 
TLR4, an important receptor for LPS, requires an extracellular protein MD-2 to detect 
the LPS 156. It also recognises endogenous ligands, such as heat shock proteins (HSP60 
and HSP70), fibronectin, hyaluronic acid, heparan sulfate and fibrinogen. TLR4 gets 
activated by endogenous ligands only at higher concentrations, whilst exposure to 
minimal quantities of LPS is sufficient for its activation. TLR4, which is also expressed on 
the cell surface can be identified by staining the cell surface using specific monoclonal 
antibodies 155, 157. 
1.2.6.5. TLR9 
Shizuo Akira from Japan, developed a TLR9 deficient (TLR9-/-) mouse and showed that 
TLR9 recognises the unmethylated CpG motif of bacterial DNA. 158. CpG DNA are of two 
types and are termed as A/D-type CpG DNA and B/K-type CpG DNA, which induces the 
production of inflammatory cytokines such as IL-6, IL-12, TNF-ɑ and IFN-ɑ 155. Lethal 
doses of CpG DNA did not cause any harm or induce any inflammation in TLR9-/- mice 
158. TLR9 is presumed to be involved in the pathogenesis of autoimmune disorders such 
as diabetes 159, in addition to recognising viral and bacterial products 155, 157. 
Apart from the above mentioned molecules, TLR2 and TLR4 are activated by damage-
associated molecular patterns (DAMPs) such as heat shock proteins including HSP22, -
70 and -72 and Gp96, high-mobility group box-1 (HMGB-1) protein, fibrinogen and 
antiphospholipid antibodies, whilst TLR9 is activated by IgG-chromatin complexes 160. 
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1.2.6.6. TLRs and neutrophils 
Human neutrophils also contain TLRs, and they express all of them other than TLR3. The 
neutrophils are not only a target, but also act as a source of activation for cytokines. Pro-
inflammatory cytokines mediated through various mechanisms of the TLR pathway 
stimulate the neutrophils and activate their antimicrobial functions. The neutrophils 
also release and synthesize various other pro-inflammatory cytokines that activate other 
immune cells (e.g. monocytes) and direct them towards the site of infection and initiate 
the adaptive immune system in the host 153. TLRs are also known to have various other 
activities on neutrophils apart from phagocytosis and cytokine production, including 
ROS generation, receptor expression and priming of neutrophils. 
TLRs activate neutrophils by pathogen-associated molecular patterns (PAMPs) and 
endogenous molecules known as damage associated molecular patterns (DAMPs) 
produced by tissues in response to infection and injury 161. Several studies have 
determined TLR activation on neutrophils. Studies show that Helicobacter pylori 
activates TLR2 and TLR4 expression in neutrophils and blocking these receptors has 
resulted in an inhibitory effect on pro-inflammatory cytokine production 162. 
1.2.6.7. TLRs and liver disease 
The liver is an organ that is particularly important to the immune system because it 
produces acute-phase reactants, and thus in patients with liver disease, the immune 
system can be severely compromised. Thus, by gaining a greater understanding of the 
dysfunction of the immune system observed in patients with liver disease, it is hoped 
that better therapeutic targets will emerge in order to treat patients with liver disease. 
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Stimulation by LPS causes SIRS and septic shock resulting in MOF and death. In D-
Galactosamine treated mice, LPS activity was greatly increased resulting in hepatocyte 
cell death causing acute liver injury. This was mainly activated by TLR4 resulting in the 
production of various inflammatory cytokines that are detrimental in the case of liver 
injury 163. When CpG DNA is induced in D-Galactosamine mice, TLR9 activation also 
results in acute liver injury mediated by the mitochondrial apoptotic pathway. TLR9 is 
activated through the MyD88 pathway similar to LPS activation 164. Unlike TLR4, the 
activation of TLR9 results only in liver damage and does not cause problems in other 
organs 165. Although there is no direct involvement of TLRs in the recognition of 
hepatitis B and C viruses, studies show there is indirect activation of some TLRs in 
relation to these viruses. Since TLRs are involved in many diseases related to the liver, 
blocking TLRs has been the focus of novel therapeutic strategies163. 
1.2.6.8. TLRs and microglia 
Microglia express TLRs 1-9 and upon activation by various TLR agonists such as LPS, 
peptidoglycan and CpG DNA they upregulate  unique patterns of innate and effector 
immune cytokines and chemokines at the mRNA and protein level 100. Activation of TLR4 
in the microglia by ammonia and LPS result in the release of reactive oxygen species, 
nitric oxide and cytokines that ultimately contribute to astrocyte swelling 166 indicating 
that microglia plays a critical role in the development of brain oedema in ALF. 
1.2.6.9. TLRs and paracetamol-induced acute liver injury 
In a paracetamol-induced mouse model, TLR9 plays a significant role in the 
development of acute liver injury and survival upon activation of free DNA released by 
the apoptotic hepatocytes. TLR9 along with Nalp3 inflammasome, activates caspase-1, 
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an enzyme required for the maturation of pro-inflammatory cytokines, IL-1β and IL-18 
108. In another mouse model, it has been shown that TLR4 plays an important role in the 
development of MOF including increased brain water content after paracetamol 
overdose, and using an inhibitor of TLR4 or mice deficient of TLR4 prevented the 




Paracetamol-induced hepatocellular necrosis is the commonest cause of ALF in the 
western world and culminates in the development of coagulopathy, encephalopathy and 
MOF in less than 7 days. The loss of hepatocellular synthetic function leads to decreased 
ammonia detoxification capacity resulting in hyperammonemia. Hyperammonemia 
plays a definitive role in the development of HE and brain oedema, with up to 25% of 
patients developing ICH. Cerebral oedema and increased intracranial pressure may be 
fatal without access to emergency LT. There is a marked propensity for patients with 
PALF to develop sepsis which may not only hasten the development of brain oedema, 
but may further progress to MOF and death. The SIRS contributes to the progression of 
HE in ALF, however the mechanism by which this occurs remains unclear. 
In response to paracetamol hepatotoxicity, neutrophils are rapidly recruited and 
infiltrate the liver where they become activated by chemokines such as CXCL8/ IL-8 and 
mitochondrial products such as formyl peptides and mitochondrial DNA amplifying 
hepatocellular damage by release of proteolytic enzymes ROS. Neutrophils alongside 
macrophages also participate in the removal of necrotic cell debris in preparation for 
tissue repair and resolution of the inflammatory response. Circulating neutrophils have 
a decreased phagocytic capacity and increased SOB in patients with ALF. Moreover, 
neutrophil function indices are important biomarkers of poor prognosis in ALF and can 
be implicated as important mediators in the development of cellular and organ 
dysfunction and the increased susceptibility to developing sepsis. Decreased neutrophil 
phagocytic activity (NPA) correlates with peak arterial ammonia concentration in 
patients with ALF and there is growing evidence to suggest that ammonia may be 
causally implicated in contributing to neutrophil dysfunction. 
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TLRs are innate pattern recognition receptors that detect microorganisms based on a 
specific molecular pattern. TLR9 is an intracellular receptor that has high affinity 
towards the oligodinucleotides (CpG motif of bacterial DNA), whilst TLR2 and TLR4 are 
surface receptors that detect PAMPs from gram-positive and gram-negative bacteria 
(LPS), respectively. Downstream signalling of TLRs activates the NF-κB pathway thereby 
upregulating the production of pro-inflammatory cytokines and chemokines, and 
recruiting key components of the adaptive immune system. Neutrophil TLRs are able to 
sense PAMPS and induce inflammatory responses but whether this is protective or 
detrimental in patients with PALF remains unknown. TLR2, -4 and -9 are the most 
prevalent TLRs on neutrophils and activation of TLRs in an in vitro experiment in 
healthy human neutrophils resulted in increased phagocytic capacity, superoxide 
generation, L-selectin shedding, and inhibition of chemotaxis and also triggered cytokine 
release. This has not been examined in patients with PALF although a TLR9 antagonist 
was recently demonstrated to have a protective effect against developing liver injury in 
a mouse model of PALF. 
Although the evidence base supporting the relationship between ammonia, 
inflammation and brain oedema is robust, there is a paucity of data characterising the 
specific pathogenic mechanisms entailed. Prof Roger F. Butterworth, an eminent 
researcher in the field of hepatic encephalopathy, once stated that “the prevention of 
central pro-inflammatory processes will undoubtedly herald a new chapter in the 
development of agents for the prevention and treatment of the CNS complications of the 





Ammonia and inflammation are increased in paracetamol-induced acute liver injury and 
they play an important role in the progression towards hepatic encephalopathy. There is 
a robust evidence base to support the role of TLR9 in the pathogenesis of neutrophil-
mediated liver injury and systemic inflammation in paracetamol-induced ALF. 
I therefore postulate that ammonia induces systemic inflammation and contributes to 
the development of brain oedema through a TLR9-mediated pathway.  
To better understand how ammonia and inflammation contribute towards the 
progression to hepatic encephalopathy in human PALF, the following hypotheses were 
formulated: 
1. Circulating neutrophil TLR9 expression is increased in PALF patients with advanced 
hepatic encephalopathy and SIRS resulting from the release of necrotic hepatocyte 
products, ammonia, DNA and IL-8 into the circulation [Figure 1.22, Q1]. 
2. Ammonia induces inflammation by activating neutrophils through a TLR9-mediated 
mechanism which then triggers the adaptive immune system culminating in pro-
inflammatory cytokine production by effector T cells, cytotoxic T cells, NK cells and 








Figure 1.22: Hypothesis figure. 
It is well established that paracetamol overdose causes necrosis in the liver and the 
resulting necrotic byproducts such as ammonia IL-8 and DNA are released into the 
circulation. This leads to systemic inflammation and as a result cytokines are produced 
by various cells. Ammonia and cytokines enter the brain through the cerebrospinal fluid 
and induce brain oedema. In my hypothesis (shown as ---->), I postulate that ammonia-
induced inflammation and subsequent brain oedema is influenced through a neutrophil-
TLR9 mediated pathway. 
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1.5. Aims and objectives 
1. To prospectively characterise circulating neutrophil function and TLR2, -4 and -9 
phenotype in healthy controls (HC) and in patients presenting with PALF, based upon 
the severity of SIRS and HE. 
2. To study the neutrophil TLR9 expression and cytokine production at baseline, and 
following ex-vivo stimulation with oligodinucleotides, ammonium chloride (NH4Cl) and 
LPS. 
3. To analyse healthy neutrophil TLR9 expression and cytokine production at baseline, 
and following ex-vivo stimulation with IL-8 and/or NH4Cl. 
4. To determine whether activation of TLR9 is a DNA dependent or DNA independent 
mechanism by examining the influence of PALF plasma and endogenous mitochondrial 
DNA on neutrophil TLR9 expression by incubating healthy neutrophils with PALF 
plasma with and without deoxyribonuclease-I (DNase-I) [Figure 22, Q4]. 
5. To determine whether innate immune cells such as neutrophils and/or macrophages 
can propagate systemic and organ TLR9 expression. 
A key objective would be to also determine if neutrophil TLR9 expression is increased 

















My PhD study comprised of two different models, human and mouse, the former was 
performed at the Institute of Liver Studies in King’s College Hospital, London, United 
Kingdom (UK), while the latter was performed at Li Wen’s laboratory in the Department 
of Endocrinology, School of Medicine at Yale University, United States of America (USA). 
The materials which were purchased at both the sites from those companies which are 
universal have been listed under general consumables while the rest have been listed 
under specific headings. 
2.1. Materials 
2.1.1. General consumables 
Rosewell Park Memorial Institute (RPMI) medium [Sigma-Aldrich, United Kingdom 
(UK)]; Flow cytometer tubes – 5mL [Becton Dickinson (BD), UK] [Corning Science, 
Mexico]; Falcon tubes / Cellstar tubes - 15 and 50 mL [Starlabs, UK] [Greiner bio one, 
USA]; Lysing solution [BD]; Polymorphprep™ solution [Axis Shield, Norway]; DNAse-I 
[Sigma-Aldrich]; Phosphate buffered saline (PBS) [Sigma-Aldrich]; Cytofix/cytoperm 
solution [BD]; Permwash buffer [BD] 
Flow cytometry Antibodies: Detailed information given in appendix tables. 
Instruments: Flow cytometer – BD Fluorescence activated cell sorting (FACS) machine 
Canto II and LSRII [BD, San Jose, California, USA] 
Analysis softwares: BD FACS DIVA software V6.0 [BD, San Jose, California, USA]; FCAP 
array software V1.0.1 [BD, San Jose, California, USA]; SPSS 20.0 [IBM statistics, UK]; 
GraphPad Prism V6.0 [UK] 
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2.1.2. Human study 
Stimulants: Lipopolysaccharide (LPS) [Sigma-Aldrich, UK]; Ammonium chloride 
(NH4Cl) [Sigma-Aldrich, UK]; Oligodinucleotides (ODN) 2395 [Innaxon, UK]; IL-8 [R&D, 
UK] 
Kits: Neutrophil function kit – Phagotest™ and Burst Test™ [Orpegen Pharma, 
Germany]; Cytometric bead array [BD, UK] – Human Soluble Protein Master Buffer Kit; 
Human Soluble Protein Flex Sets – IL-6, IL-8, IL-10 and TNF-α 
Instruments: Centrifuge [Rotina, Germany]; Water bath [Grant, UK] 
2.1.3. Animal study 
In-vivo Stimulation: Ammonium acetate (NH4-Ac) [J.T. Baker, USA]; Sodium Chloride 
[J.T. Baker, USA]; ODN2088 [Invivogen, USA] 
In-vitro stimulation: Phorbol 12-myristate 13-acetate (PMA) [Invivogen, USA]; 
Ionomycin [Invivogen, USA]; Golgi plug [BD, USA] 
Other materials: Tris pH-8.0 [American Bioanalytical, USA]; EDTA [American 
Bioanalytical, USA]; SDS [American Bioanalytical, USA]; Pronase [Roche, USA]; Ethanol 
[Dacon Laboratories, USA]; Iso-fluorane [Butler Schein Animal Health, USA]; Iso-
propanol [Sigma-Aldrich, USA]; Pronase [Roche, USA]; 25G needle [BD, USA]; 1mL, 3mL 
and 5mL syringes [BD, USA]; collagenase-IV [Worthington, USA] 
Kits: Quant-iT ™ PicoGreen® dsDNA (Life Technologies, USA); DNA plate reader – Bio 
Tek, USA 
Instruments: Centrifuge [Corning, USA]; Water bath [Precision, USA] 
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2.2. Human study design 
A prospective cohort study was performed on patients presenting with PALF. Circulating 
neutrophil function and TLR phenotype were determined and compared to HC. Blood 
samples were collected from patients with PALF within 24 hours of admission to the 
intensive care unit (ICU) [day 1] and followed longitudinally (days 4 and 7) until 
recovery, death or LT. HCs were only studied on day 1 as we have previously shown that 
HC variability is negligible over 7 days. 
2.3. Patients 
Twenty four consecutive patients with PALF were recruited on admission to the liver 
ICU at King’s College Hospital between January 2011 and December 2013. PALF was 
defined by the onset of hepatocellular dysfunction in the absence of pre-existing liver 
disease characterised by coagulopathy and encephalopathy following an intentional or 
unintentional overdose of paracetamol 167. 
2.4. Inclusion and exclusion criteria 
Patients with PALF were included aged 18-75 years. Healthy age and sex-matched non-
smoking volunteers with no history of liver disease were used as HC. The HC alcohol 
intake was <20g/day and they had not drunk alcohol or exercised excessively, 72-hours 
prior to blood being drawn. 
Patients were excluded if they had evidence of sepsis on clinical examination, 
radiological or laboratory evidence of infection, malignancy and any coexisting history 
of immunodeficiency including HIV and glycogen storage disease. Patients who had an 
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alcohol intake of >20g/day prior to the paracetamol overdose or who were treated with 
immunosuppressant drugs were also excluded. 
2.5. Consent and data collection 
The study was performed in accordance with the declaration of Helsinki and ethical 
permission was granted from the North East London Research Ethics Committee (Ref 
08/H0702/52) and King’s College Hospital Local Research Ethics Committee (Ref 01-04-
005). After obtaining fully informed consent or declaration by an appropriate consultee, 
clinical, biochemical and physiological data were collected.  The information included 
tobacco and alcohol use, arterial ammonia (mol/L), sodium (mmol/L) and differential 
leucocyte count (x109). The grade of encephalopathy according to the West-Haven 
criteria 42, admission SIRS score 36, Sequential Organ Failure Assessment (SOFA) score 
168 and the Acute Physiology and Chronic Health Evaluation (APACHE) II score 169 were 
also calculated. Length of ICU stay, survival and number of days requiring vasopressors, 
ventilation or renal replacement therapy were also recorded. 
Antibiotic use and immunomodulatory therapies such as corticosteroids, hypothermia, 
haemofiltration and plasmapheresis were recorded. None of the patients were treated 
with albumin dialysis or biological liver support devices but one patient underwent 
plasmapheresis. The occurrence of bacterial, fungal and viral infection was noted along 
with other relevant patient outcomes including the development of MOF. 
2.6. Sample collection and storage 
All experiments were performed within 1 hour of blood being drawn. Twenty millilitres 
of venous blood was collected into heparinised pyrogen-free tubes. Neutrophil function 
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and TLR phenotyping were performed and plasma was obtained by centrifugation of 
whole blood at 4750g for 10 minutes at 4C and stored at -80C for subsequent cytokine 
determination by cytometric bead array (CBA). 
2.7. Measurement of blood ammonia 
Arterial blood was collected from all patients soon after admission in pre-heparinised 
syringes from indwelling catheters. Ammonia was measured using the Ammonia Test 
Kit II for the PocketChem BA device (Arkay, Inc., Kyoto, Japan) with 20 μL of blood 
sample applied to a reagent strip. The continuous measurement range is 7–286 μmol/L 
and the normal blood ammonia level for healthy adults in this device was < 54 μmol/L. 
The device was maintained in accordance with the manufacturer’s specification, with 
daily internal and monthly external calibration. The device was located within the ICU 
and testing was performed by trained technical staff immediately after collection so the 
delay in processing the sample was never more than 5 min from collection 170. Since 
blood ammonia was measured in the ICU as part of standard care, it was deemed 
unethical and a poor use of resources to repeat testing in the laboratory. Therefore I was 
not able undertake a comparison of blood ammonia with the plasma ammonia. 
2.8. Flow cytometry 
In humans and mice, the expression [mean fluorescence intensity (MFI) and frequency] 
of various surface and intracellular receptors present on the white blood cells were 
analysed using a flow cytometer. After white blood cells were isolated from whole blood 




2.9. Isolation of white blood cells after lysis of red cells 
To stain the cells for flow cytometry, 100 µL of whole blood was placed in 5 mL tubes 
and 1 mL of lysis solution [<15% formaldehyde and <50% di-ethylene glycol] was 
added. The lysate was mixed gently and left at room temperature (RT) for 15 minutes. 
The reaction was stopped by adding 2 mL of phosphate-buffered saline (PBS). The 
solution was centrifuged at 600g for 5 minutes at 18°C and the supernatant was 
discarded leaving the cell pellet at the bottom of the tube. The cells were then re-
suspended in 100 µL of PBS before staining for flow cytometry. 
Alternatively red blood cells were also lysed using distilled water. To lyse the red blood 
cells in whole blood or immune cells isolated from animal tissues, cells were gently 
suspended and 900 µL of de-ionised water was added and mixed well for ten seconds. 
The reaction was stopped immediately using 100 µL of 10x PBS and 5 mL of 1x PBS and 
the tissue debris were removed. Cells were centrifuged at 600g for 5 minutes at 18°C 
and the supernatant was discarded. The lysis of red blood cells using water was not used 
in the human study since water can affect neutrophil function. 
2.10. Isolation of white blood cells using Polymorphprep™ solution 
Polymorphprep™ solution is a density gradient solution which separates white blood 
cells and other blood components based on their density. To isolate the white blood cells 
using Polymorphprep™ solution, 20 mL of heparinised blood was collected and 
processed under aseptic conditions in a bio-safety cabinet. Whole blood was layered 
over 15 mL of Polymorphprep™ solution in a 50 mL falcon tube. The tubes were 
balanced and centrifuged at 800g for 35 minutes at 18°C, with least acceleration and 
zero brakes. After centrifugation the tubes were placed carefully in the safety cabinet to 
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avoid mixing of separated cells. The separated blood contained peripheral blood 
mononuclear cells (PBMC) on top, granulocytes in the middle and red blood cells at the 
bottom [Figure 2.1]. PBMC and granulocytes were isolated in two different sterile 50 mL 
falcon tubes. Granulocytes were washed twice with PBS and centrifuged at 800g for 10 
minutes at 18°C with brakes. When there was red blood cell contamination in the 
granulocytes, red blood cells were lysed and washed as above.  
 





2.11. Cell count 
The granulocytes or PBMCs were suspended with PBS and diluted (1/10) with Trypan 
Blue solution. Cells were counted using a Neubauer haemocytometer and up to 1 million 
(1x106) viable cells were re-suspended with 100 µL of PBS in a single tube for flow 
cytometry staining. 
The total number (no.) of cells in the PBS (isolated from a single sample) was calculated 
as follows: 
Total no. of cells = Cells counted x dilution factor x depth factor x 103 x volume of PBS 
      Area counted 
        = Cells counted x 10 x 10 x 103 x volume of PBS 
      4 
Cells counted – number of cells counted in the haemocytometer 
Dilution factor – the dilution of cells with trypan blue (1 in 10 dilution – 5 µL cells with 
45 µL of trypan blue) 
Depth factor – the distance between the cytometer and cover slip (0.1 mm - 10) 
103 – for the conversion of per mL 
Volume of PBS – 5 mL of PBS in which the cells were suspended 
Area counted – four, the 16 small squares in the areas 1, 2, 3 and 4 of the 











2.12. Staining of cells for flow cytometry 
For flow cytometry, up to 1 million (1 x 106) white blood cells were re-suspended in 100 
µL of staining buffer and stained with fluorochrome conjugated antibodies in one tube. 
To stain for receptors present on cell surface, monoclonal antibodies conjugated with 
fluorochromes were added to the white blood cells, mixed and incubated at RT in 
darkness for 30 minutes. Following this the cells were washed with 1 mL of sterile PBS, 
centrifuged at 600g for 5 minutes at 18 C and the supernatant was discarded. To 
prepare the cells for intracellular staining, 100 µL of cytofix/cytoperm solution was 
added to the cell pellet after surface stain, mixed gently and left at RT for 20 minutes. 
The cells were washed with 1 mL of BD permeabilisation wash buffer, centrifuged at 
600g for 5 minutes at 18C and the supernatant was discarded. To prepare the cells for 
intranuclear staining, 1 mL of Tonbo’s transcription factor fix/perm buffer (1x) was 
added to the cell pellet after surface stain, mixed gently and left at RT for 1 hour. The 
cells were washed with 1 mL of Tonbo’s permwash buffer, centrifuged at 600g for 5 
minutes at 18C and the supernatant was discarded. The cells were then stained with 
intracellular or intranuclear antibodies and incubated at RT in darkness for 30 minutes. 
The cells were washed again with 1 mL of permeabilisation buffer, centrifuged at 600g 
for 5 minutes at 18C and the supernatant was discarded. The cells were then re-
suspended in 300 µL of PBS and analysed using a flow cytometer. 
For the human study, all antibodies were titrated by staining them with blood samples 
collected from HC to determine the right concentration of antibody required to be added 
to the cells. The stock antibodies were diluted with PBS and those dilutions which 
expressed maximum mean fluorescence intensity (MFI) were chosen for the experiment. 
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The final concentration and detailed information of all the antibodies used for the 
human study are given in the appendix. For the animal study, the appropriate amount of 
antibody added to the cells was based on the protocols followed at Li Wen’s laboratory 
in Yale University. The concentration of all the antibodies were calculated and optimised 
using immune cells isolated from spleen. 
2.13. Stimulation of intracellular cytokine production 
To determine the intracellular cytokine production of PBMCs, up to 5.0 x 106 cells per 
mL were stimulated with phorbol 12-myristate 13-acetate (PMA) (50 ng) and ionomycin 
(500 pg) in complete media with Golgi plug (1 µL) and incubated at 37°C for 5 hours in 
the presence of 5% CO2. At the end of 5 hours, stimulated cells were centrifuged at 600g 
for 5 minutes at 18°C, and supernatants were discarded. The cells were first stained with 




2.14. Flow cytometer 
Cytometry is a process by which physical and chemical characteristics of a single cell are 
measured. Flow cytometry is a technique mainly used for analysing multiple 
characteristics of single cells that pass through a single apparatus in a fluid stream 171, 
172. The first flow cytometer was patented by Wallace coulter in 1953 based on the 
disturbances particles exert when moving in an electric field and the fluorescence-based 
flow cytometer was patented by Wolfgang Gohde in 1968. Although Coulter counters are 
still widely used in clinical practice, it was fluorescence activated cell sorter (FACS) 
machine that transformed the understanding of cellular immunology. 
Flow cytometry is used for immunophenotyping of cells from various specimens 
including whole blood, body fluids and bone marrow 173. The optical and fluorescence 
characteristics of single cells are measured in a flow cytometer to determine its size, 
DNA or RNA content, cytoplasmic complexity, and proteins expressed in the surface and 
intracellular region. The size and internal complexity of cells are measured using the 
light scattered by forward angle and right angle respectively. The nucleic acid contents 
and the protein expression are determined by measuring the fluorescent dyes 
conjugated to antibodies that bind to them. When cells are labelled with different 
fluorochromes and are passed through a light source, they get excited to a high energy 
state. When they return to their resting state, these fluorochromes emit light at different 
wavelengths and are measured simultaneously. The most common dyes used are 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), Peridinin chlorophyll protein 
(PerCP) and propidium iodide (PI) and allophycocyanin (APC). To produce dyes of 
longer wavelengths and more colours, tandem dyes with internal fluorescence 
resonance energy transfer (PE-Cy5, PE-Cy7, APC-Cy7 & PerCP-Cy5.5) are used 171. 
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2.14.1. Acquisition of samples in the flow cytometer 
The samples were acquired in a BD FACSCanto II ™ instrument consisting of 2-lasers and 
6-colours at King’s College Hospital [Figure 2.4], whilst the samples at Yale University 
were acquired in a BD LSRII instrument which consisted of 4-lasers and 13-colours. The 
flow cytometer was connected to a fluidic cart containing the sheath and cleaning 
solutions necessary for running the machine smoothly and the instrument was operated 
using the BD FACS Diva software 6.1.2 installed in a computer. 
2.14.1.1. Setting up an experiment 
A new experiment was created and compensation settings were applied to the 
experiment. In a new global worksheet, a dot plot was created to display the cells. Cells 
were identified in the forward scatter channel area (FSC-A) and side scatter channel 
area (SSC-A) of the dot plot based on their size and internal complexity. With the 
increase in size and internal composition, cells lie away from zero in the FSC-A and SSC-
A, respectively. The FSC-A and SSC-A are measured on a linear scale and the 
fluorochrome expression was measured on a logarithmic scale in a dot plot. 
2.14.1.2. Identification of white blood cells and the different subsets 
In the global worksheet, a dot plot with FSC-A/SSC-A was created. To display the human 
or mouse white blood cells in the dot plot, PMT voltages for FSC and SSC were usually 
set between 250 - 400V. The population close to the X-& Y-axis were considered as 
lymphocytes since they are the small cells among the white blood cells without granules. 
The population observed further along the X-axis were considered as monocytes since 
they are the large cells among the white blood cells without granules. The large 
population found above were identified as granulocytes, since they are present in the 
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majority amongst the white blood cell and contain granules in their cytoplasm [Figure 
2.5]. 
After classifying the white blood cells in the cell suspension based on FSC-A/SSC-A 
characteristics, the different types of white blood cells were identified by staining for the 






Figure 2.3: Flow cytometry image of human white blood cells (leucocytes) 
showing the position of granulocytes, lymphocytes and monocytes on a FSC-





2.14.1.3. Identification and characterisation of neutrophils 
In humans, CD16, CD11b and CD62L have been shown to be useful markers for the 
identification of neutrophils. Depending on the experimental set up these markers were 
used as an individual marker or in different combinations to identify the neutrophils. 
CD16, an FcγRIII molecule, is an important receptor present on the cell surface which 
helps in the activation of neutrophils. CD11b is an ICAM-1 molecule which binds to the 
integrin present on the surface of neutrophils that helps in the adhesion of neutrophils 
to endothelial cells and other cells. CD62L or L-selectin is an adhesion molecule present 
on the surface of neutrophils. 
In humans, baseline neutrophil phenotype was characterised by determining the 
expression of CD16, CD11b, CD282, TLR4 and TLR9 in granulocytes isolated from whole 
blood after red blood cell lysis. The panel of antibodies used for characterising 
neutrophil phenotype are given in appendix table – 1. The panel of antibodies used for 
characterising the expression of IL-8 in neutrophils are given in appendix table – 2. 
Lys6-G and CD11b are the best markers for the identification of neutrophils in mice. 
Lys6-G, also known as Gr-1 is a protein expressed by the myeloid lineage and this is 
mainly present on the surface of peripheral neutrophils. Expression of extracellular 
myeloperoxidase was also measured in the neutrophils (appendix table – 3). 
2.14.1.4. Identification and characterisation of T cells 
The different subsets of lymphocytes were identified using their specific markers. T cells 
were identified using CD3 an important receptor present on the surface of T cells that 
helps in its activation. Following that, CD4 and CD8 markers were used to characterise 
the different subsets of T cells. Frequency (%) of activated cells (CD69+), memory cells 
 88 
 
(CD44+/CD62L-) and naive cells (CD44-/CD62L+) were characterised further amongst 
the different T cell subsets (appendix table – 4). In mice, the memory and naive cells are 
usually characterised using CD44 and CD62L compared to the CD45RA and CD45RO 
isoforms found only in humans. Intracellular cytokine production [IL-6, IFN-γ, TNF-α 
and IL-17] were determined in the CD4+ and CD8+ T cell subsets (appendix table – 5 and 
6). 
2.14.1.5. Identification and characterisation of NK cells 
NK cells were identified primarily using DX-5 also known as CD49b which is expressed 
on the surface of NK cells along with CD122. Activation marker KLRG-1 was used to 
characterise the frequency (%) of KLRG-1pos amongst the NK cells (appendix table – 7). 
Cytokine production of IFN-γ and TNF-α were determined in the KLRG-1 activated NK 
cells (appendix table – 8 and 9). 
2.14.1.6. Identification and characterisation of macrophages 
Macrophages in mice were identified mainly using F4/80 and CD11b markers. 
Intracellular cytokine production [IL-6, IFN-γ and TNF-α] was determined in the F4/80 
and CD11b+ macrophage (appendix table – 10). 
2.15. Ex-vivo neutrophil TLR9 stimulation with LPS, NH4Cl and 
ODN2395 
Whole blood was incubated at 37°C with Roswell Park Memorial Institute (RPMI)-1640 
media and stimulated with either LPS (E. coli 0111:B4) (200ng/mL) or NH4Cl (400µM) 
or ODN 2395 (oligodinucleotides) (0.25µM) or with PBS in controls for 2 hours 
(unstimulated). The stimulated cells were then stained and analysed by flow cytometry 
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as mentioned previously. The panel of antibodies used for characterising neutrophil 
phenotype and the expression of IL-8 in neutrophils are given in appendix table – 1 and 
2, respectively. The supernatant was collected for defining cytokine profiles. The time 
and concentration of the stimulants used for the ex-vivo studies were optimised after 
performing sequential assays using different concentrations of stimuli with healthy 
blood. 
2.15.1. RPMI and incubation time 
This was performed to calculate the amount of RPMI medium and the duration of 
incubation at 37°C, required for ex-vivo stimulation. For this purpose, 100µL of whole 
blood from healthy controls were incubated at 37°C from 0 hour to 3 hours, with 
different concentrations of RPMI. The incubation period and the amount of RPMI 
required for the experiment were calculated by determining the maximum percentage of 
granulocyte population in the concentration that maintained cell viability. There was 




According to the manufacturer’s instruction, the concentration of lipopolysaccharide 
(LPS) stock solution was 1 mg/mL and the optimal concentration of LPS for in-vitro 
experiments was 0.05 to 1 µg/mL. The optimal concentration of LPS for this experiment 
was determined by measuring the changes in neutrophil TLR4. For this experiment, the 
whole blood from healthy controls was stimulated with different concentrations of LPS, 
ranging from 0 to 400 ng/mL. For a concentration of zero, PBS was used instead of LPS. 
Based on the results, the final concentration of 200 ng/mL LPS was determined to be the 




Figure 2.4: Titration curve of LPS used for determining the dose required for 




2.15.3. Ammonium chloride 
A 1M (53.49 g/litre) ammonium chloride (NH4Cl) was freshly prepared by dissolving the 
salt in de-ionised water. The optimal concentration of NH4Cl was determined by 
measuring the changes in neutrophil TLR4 and TLR9. For this experiment, the whole 
blood from healthy controls was stimulated with different concentrations of NH4Cl, 
ranging from 0 to 800µM. For a concentration of zero, PBS was used instead of NH4Cl. 
Based on the results, the final concentration of 400µM NH4Cl was determined to be the 
appropriate concentration required for stimulation of neutrophils in the experiment 
[Figure 2.7]. Although the highest concentration of ammonia amongst the PALF patients 
in this study was 234 µM, it was higher than the detectable range >286 µM in two 
patients, suggesting that the 400µM NH4Cl used in the ex vivo studies would be 
representative of the pathophysiological levels observed in ALF. Following the two-hour 
incubation NH4Cl did not change the pH and osmolality of the incubation medium. It was 
also reflected in the colour of the incubation media, which remained the same. 
 
Figure 2.5: Titration curve of NH4Cl used for determining the dose required 
for ex-vivo stimulation of neutrophil TLRs. 
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2.15.4. Oligodinucleotide 2395 
According to the manufacturer’s instruction, the concentration of oligodinucleotide 
(ODN) 2395 stock solution was 100 µM and the optimal concentration of ODN 2395 for 
in-vitro experiments was 0.1 to 1 µM. The optimal concentration of ODN 2395 for this 
experiment was determined by measuring the changes in neutrophil intracellular IL-8 
and TLR9. The whole blood from healthy controls was stimulated with different 
concentrations of ODN 2395 ranging from 0 to 1 µM (0 – 1000 nM). For a concentration 
of zero, PBS was used instead of ODN 2395. Based on the results, the final concentration 
of 0.25µM (250 nM) ODN 2395 was determined to be the appropriate concentration 
required for stimulation of neutrophils in the experiment [Figure 2.8]. 
 
Figure 2.6: Titration curve of ODN2395 used for determining the dose 
required for ex-vivo stimulation of neutrophil TLR9 and IL-8. 
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2.16. Ex-vivo stimulation of neutrophils with IL-8 and NH4Cl 
To examine the effect of IL-8 and ammonia on TLR9 expression, healthy neutrophils 
were incubated at 37°C with RPMI and stimulated either with different concentrations 
of recombinant IL-8 (125, 250 and 500 pg/mL) or in combination with NH4Cl (400µM) 
for 2 hours; PBS was used as a control. These IL-8 concentrations were chosen to reflect 
the levels of IL-8 measured in patients with PALF; the highest levels being observed in 
those with high-grade SIRS. For the purposes of this study, the SIRS score of patients 
with PALF has been classified as either low SIRS score (0 – 1) or high SIRS score (2 – 4). 
Futhermore, the HE of PALF patients have been classified as either mild HE (grade 0 – 2) 
or advanced HE (grade 3/4). The different concentrations of IL-8 and/or NH4Cl used to 
stimulate 100 µL of whole blood and 380 µL of RPMI are given in table – 2.1. 
Table 2.1: Stimulation of healthy neutrophils with various concentrations of 
IL-8 and NH4Cl 
Tubes Whole blood RPMI PBS IL-8 NH4Cl 
Tube – 1 100 µL 380 µL 25 µL -- -- 
Tube – 2 100 µL 380 µL -- -- 400 µM 
Tube – 3 100 µL 395 µL -- 125 pg/mL -- 
Tube – 4 100 µL 375 µL -- 125 pg/mL 400 µM 
Tube – 5 100 µL 395 µL -- 250 pg/mL -- 
Tube – 6 100 µL 375 µL -- 250 pg/mL 400 µM 
Tube – 7 100 µL 395 µL -- 500 pg/mL -- 




After two hours of incubation, the whole blood treated with different kinds of IL-8 and 
NH4Cl were centrifuged at 600g for 5 minutes at 18°C and the supernatant was 
discarded leaving the cell pellet at the bottom of the tube. The red blood cells were then 
lysed and white blood cells were stained for flow cytometry. The panel of antibodies 
used for characterising neutrophil phenotype after stimulation with IL-8 and NH4Cl are 
given in appendix table – 2. 
2.17. Ex-vivo neutrophil TLR9 stimulation with patient plasma 
To examine the influence of PALF plasma and endogenous DNA on TLR9 expression, 
healthy neutrophils were isolated and incubated with different PALF patient plasma 
samples for 2 hours, with and without pre-treatment of DNAse-I (5µg). The cells were 
then analysed by flow cytometry. To examine the effect of patient plasma on healthy 
neutrophils, whole blood was collected from HC; 750, 000 (7.5x 105) neutrophils were 
isolated and incubated at 37°C with 100 µL of patient plasma for 2 hours. Granulocytes 
were isolated from whole blood using Polymorphprep™ solution as mentioned 
previously. The ratio of neutrophils and patient plasma was determined by calculating 
the average neutrophil count in PALF patients. To determine the influence of 
endogenous DNA on neutrophil TLR9, patient plasma was pre-treated with DNAse-I 
(5µg) for 30 minutes at 37°C before incubating them with healthy neutrophils 
separately. The time and concentration of DNAse-I enzyme were optimised based on the 
assays performed in the lab. Following the 2 hour incubation, cells were washed with 
PBS and stained with antibodies and analysed by flow cytometry. The panel of 
antibodies used for characterising neutrophil phenotype and IL-8 expression in 
neutrophils are given in appendix table – 2. 
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2.18. Cytokine level determination 
Pro- and anti-inflammatory cytokines [CXCR-8/IL-8, IL-6, IL-10 and TNF-α] levels were 
determined from previously stored plasma and supernatant samples using cytometric 
bead array (CBA). Cytokine levels were quantified using the capture and detection beads 
from different Human Soluble Protein Flex Sets and a Master Buffer Kit. The advantage 
of using a CBA is it measures multiple cytokines with fewer sample dilutions in a short 
time. There was no variability between the experiments, since all the samples were 
analysed in a single batch. 
2.18.1. Preparation of standards 
CBA top standards are lyophilised standard spheres which were reconstituted and 
serially diluted and prepared fresh just before the experiment. A lyophilised standard 
sphere from the flex set of each cytokine to be tested, IL-6, IL-8, IL-10 and TNF-α were 
pooled into one 15 mL polypropylene tube and reconstituted with assay diluent. The 
reconstituted standards were allowed to equilibrate for 15 minutes at RT followed by 
gentle mixing using a pipette. A serial dilution was performed by transferring 500 µL of 
top standard with equal volume of assay diluent to 1:2 dilution and then further up to 
1:256.  Assay diluent was used to serve as the 0-pg/mL. 
2.18.2. Preparation of capture and detection beads 
Based on the instruction manual provided by the manufacturer, equal volumes (50µL) of 
capture bead and detection bead were used for testing the plasma or supernatants and 
the beads were 50x concentration. After optimising this experiment in our laboratory, I 
found that the capture and detection beads yield a good result when diluted 100 times. 
All the beads were mixed using a vortex for 15 seconds just before use. 
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2.18.2.1. Capture bead 
The procedure for capture beads preparation was different for supernatant samples 
compared to the plasma, therefore the total bead volume was calculated based on the 
number of samples (including standards) and cytokines measured for each experiment. 
For plasma samples: 
The appropriate amount of capture beads (as shown below) from the stock vials of each 
Human Soluble Protein Flex Set were pooled into a 15-mL polypropylene tube and 0.5 
mL of wash buffer was added to them. The tube was then centrifuged at 200 g for 5 
minutes and the supernatant was discarded by carefully aspirating it without disturbing 
the bead pellet. The bead pellet was then re-suspended in capture bead diluent to a final 
concentration of 50 µL / test. 
An example calculation: 
No. of tests – 50; Volume of capture beads from each flex set – 25 µL; No. of flex sets 
(cytokine beads) – 4; final concentration – 50 µL 
Therefore Total bead volume = 50 No. of tests x 50 µL of final concentration = 2500 µL 
For supernatants: 
The appropriate amount of capture beads (as shown below) from the stock vials of each 
Human Soluble Protein Flex Set were pooled into a 15-mL polypropylene tube and 
mixed with capture bead diluent. The final concentration of capture bead volume was 50 
µL / test. The volume of the capture bead diluent was calculated by subtracting the 




An example calculation: 
No. of tests – 50; volume of capture beads from each flex set – 25 µL; final concentration 
– 50 µL; No of flex sets (cytokine beads) – 4 
Total bead volume = No. of tests – 50 x Final concentration – 50 µL = 2500 µL 
So when 4 cytokines were tested, diluent volume = 2500 µL – (25 µL x 4) = 2400 µL 
2.18.2.2. Detection bead 
The procedure for detection bead preparation was the same for supernatant samples 
and plasma. Therefore the appropriate amount of detection beads (as shown below) 
from the stock vials of each Human Soluble Protein Flex Set were pooled into a 15-mL 
polypropylene tube and mixed with detection bead diluent. The final concentration of 
detection bead volume was 50 µL/test. The volume of the detection bead diluent was 
calculated by subtracting the volume for each bead tested from the total bead volume 
required for the assay. 
An example calculation: 
No. of tests – 50; Volume of detection beads from each flex set – 25 µL; No of flex sets 
(cytokine beads) – 4; Final concentration – 50 µL 
Total bead volume = No. of tests – 50 x Final concentration – 50 µL = 2500 µL 
When 4 cytokines were tested, diluent volume = 2500 µL – (25 µL x 4) = 2400 µL 
2.18.3. Assay procedure 
The assay was performed on tubes and 50 µL of flex standards starting from 0 to 2000 
pg/mL (top standard) and plasma and supernatant samples were placed in FACS tubes. 
The mixed capture beads were vortexed for at least 5 seconds and 50 µL was added to 
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the standards and samples. The tubes were mixed gently and incubated at RT in 
darkness. After an hour, the mixed PE detection reagent was vortexed for at least 5 
seconds and 50 µL was added to all the tubes. The tubes were mixed gently and left to 
incubate at RT in darkness. After two hours of incubation, 1 mL of wash buffer was 
added to all the tubes and centrifuged at 200g for 5 minutes. The supernatant was 
discarded carefully and the beads were re-suspended in 300 µL of wash buffer for flow 
cytometry analysis. 
2.18.4. Sample acquisition and analysis 
All samples were acquired in the BD FACS CantoII flow cytometer using the BD FACS 
DIVA software. Compensation was performed using the instrument setup beads 
provided along with the Master Buffer Kit, to avoid spectral overlap. Standards were 
acquired starting from negative or 0-pg/mL to top standard or 2000 pg/mL followed by 
the plasma or supernatant samples. Files were saved as FCS 3.0 and the results were 
analysed using the FCAP array software. 
2.19. Neutrophil function 
2.19.1. Neutrophil phagocytic activity 
2.19.1.1. Principle and assay procedure 
Neutrophil phagocytic activity (NPA) was determined using a Phagotest kit, using FITC-
labelled opsonised E. coli bacteria. For this experiment, 100 µL of whole blood was 
incubated in a water bath at 37°C in darkness for 20 minutes with 20 µL of FITC labelled 
opsonized E. coli along with a control (PBS). Ice cold trypan blue was added to all the 
tubes and left at RT for 20 minutes to quench the fluorescence of bacteria attached to the 
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cell surface. Cells were washed with PBS by gently mixing with a pipette, centrifuged at 
600g for 5 minutes and the supernatant was discarded. Red blood cells were lysed using 
a lysis buffer as mentioned previously. Four µL of fluorochrome conjugated antibody 
CD16 (PE) was added to the tube containing FITC E. coli and the control tube incubated 
at RT in darkness for 30 minutes. Cells were washed with 2 mL of PBS, centrifuged at 
600g for 5 minutes and the supernatant was discarded to remove the excess antibody. 
Three hundred µL of PBS was added to all the tubes and acquired in a flow cytometer. A 
negative control tube (100 µL of whole blood) was treated in similar conditions without 
the addition of FITC-labelled E. coli and CD16-PE. An overview of the NPA experiment is 
summarised in Table – 2.2. 
Table 2.2: Stimulation of neutrophils with E. coli to determine NPA. 
 Negative Tube – 1 Tube – 2 
Whole blood 100 µL 100 µL 100 µL 
FITC-labelled E. coli -- -- 20 µL 
PBS 20 µL 20 µL -- 
All tubes were incubated at 37°C in a water bath for 20 minutes 
Trypan blue 
(Quenching soln.) 
100 µL 100 µL 100 µL 
All tubes were left at RT in darkness for 20 minutes 
Red blood cell Lyse 
solution 
1.5 mL 1.5 mL 1.5 mL 
CD16 (PE) -- 4 µL 4 µL 




2.19.1.2. Flow cytometer set up for NPA experiment 
In the DIVA software, a new experiment was created and the specimen tubes were 
labelled as negative, tube – 1 and tube – 2.  In the inspector, settings were adjusted to 
show FSC-A, SSC-A, FITC and PE in the panel. In the global worksheet, a dot plot with 
FSC-A (X-axis) and SSC-A (Y-axis) was created. Cells in the negative tube were acquired 
and the FSC/SSC voltages were adjusted between 250 - 400 V to identify the white blood 
cells in the dot plot. The large population in the dot plot was identified as granulocytes 
[Figure 2.9]. Another dot plot with CD16-PE (X-axis) and SSC-A (Y-axis) were created 
showing the granulocytes. While cells from tube – 1 (without FITC E. coli) were acquired, 
granulocytes expressing CD16+ were gated and identified as CD16+ neutrophils. A 
histogram with FITC E. coli showing CD16+ neutrophils was created and voltages in the 
FITC channel were adjusted to show the CD16+ neutrophils over 102 in the FITC-
histogram plot or CD16+ neutrophils showing an MFI of 100+10 in the statistics view. In 
the histogram, an interval gate was fixed next to the population to identify the cells 
undergoing phagocytosis [Figure 2.10]. Cells from tube – 2 were acquired with the 
voltages adjusted based on tube – 1 to identify the neutrophils undergoing phagocytosis 



















2.19.2. Phagoburst assay 
2.19.2.1. Principle and assay procedure 
Neutrophil oxidative burst (OB) was determined with a Burst kit using different 
stimulants and dihydrorhodamine as fluorogenic substrate. Reactive oxygen species 
(ROS) produced by phagocytic neutrophils convert dihydrorhodamine to rhodamine, 
therefore oxidative burst of neutrophils was determined by measuring the converted 
rhodamine using a flow cytometer indirectly. 
Neutrophil low burst (LB) was assessed by stimulating the whole blood using 20 µL of 
chemotactic synthetic peptide, formyl-Met-Leu-Phe (fMLP) (0.2µM) and high burst (HB) 
was assessed by stimulating whole blood using 20 µL of PMA (0.2µM), a protein kinase C 
activator. Neutrophil phagoburst (PB) was assessed by stimulating the whole blood with 
20 µL of E. coli (2x107) while spontaneous oxidative burst (SOB) was assessed by adding 
20 µL of PBS to the whole blood. To measure the ROS production, 20 µL of 
dihydrorhodamine was added to all the tubes and incubated in a water bath at 37°C in 
darkness for 20 minutes. Whole blood without dihydrorhodamine was added to a tube 
separately as a control. Cells were washed with 1 mL of PBS by gently mixing with a 
pipette, centrifuged at 600g for 5 minutes and the supernatant was discarded. Red blood 
cells were lysed using a lysis solution as mentioned previously. Four µL of fluorochrome 
conjugated antibody CD16 (PE) was added to all the tubes and incubated at RT in 
darkness for 30 minutes. Cells were washed with 2 mL of PBS, centrifuged at 600g for 5 
minutes and the supernatant was discarded to remove the excess antibody. Three 
hundred µL of PBS was added to all the tubes and acquired in a flow cytometer. A 
negative control (100 µL of whole blood) was treated in similar conditions without the 
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addition of dihydrorhodamine and CD16-PE. An overview of the neutrophil OB 
experiment is summarised in Table – 2.3. 
Table 2.3: Stimulation with fMLP, PMA and E. coli to determine Neutrophil 
OB. 
 Negative Tube – 1 Tube – 2 Tube – 3 Tube – 4 Tube – 5 
Whole blood 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
PBS 20 µL 20 µL 20 µL -- -- -- 
fMLP -- -- -- 20 µL -- -- 
PMA -- -- -- -- 20 µL -- 
E. coli -- -- -- -- -- 20 µL 
All tubes were incubated at 37°C in a water bath for 20 minutes 
Dihydrorhodamine -- -- 20 µL 20 µL 20 µL 20 µL 
All tubes were incubated at 37°C in a water bath for 20 minutes 
Red blood cell Lyse 
solution 
1.5 mL 1.5 mL 1.5 mL 1.5 mL 1.5 mL 1.5 mL 




2.19.2.2. Flow cytometer set up for neutrophil oxidative burst 
experiment 
In the DIVA software, a new experiment was created and the specimen tubes were 
labelled as negative, tube – 1, 2, 3, 4 and 5. In the inspector, settings were adjusted to 
show FSC-A, SSC-A, rhodamine and PE in the panel. In the global worksheet, a dot plot 
with FSC-A (X-axis) and SSC-A (Y-axis) was created. Cells in the negative tube were 
acquired and the FSC/SSC voltages were adjusted between 250 - 400 V to identify the 
white blood cells in the dot plot. The large population in the dot plot was identified as 
granulocytes. Another dot plot with CD16-PE (X-axis) and SSC-A (Y-axis) were created 
showing the granulocytes [Figure 2.12]. While cells from tube – 1 (without rhodamine) 
were acquired, granulocytes expressing CD16+ were gated and identified as CD16+ 
neutrophils. A histogram with rhodamine showing CD16+ neutrophils was created and 
voltages in the rhodamine channel were adjusted to show the CD16+ neutrophils over 
102 in the rhodamine-histogram plot or CD16+ neutrophils showing an MFI of 100+10 in 
the statistics view. In the histogram, an interval gate was fixed next to the population to 
identify the cells undergoing phagocytosis [Figure 2.13]. Cells from tube – 2 were 
acquired with the voltages adjusted based on tube – 1 to identify the neutrophils 





















2.20. Endotoxin measurement 
Endotoxin levels were measured in the plasma samples stored at -80°C, using the 
Toxisensor Chromogenic Limulus Amoebic Lysate (LAL) Endotoxin Assay (Genscript, 
UK). This method detects endotoxin based on a chromogen using a modified LAL and a 
synthetic substrate. This kit is very sensitive and can measure from 0.005 to 1 endotoxin 
unit / mL (EU/mL). This assay was performed based on the protocol booklet provided 
along with the kit. 
2.21. Animals used for in-vivo experiments 
All the animals used for this experiment were bred and maintained at the animal facility 
in Yale University, USA. The animals used for this study were categorised under United 
States Department of Agriculture (USDA) category E of pain and distress. The 
experiments were performed and animals were sacrificed after obtaining the approval 
of the Institutional Animal Care and Use Committee (IACUC) at Yale University. All the 
animals were sacrificed under anaesthesia (appendix table – 11) and treated with 
minimal or no pain and distress. 
For in-vivo experiments, C57/Black 6 (C57/B6) mice between seven to nine weeks of 
age were used. Four different strains, wild type (WT), TLR9-/-, TLR9flox/flox LysCre 
(TLR9fl/fl LysCre) and TLR9flox/flox (TLR9fl/fl) mice were used for this experiment. WT 
B6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine, USA) and have 
been breeding and maintained by Li Wen’s laboratory at the animal facility in Yale 
University for more than eight years. The original TLR9-/- B6 mice were obtained from 
Shizuo Akira, Japan, who originally developed this strain and the mice used for this 
experiment have been breeding and maintained by Li Wen’s laboratory for more than 10 
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years. The original TLR9fl/fl B6 mice and TLR9fl/fl LysCre B6 mice were obtained from 
Prof Mark Schlomchik’s laboratory at Pittsburgh University and the mice used for this 
experiment have been breeding and maintained at Li Wen’s laboratory for more than 2 
years. 
2.22. Breeding and maintenance conditions 
All animals were bred in specific pathogen-free (SPF) conditions and were fed on a 
regular chow diet with no other special needs. For breeding any particular strain, one 
male and two females were left in a separate cage until a female mouse became 
pregnant. The pregnant mother was then left in the same cage whilst the others were 
changed to a different cage. The mice used for breeding were not used for any 
experiment. The newborn pups were left with the mother until they were three weeks 
old. After three weeks of birth, mice were separated as male and females and left in 
different cages until the time of experiment. Only male mice were used for the 
experiment. 
2.23. Mouse genotyping 
Mice genotyping was usually performed within seven days of birth to identify the strain 
of each mouse. Since these strains have been maintained for a long time and many 
generations have been raised by this group, genotyping was performed only in the 
breeders. This was usually performed by an animal care technician on a regular basis; I 
performed this on some of the animals to learn this technique and also at other times 
when the technician was absent. 
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2.23.1. Isolation of DNA from the mouse tail 
To perform genotyping, mice tails (~1cm) were clipped and placed in a 1.5 mL 
Eppendorf. The tail was then mixed with digesting buffer (500 µL) (appendix table – 14) 
and pronase (450 µg) and left in a 55°C water bath for overnight incubation. Saturated 
sodium chloride (1 litre) was added to the samples incubated overnight and mixed well 
after they were cooled in 4°C. Samples were then centrifuged at 16000g for 15 minutes 
at 4°C and the nucleic acid containing supernatant was transferred to another 1.5 mL 
tube. The tube was then filled with 100% ethanol and mixed by inverting the tube 
several times and the DNA was seen like a hair ball structure in the tube. The tubes were 
then centrifuged at 16000g for 15 minutes at 4°C and the supernatant was discarded. 
The DNA pellet was re-suspended with 70% ethanol (500 µL) and centrifuged at 16000g 
for 5 minutes at 4°C. The supernatant was discarded and the DNA pellet was left at RT 
until it was completely dry. The pellet was then re-suspended with 100 µL of de-ionised 
water and incubated in a water bath at 37°C for overnight and stored in 4°C. 
2.23.2. Molecular genotyping 
A PCR master mix comprising de-ionised water, buffer (1x), primers (100µM), dNTPs 
(10mM) and Taq DNA polymerase was prepared and placed in a 96-well PCR plate and 
added to the DNA extracted from the mice tail clipping. After mixing it by gentle 
pipetting, 10ul of the sample was loaded onto a 1% agarose gel with the respective 
positive and negative controls loaded on separate wells. The 1% agarose gel was 
prepared earlier by dissolving one gram of agar in 100 mL of de-ionised water by 
heating, 3 µL of ethidium bromide was added to the agar solution after it was cooled and 
poured on a tray and solidified. After running the samples for 20 minutes using 
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electrophoresis, a photograph of the gel was taken using a gel document. The samples 
positive for a particular genotype expressed a band similar to the positive control in the 
gel [Figure 2.15]. 
 
Figure 2.13: Gel images of TLR9-/- B6 mice, TLR9fl/fl B6 mice and TLR9fl/fl 
LysCre B6 mice to identify their genotype. 
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2.24. Stimulation with ammonium acetate 
Stimulation with 12mmol/kg of ammonium acetate (NH4COONH3) (NH4-Ac) in the mice 
resulted in severe convulsions and death. To determine whether TLR9 plays a role in the 
brain oedema in the mice, ammonium acetate (NH4-Ac) (4 mmol/kg of bodyweight) was 
injected intraperitoneally and stimulated for six hours in wild type (WT) B6 mice, TLR9-
/- B6 mice, TLR9flox/flox LysCre (TLR9fl/fl LysCre) mice and TLR9flox/flox (TLR9fl/fl) 
mice.  
2.24.1. Optimisation of ammonium acetate 
Stimulation with 12 mM/kg of NH4-Ac resulted in seizure and death of the WT-B6 mice, 
whereas 7 mM/kg caused immune cell death within 15 minutes. Therefore to optimise 
the concentration and time of NH4-Ac required for in-vivo stimulation, different 
concentrations of NH4-Ac between 1 and 4 mM/kg were injected intraperitoneally in 
WT-B6 mice. Changes in neutrophil phenotype [TLR9] were measured using flow 
cytometry to determine the influence of NH4-Ac at different time points up until 24 
hours following the stimulation in those mice. There was no difference in pH in the 
plasma and urine samples collected before and after the stimulation of NH4-Ac. 
There was an increasing trend in the neutrophil TLR9 expression as measured by mean 
fluorescent intensity (MFI) following the stimulation of 1, 2, 3 and 4 mM/kg of NH4-Ac 
with time until 6 hours and this returned to baseline after 8-hour time point. There was 
no difference in the neutrophil TLR9 expression between these concentrations [Figure 
2.16]. Based on the results, 4 mM/kg of bodyweight of NH4-Ac for 6 hours was used for 
the experiments. There was a decreasing trend in the neutrophil TLR4 expression as 
measured by mean fluorescent intensity (MFI) following the stimulation of 1, 2, 3 and 4 
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mM/kg of NH4-Ac with time until 6 hours and this returned to baseline after 8-hour time 
point. There was no difference in the neutrophil TLR4 expression between these 
concentrations [data not shown]. 
 
Figure 2.14: Titration curve showing the changes in neutrophil TLR9 MFI in 
mice following escalating doses of NH4-Ac stimulation at different time 
points. 
2.25. Stimulation with sodium acetate 
To determine whether the brain oedema and inflammation were induced by ammonia 
per se and not influenced by acetate or changes in pH, sodium acetate (CH3COONa) (Na-
Ac) (4 mmol/kg of bodyweight) was injected intraperitoneally and stimulated for six 
hours in wild type (WT) B6 mice. 
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2.26. Blood collection and tissue harvesting 
Six hours after the NH4-Ac stimulation, mice were anaesthetised according to the 
guidelines. Blood was collected from the retro-orbital region using a heparinised blood 
tube and was stored at 4°C and cervical dislocation was performed after blood collection 
to ensure the animals were dead before the tissues were harvested. This method was 
performed mainly because this was easier for me and also this allowed me to harvest the 
brain used for the measurement of water content without containing any blood. 
Immediately after the mouse death the circulatory blood clots, therefore the liver was 
quickly injected with PBS (1x) using a 5 mL syringe and 25G needle through the portal 
vein to remove any circulating immune cells. The injected PBS was flushed from 
circulation by puncturing the systemic vein using a needle. Liver weight was measured 
using an electronic balance and the tissue was placed in ice-cold media (RPMI 1640), 
until they were processed further. Spleen and mesenteric lymph nodes (MLN) were 
harvested next and placed in ice-cold media, until they were processed further. Femur 
and tibia bones of the mice were collected and placed in ice-cold media, until they were 
processed further. The head of the mouse was cut separately from the body and placed 
in a petri dish at RT to harvest the brain. 
2.26.1. Storage of plasma 
Plasma was collected from the mouse blood and stored in a 1.5 mL Eppendorf at -80°C 
as mentioned previously. 
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2.26.2. Isolation of immune cells from tissues 
2.26.2.1. Homogenisation and isolation of immune cells from liver 
Liver tissue was homogenised using a plunge through a wire mesh. The homogenised 
tissue was then incubated with liver digestion solution (appendix table 11) for 45 
minutes at 37°C in a water bath. The digested tissue was centrifuged at 600g for 5 
minutes at 18°C and the supernatant was stored in -80°C. The sedimented pellet was 
mixed with 3 mL of 40% Polymorphprep™ solution (appendix table 11) and layered over 
3 mL of 70% Polymorphprep™ solution (appendix table 11) in a 15 mL falcon tube. The 
tubes were then centrifuged at 1000g for 20 minutes at 18°C. The immune cells that 
formed a layer at the interface of the two density-gradient solutions were carefully 
isolated using a pipette. The isolated cells were then washed with 10 mL of PBS and 
centrifuged at 600g for 5 minutes at 18°C. The supernatant was discarded and cells were 
suspended in PBS (1x) and the viable cells were counted using Trypan blue as 
mentioned previously. The immune cells were then stained to determine the phenotype 
and intracellular cytokine production of T cells. 
2.26.2.2. Homogenisation and isolation of immune cells from spleen 
The spleen was cut into small pieces and the tissue was homogenised using the rough-
edge of two grinding slides. The homogenised cells were centrifuged at 600g for 5 
minutes at 18°C and the supernatant was discarded. The sedimented cell pellet was re-
suspended and red blood cells were lysed using distilled water as mentioned previously. 
The cells were suspended in PBS (1x) and the viable cells were counted using Trypan 
blue. The immune cells were then stained with flow cytometry antibodies to determine 
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the phenotype and intracellular cytokine production of T cells, NK cells and 
macrophages. 
2.26.2.3. Homogenisation and isolation of immune cells from MLN 
The MLN were homogenised using the rough-edge of two grinding slides. The 
homogenised cells were centrifuged at 600g for 5 minutes at 18°C and the supernatant 
was discarded. Cells were re-suspended in PBS (1x) and the viable cells were counted 
using Trypan blue. The immune cells were then stained with flow cytometry antibodies 
to determine the phenotype and intracellular cytokine production of T cells. 
2.26.2.4. Homogenisation and isolation of immune cells from bone 
marrow 
To isolate the immune cells from bone marrow, the femur and tibia bones were flushed 
with PBS (1x) using a 3 mL syringe and 30G needle and the cells were then homogenised 
by mixing them using a syringe. The homogenised cells were centrifuged at 600g for 5 
minutes at 18°C and the supernatant was discarded. The sedimented cell pellet was re-
suspended and red blood cells were lysed using distilled water as mentioned before. The 
cells were suspended in PBS (1x) and the viable cells were counted using Trypan blue. 
The immune cells were then stained with flow cytometry antibodies to determine the 
phenotype of T cells and NK cells. 
2.26.2.5. Processing of brain tissue 
After removing the skin over the head, the skull was opened and the whole brain was 
carefully removed without any damage. The brain is divided into regions and the water 
content is assessed from different areas of the brain. Since I did not have the training to 
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handle the brain tissue, I chose to examine the whole brain. The entire brain was 
weighed immediately using an electronic balance to determine the wet weight. The 
brain was then dried in an oven at 100°C for 24 hours to obtain the dry weight. The 
brain water content was then calculated according to the formula: 
Brain water content (%) = Wet weight – Dry weight x 100 
Wet weight 
2.26.2.6. Preservation of tissues for histopathological examination 
For histopathological examination of animal tissues, the mice were anaesthetised and 
the abdomen was cut open from the neck to the intestine region. To remove the systemic 
blood, PBS (1x) was injected through the left ventricle and flushed by puncturing the 
right atrium. When the liver and lungs turned from red to pale, it was an indicator that 
the organs were flushed and were devoid of any blood. Ten percent formalin was 
injected through the left ventricle for ten minutes and the animal was left on the table 
for 30 minutes for the tissues to be fixed properly. Brain and liver were harvested and 
stored in a container with 10% formalin at RT. This method was performed to mainly 
isolate the brain tissues without any damage for histopathological examination. 
Specimens were then processed routinely, embedded in paraffin and stained with 
haematoxylin and eosin (H & E). 
Immunohistochemistry for detection of TLR9 in astrocytes was performed using anti-
TLR9 and S-100 (for astrocytes) antibodies. 
2.27. Total DNA estimation 
Total DNA was measured from the plasma samples stored in -80°C using the Quant-iT 
™ PicoGreen® dsDNA quantitation assay according to the manufacturer instructions. 
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Each sample was analyzed by mixing the plasma in a black microtitre plate with the 
reagents provided in the kit. The plates were then read in a plate reader at emission 
wavelength of 520 nm and excitation wavelength of 480 nm. 
2.28. TLR9 antagonist injection 
To determine whether an inhibitor of TLR9 offers protective effect against NH4-Ac 
stimulation, a TLR9 antagonist (ODN2088) (50 µG/mouse), or PBS, were injected 
intraperitoneally in WT-B6 mice immediately following NH4-Ac injection, and 6 hours 
after the stimulation blood was collected and organs were harvested as mentioned 
previously. The time and concentration of ODN2088 were used based on the recently 
established mouse model of paracetamol hepatotoxicity 108. 
2.29. Statistics 
Patient demographics are expressed as median (inter-quartile range), frequency 
(percentage) as appropriate. Student t-test and Friedman’s with Conover’s multiple 
comparison tests are used for hypothesis testing. Mean and 95% confidence intervals 
are reported. Pearson’s and Spearman’s correlations were used for parametric and non-
parametric data, respectively. In the animal studies, for comparisons between NH4-Ac 
stimulated and control group or between two NH4-Ac stimulated groups independent t-
test or Mann-Whitney U test was used; for comparisons between three groups One-way 
ANOVA or Kruskal Wallis with Dunn’s multiple comparison test was used based on the 
normal distribution of the data. All the results are reported as mean or median 
differences with 95% confidence intervals (C.I.). Hypothesis testing was two-tailed at an 
alpha level 0.05. All statistical analyses were performed using SPSS 20.0 for windows; 
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This chapter aims to test the first hypothesis that circulating neutrophil TLR9 
expression is increased in PALF patients with advanced hepatic encephalopathy and 
SIRS resulting from the release of necrotic hepatocyte products, ammonia, DNA and IL-8 
into the circulation.  
3.1. Basic study design 
3.1.1. Patient demographics and clinical parameters 
Twenty four patients with PALF were recruited and their baseline demographics, 
biochemical and physiological parameters are detailed in Tables 3.1 and 3.2. Amongst 
the PALF cohort seven patients (29%) fulfilled King’s College Hospital criteria for poor 
prognosis 174, of whom five underwent successful LT, two died (one died two-days post-
LT) and one recovered spontaneously following plasmapheresis. All patients were 
profoundly unwell with MOF and this was reflected by high organ failure scores. There 
was a significant decrease in arterial ammonia and Model for End-stage Liver Disease 
(MELD) score in PALF patients on days 4 and 7 compared to day 1. There was no 
difference in the ammonia concentrations and other biochemistry parameters in the 
patients based upon severity of HE or SIRS score. Even though microbial cultures were 
negative, all patients were treated empirically on admission with tazocin (piperacillin 
and tazobactam) 4.5 grams every 8 hours (substituted for meropenem 1 gram every 8 
hours if penicillin allergic) and fluconazole 400mg once daily. All PALF patients were 
also treated with a continuous infusion of N-acetyl cysteine following ICU admission for 




Table 3.1: Demographic and clinical data for patients with PALF and HC 
Number HC 
(n=10) 
PALF Day 1 
(n=24) 
PALF Day 4 
(n=20) 
PALF Day 7 
(n=17) 
Median Age (range) 29.5 (23.5 – 41) 36 (33 – 45) 35.5 (32.5 – 46) 35.5 (32.5 – 46) 
Female (%) 3 (30%) 13 (54%) 11 (55%) 9 (53%) 
Transplant-free 90 day survival (%) - 22 (92%) 20 (100%) 17 (100%) 
Met King’s Criteria for LT (%) a - 7 (29%) 1 (5%) 0 
Declined LT due to co-morbidity (%) - 0 0 0 
Underwent LT (%) - 5 (21%) 1 (5%) 0 
Listed for LT but died before graft 
became available (%) 
- 0 0 0 
Listed but survived without LT - 1 (4%) 1 (5%) 1 (5%) 
Died (%) - 2 (8%) b 0 0 






























Number requiring ventilation (%) - 18 (75%) 11 (55%) 9 (53%) 
Number requiring vasopressors (%) - 18 (75%) 10 (50%) 9 (53%) 
Number requiring hemofiltration (%) - 21 (88%) 13 (65%) 11 (65%) 
a - Fulfilled King’s College Hospital Criteria for poor prognosis, b - one patient died post-LT 
Abbreviations: Paracetamol-induced acute liver failure: PALF; Liver transplantation: LT 
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Table 3.2: Biochemical and organ failure parameters for patients with PALF. 
Parameters 
Median (Interquartile range) 
PALF Day 1 
(n=24) 
PALF Day 4 
(n=20) 
PALF Day 7 
(n=17) 
Bilirubin (3-20 µmol/L) 78 (39.8 – 104) 133 (45.5 – 172) 141 (45.5 – 192.5) * 
Albumin (35-50 g/L) 27 (24 – 30.8) 28 (25 – 29) 27 (24 – 28.5) 
INR (0.9-1.2 Ratio) 6.7 (3.4 – 8.9) 1.7 (1.4 – 2) **** 1.2 (1.1 – 1.4) $$ 
Creatinine (45-120 µmol/L) 152.5 (80.3 – 232.5) 122 (70.5 – 176.5) 118 (90 – 201) 
Sodium (135-145 mmol/L) 140 (137 – 146) 140 (138 – 145) 138 (136 – 140) * 
C-reactive Protein (<5.0 mg/L) 10.8 (8.2 – 17.1) 31 (17.6 – 60.4) 46.5 (28.6 – 85.3) ** 
Aspartate aminotransaminase (10-50 IU/L) 5696 (3955 – 9289) 390 (167 – 521) **** 88 (71 – 124) 
Arterial ammonia (<54 µmol/L) 111 (66 – 139) 69 (55 – 102) ** 51 (19 – 56) 
Total white blood cell count (4.0-11.0 x 109/L) 9.2 (5.4 – 11.7) 7.1 (4 – 9.4) 9.4 (6.5 – 14.4) 
Neutrophil count (2.2-6.3 x 109/L) 8.8 (4.8 – 10.1) 5.7 (2.7 – 6.9) 7.3 (5.2 – 11.6) 
Lymphocyte count (1.3-4.0 x 109/L) 0.4 (0.2 – 0.8) 0.9 (0.6 – 1.3) * 1.2 (0.9 – 1.6) 
Lactate (0.5-2.2 mmol/L) 3 (2.3 – 4.3) 1.6 (1.1 – 2) * 1 (0.7 – 1.5) $ 
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Arterial pH (7.38-7.42) 7.4 (7.35 – 7.45) 7.43 (7.39 – 7.45) 7.45 (7.4 – 7.48) 
SIRS Score 36 2 (1 – 2.75) 1 (1 – 2) 2 (0 – 3) 
MELD Score 176 37.9 (31.6 – 42) 23.7 (18.7 – 27.5) **** 19.1 (13.8 – 25.6) $ 
SOFA Score 168 12 (10 – 15) 15 (10 – 18) 16 (13 – 16) 
APACHE II Score 169 19 (15 – 24) 21 (15 -24) 18 (14 – 20) 
 
* - indicates the difference between PALF patients on day 4 compared to day 1. $ - indicates the difference between PALF patients on day 7 
compared to day 4. *, $ - p<0.05; **, $$ - p<0.01; **** - p<0.0001 
Abbreviations: Paracetamol-induced acute liver failure: PALF; Acute Physiology and Chronic Health Evaluation: APACHE; International 
Normalised Ratio: INR; Model for End-stage Liver Disease: MELD; Sequential Organ Failure Assessment: SOFA; Systemic inflammatory 
response syndrome: SIRS. 
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3.2. Neutrophil phenotype 
In PALF, baseline neutrophil surface receptor expression of the FcγRIII molecule CD16 
and the β-integrin CD11b (C3bi), which binds to the surface of opsonised microbes along 
with TLR2, -4 and -9 was determined on days 1, 4 and 7 and compared to HC. CD16 and 
TLR4 expression were significantly decreased in PALF patients on day 1 compared to HC 
(p<0.0001). There was no difference in CD16 expression between PALF patients on days 
1, 4 and 7 [Figure 3.1]. There was no difference in CD11b expression in PALF patients 
compared to HC [Figure 3.2] [Method – 2.14.4.6]. 
Baseline neutrophil TLR4 expression was significantly decreased in PALF patients on 
day 1 compared to HC (p<0.0001). There was no difference in TLR4 expression between 
PALF patients on days 1, 4 and 7 [Figure 3.3]. Baseline neutrophil TLR9 expression was 
significantly increased in PALF patients on day 1 compared to HC (p=0.0002). There was 
no difference in TLR9 expression between PALF patients on days 1, 4 and 7 [Figure 3.4]. 
There was no difference in the baseline neutrophil TLR2 expression in PALF patients 
compared to HC [Figure 3.5]. 
3.3. Plasma endotoxin and cytokines 
Cytokine levels were increased in PALF patients compared to HC. Plasma IL-8 
(p<0.0001), IL-6 (p<0.0001) and IL-10 (p=0.04) were significantly increased in PALF 
patients on day 1 compared to HC. There was no difference in the cytokine levels 
between ALF patients on days 1, 4 and 7 [Figures 3.6 – 3.8] [Method- 2.18]. There was 
no association of cytokines with the recovery in patients with PALF on days 4 and 7. 
Endotoxin levels in sera of all PALF patients and HC were <0.01 EU/ml, the detectable 
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Figure 3.1: Decreased circulating neutrophil CD16 receptor expression in 
patients with PALF on day 1 compared to HC. 
CD16 was significantly decreased in PALF on day 1 (n=21) compared to HC (n=10) (* - 
compared to HC; **** - p<0.0001) [mean: -42589; 95% C.I.: -58223 to -26594 and r2-
0.52]. There was no difference in the CD16 expression in PALF between days 1, 4 and 7. 
Normality assumptions were checked; p<0.05 were considered statistically significant. 
Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s with multiple Conover’s 
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Figure 3.2: Circulating neutrophil CD11b receptor expression in patients 
with PALF on day 1 compared to HC. 
There was no difference in the CD11b expression in patients with PALF on day 1 (n=21) 
compared to HC (n=10). Normality assumptions were checked; p<0.05 were considered 
statistically significant. Student t-test (HC Vs PALF day 1) (normal data) was used to 










H C P A L F  D a y  1 P A L F  D a y  4 P A L F  D a y  7
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0











Figure 3.3: Decreased circulating neutrophil TLR4 expression in patients 
with PALF on day 1 compared to HC. 
Neutrophil TLR4 was significantly decreased in PALF on day 1 (n=21) compared to HC 
(n=10) (* - compared to HC; **** - p<0.0001) [mean: -11075; 95% C.I.: -14047 to -8102 
and r2-0.67]. There was no difference in the TLR4 expression in PALF between days 1, 4 
and 7. Normality assumptions were checked; p<0.05 were considered statistically 
significant. Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s with 
multiple Conover’s testing (PALF day 1 Vs day 4 Vs day 7) (normal data) were used to 
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Figure 3.4: Increased circulating neutrophil TLR9 expression in patients with 
PALF on day 1 compared to HC. 
Neutrophil TLR9 was significantly increased in PALF on day 1 (n=21) compared to HC 
(n=10) (* - compared to HC; *** - p=0.0002) [mean: 4176; 95% C.I.: 1727 to 6625 and r2-
0.3]. Normality assumptions were checked; p<0.05 were considered statistically 
significant. Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s with 
multiple Conover’s testing (PALF day 1 Vs day 4 Vs day 7) (normal data) were used to 
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Figure 3.5: Circulating neutrophil TLR2 expression in patients with PALF on 
day 1 compared to HC. 
There was no difference in the neutrophil TLR2 expression in patients with PALF on day 
1 (n=21) compared to HC (n=10). Normality assumptions were checked; p<0.05 were 
considered statistically significant. Student t-test (HC Vs PALF day 1) (normal data) was 





















Figure 3.6: Increased circulating IL-8 in patients with PALF compared to HC. 
Plasma IL-8 (pg/ml) measured using CBA was significantly increased in PALF on day 1 
(n=21) compared to HC (n=10) (* - compared to HC; *** - p=0.0004) [mean: 177; 95% 
C.I.: 86 to 268 and r2-0.36]. There was no difference in the plasma IL-8 level in PALF 
between days 1, 4 and 7. Normality assumptions were checked; p<0.05 were considered 
statistically significant. Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s 
with multiple Conover’s testing (PALF day 1 Vs day 4 Vs day 7) (normal data) were used 


























Figure 3.7: Increased IL-6 production in patients with PALF compared to HC. 
Plasma IL-6 (pg/ml) measured using CBA was significantly increased in PALF on day 1 
(n=21) compared to HC (n=10) (p<0.0001; * - compared to HC) [mean: 186; 95% C.I.: 21 
to 351 and r2-0.2]. There was no difference in the plasma IL-6 level in PALF between 
days 1, 4 and 7. Normality assumptions were checked; p<0.05 were considered 
statistically significant. Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s 
with multiple Conover’s testing (PALF day 1 Vs day 4 Vs day 7) (normal data) were used 

























Figure 3.8: Increased IL-10 production in patients with PALF compared to HC. 
Plasma IL-10 (pg/ml) measured using CBA was significantly increased in PALF on day 1 
(n=21) compared to HC (n=10) (* - compared to HC; * - p=0.04) [mean: 65; 95% C.I.: 0.5 
to 130 and r2-0.15]. There was no difference in the plasma IL-10 level in PALF between 
days 1, 4 and 7. Normality assumptions were checked; p<0.05 were considered 
statistically significant. Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s 
with multiple Conover’s testing (PALF day 1 Vs day 4 Vs day 7) (normal data) were used 
to analyse the data. 
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3.4. Relationship of TLR9 with ammonia and IL-8 
There was a positive correlation between peak arterial ammonia and neutrophil TLR9 
expression in patients with PALF on day 1 (r=0.63; p=0.005) [Figure 3.9]. There was also 
a positive correlation between plasma IL-8 and TLR9 in patients with PALF on day 1 
(r=0.6; p=0.012) [Figure 3.10]. There was no significant correlation between neutrophil 
TLR4 expression and arterial ammonia or plasma IL-8 [Figures 3.11 and 3.12]. There 
was no correlation between arterial ammonia and plasma IL-8 levels (data not shown). 
As one patient underwent plasmapheresis before sampling and three patient’s pre-
haemofiltration ammonia level was not available, TLR9 expression in these patients was 




















0 5 0 1 0 0 1 5 0 2 0 0 2 5 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0









r = 0 .6 3 ;
p < 0 .0 0 5
 
Figure 3.9: Correlation between neutrophil TLR9 expression and peak 
arterial ammonia in patients with PALF on day 1. 
There was a direct correlation between peak arterial ammonia and TLR9 MFI in the 
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Figure 3.10: Correlation between neutrophil TLR9 expression and plasma IL-
8 in patients with PALF on day 1. 
There was a direct correlation between plasma IL-8 and neutrophil TLR9 MFI in PALF 
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Figure 3.11: Relation between neutrophil TLR4 expression and peak arterial 
ammonia in patients with PALF. 
There was no significant correlation between arterial ammonia and neutrophil TLR4 
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Figure 3.12: Relation between neutrophil TLR4 expression and plasma IL-8 
in patients with PALF on day 1. 
There was no significant correlation between plasma IL-8 and neutrophil TLR4 MFI in 
PALF on day 1. 
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3.5. Neutrophil TLR9 and IL-8 expression and severity of HE and SIRS 
score 
The correlation between TLR9 and arterial ammonia and plasma IL-8 in PALF led us to 
investigate the association between severity of SIRS (scores: 0-1 versus 2-4) and (i) 
neutrophil TLR9 expression and (ii) plasma IL-8 concentration. Neutrophil TLR9 
expression was significantly higher in patients with high SIRS score (2-4) on day 1 
(p=0.04) and 7 (p=0.007), compared to those with low SIRS score (0-1) [Figure 3.13]. 
Neutrophil TLR9 expression was then compared amongst PALF patients cohorted based 
upon HE grade (grades: 0-2 versus 3/4). On day 1, TLR9 was significantly higher in 
patients with advanced (grade 3/4) HE compared to those with milder (grade 0-2) HE 
(p=0.006) [Figures 3.14 and 3.15]. Neutrophil TLR9 expression in relation to both SIRS 
score and HE grade was reflected in the plasma IL-8 levels. On day 1, plasma IL-8 was 
significantly higher in patients with SIRS score 2-4 or advanced HE (grade 3/4) 
compared to those with SIRS score 0-1 (p=0.004) or milder HE (grade 0-2) (p=0.03) 
[Figures 3.16 and 3.17]. There was no difference observed in other cytokines based 
upon SIRS score or HE grade. Amongst the PALF day 1 patients, 72.3% of those with low 
SIRS score developed mild HE and 75% of those with high SIRS score developed 
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Figure 3.13: High SIRS score (2-4) was associated with increased neutrophil 
TLR9 expression in patients with PALF. 
Neutrophil TLR9 expression was significantly increased in PALF patients with high SIRS 
score (2-4) on days 1 (n=11) (p=0.04) [mean: 3206; 95% C.I.: 129 to 6284 and r2-0.2] 
and -7 (p=0.007), compared to low SIRS score (0-1) (n=11). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test (SIRS: 0 - 1 Vs SIRS: 2 - 4) (normal data) was used 
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Figure 3.14: Advanced HE (grade 3/4) was associated with increased 
neutrophil TLR9 expression in patients with PALF. 
Neutrophil TLR9 expression was significantly increased in patients with PALF on day 1 
with advanced HE (grade 3/4) (n=12) compared to milder HE (grade 0-2) (n=10) 
(p=0.006) [mean: 3818; 95% C.I.: 1284 to 6352 and r2-0.5]. Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test (HE: 0 - 2 Vs HE: 3 - 4) (normal data)was used to 






Figure 3.15: Representative FACS plots and histograms of neutrophil TLR9 
expression amongst PALF patients on day 1. 
These are the FACS plots (left panels) and histograms (right panels) of TLR9 in 
neutrophils showing increased expression in PALF patients with HE: 3 – 4 (bottom 
panels) compared to PALF patients with HE: 0 – 2 (top panels). TLR9 expression was 
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Figure 3.16: High SIRS score (2-4) was associated with increased plasma IL-8 
in patients with PALF. 
Plasma IL-8 was significantly higher in PALF on day 1 in those with high SIRS score (2-4) 
(n=11) compared to low SIRS score (0-1) (n=11) (p=0.004) [mean: 170; 95% C.I.: 61.5 to 
279 and r2-0.39]. Normality assumptions were checked and the data are expressed as 
mean with S.D.; p<0.05 were considered statistically significant. Student t-test (SIRS: 0 - 
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Figure 3.17: Advanced HE (grade 3/4) was associated with increased plasma 
IL-8 in patients with PALF. 
 Plasma IL-8 was significantly increased in PALF on day 1 in those with advanced HE 
(grade 3/4) (n=12) compared to milder HE (grade 0-2) (n=10) (p=0.03) [mean: 136; 
95% C.I.: 15 to 257 and r2-0.25]. Normality assumptions were checked and the data are 
expressed as mean with S.D.; p<0.05 were considered statistically significant. Student t-
test (HE: 0 - 2 Vs HE: 3 - 4) (normal data) was used to analyse the difference. 
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3.6. Neutrophil response to IL-8 and NH4Cl stimulation and patients’ 
plasma 
When HC neutrophils were stimulated with either IL-8 or NH4Cl no change in TLR9 
expression was observed. However TLR9 expression was significantly increased when 
the neutrophils were co-stimulated with NH4Cl and IL-8 at 125 and 250 pg/ml, 
compared to baseline (p<0.05), stimulation with IL-8 at 125 pg/ml alone (p<0.05) and 
NH4Cl alone (p<0.05) [Figure 3.18] [Method – 2.16]. 
There was a significant increase in TLR9 expression when HC neutrophils were 
incubated with PALF plasma compared to unstimulated cells (p=0.01) and there was a 
significant decrease in TLR9 expression when those plasma samples were pre-incubated 
with DNase-I (p=0.0003) [Figure 3.19]. The changes in TLR9 reflected neutrophil 
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Figure 3.18: Upregulation of TLR9 in healthy neutrophils following 
stimulation with NH4Cl and IL-8. 
Neutrophil TLR9 expression was significantly increased following co-stimulation with 
IL-8:125 and NH4Cl compared to unstimulated (p=0.03) [mean: 2667; 95% C.I.: 423.2 to 
4911 and r2-0.73], NH4Cl alone (p=0.01) [mean: 3303; 95% C.I.: 1256 to 5350 and r2-
0.83] and IL-8:125 alone (p=0.016) [mean: 2134; 95% C.I.: 662 to 3606 and r2-0.8]. 
Neutrophil TLR9 expression was also significantly increased following co-stimulation 
with IL-8:250 and NH4Cl compared to unstimulated (p=0.015) [mean: 1915; 95% C.I.: 
618 to 3213 and r2-0.8], NH4Cl alone (p=0.03) [mean: 2551; 95% C.I.: 457 to 4645 and 
r2-0.74] and IL-8:250 alone (p=0.03) [mean: 1749; 95% C.I.: 284 to 3214 and r2-0.8]. 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. Student t-test was used to analyse the 
differences between two groups (normal data). 
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                                                                        (a)                                                                                                             (b) 
Figure 3.19: Upregulation of TLR9 in healthy neutrophils following stimulation with PALF plasma. 
(a) Neutrophil TLR9 expression was significantly increased when neutrophils from a HC were incubated with PALF plasma (patients who 
fulfilled King’s criteria for liver transplantation, n=6) compared to unstimulated cells (p=0.01) [mean: 559; 95% C.I.: 186 to 932 and r2-0.74]. 
(b) Neutrophil TLR9 expression was significantly decreased when neutrophils from a HC were incubated with PALF plasma pre-incubated 
with DNase-I (p=0.0003) [mean: 1644; 95% C.I.: -2133 to -1155 and r2-0.94]. Normality assumptions were checked; p<0.05 were considered 
statistically significant. Paired t-test was used to analyse the difference (normal data). 
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                                                                        (a)                                                                                                             (b) 
Figure 3.20: Changes in intracellular IL-8 in healthy neutrophils following exposure to PALF plasma. 
(a) Neutrophil intracellular IL-8 expression was significantly increased when neutrophils from a HC were incubated with PALF plasma 
(patients who fulfilled King’s criteria for liver transplantation, n=6) compared to unstimulated cells (p=0.0003) [mean: 190; 95% C.I.: 136 to 
245 and r2-0.94]; (b) Neutrophil intracellular IL-8 expression was significantly decreased when neutrophils from a HC were incubated with 
PALF plasma pre-incubated with DNase-I enzyme (p<0.0001) [mean: -228; 95% C.I.: -279 to -177 and r2-0.96]. Normality assumptions were 
checked; p<0.05 were considered statistically significant. Paired t-test was used to analyse the difference (normal data). 
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3.7. Ex-vivo stimulation of neutrophils with LPS, NH4Cl and ODN 2395 
Following NH4Cl or LPS stimulation, neutrophil TLR9 expression remained unchanged in 
HC and PALF patients with low SIRS score (0-1) on day 1 compared to unstimulated 
cells. Whereas neutrophil TLR9 expression was downregulated significantly in PALF 
patients with high SIRS score (2-4) on day 1 (p<0.05) compared to unstimulated cells 
[Figure 3.21] [Methods – 2.15.2 and 2.15.3].  
Following NH4Cl or LPS stimulation, neutrophil TLR9 expression remained unchanged in 
HC and PALF patients with mild HE (grade 0-2) on day 1 compared to unstimulated 
cells. Whereas neutrophil TLR9 expression was downregulated significantly in PALF 
patients with advanced HE (grade 3/4) on day 1 (p<0.05) compared to unstimulated 
cells [Figures 3.22 and 3.23]. 
Neutrophil TLR9 expression was not changed by stimulation with ODN 2395 
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Figure 3.21: Changes in neutrophil TLR9 expression in PALF patients with 
high SIRS score (2-4) following ex-vivo stimulation with LPS and NH4Cl. 
Neutrophil TLR9 was significantly downregulated in PALF patients with high SIRS score 
(2-4) on day 1 (n=11) in response to NH4Cl [mean: -2728; 95% C.I.: -4712 to -745 and r2-
0.48] and LPS [mean: -4757; 95% C.I.: -9513 to -1.5 and r2-0.65] stimulation compared 
to unstimulated cells (p<0.05; *- compared to unstimulated). There was no change in 
PALF patients with low SIRS score (0-1) on day 1 (n=11) or in HC (n=10) following 
NH4Cl and LPS stimulation. Normality assumptions were checked and the data are 
expressed as mean with S.D.; p<0.05 were considered statistically significant. Paired t-
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Figure 3.22: Changes in neutrophil TLR9 expression and cytokine production 
in PALF patients with advanced HE (grade 3/4) following ex-vivo stimulation 
with LPS and NH4Cl. 
Neutrophil TLR9 was significantly downregulated in PALF patients with high HE score 
(3/4) on day 1 (n=12) in response to NH4Cl [mean: -3469; 95% C.I.: -6919 to -19 and r2-
0.57] and LPS [mean: -3648; 95% C.I.: -9256 to -142 and r2-0.64] stimulation compared 
to unstimulated cells (p<0.05; *- compared to unstimulated). There was no change in 
PALF patients with milder HE score (0-2) on day 1 (n=10) nor in HC (n=10) following 
NH4Cl and LPS stimulation. Normality assumptions were checked and the data are 
expressed as mean with S.D.; p<0.05 were considered statistically significant. Paired t-




       
  
Figure 3.23: Histograms illustrating the TLR9 expression in neutrophils in patients with PALF and HC before and after LPS or 
NH4Cl stimulation. 
These histograms show that neutrophil TLR9 expression is downregulated in PALF patients with HE: grade 3/4 after LPS or NH4Cl stimulation 
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Figure 3.24: Neutrophil TLR9 expression following ex-vivo stimulation with 
ODN 2395. 
Neutrophil TLR9 remained unchanged in PALF patients (n=8) and HCs (n=10) on day 1 
in response to ODN 2395 stimulation compared to unstimulated cells. Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 





3.8. Neutrophil cytokine production in response to stimulation 
Cytokines were measured in the supernatants collected from cells stimulated by NH4Cl 
and/or LPS and compared to unstimulated cells from both HC and PALF patients. There 
was a 400-800 fold increase in TNF-α and IL-8 production following LPS stimulation in 
HC compared to their unstimulated counterparts (p<0.0001). In PALF patients with low 
SIRS score (0-1) on day 1, the cytokine production was increased 40-60 fold compared 
to unstimulated cells (p<0.05). However in PALF patients with high SIRS score (2-4) 
there was no change or a maximum two fold increase in the cytokine production 
compared to their unstimulated counterparts on day 1 [Figure 3.25]. A similar trend was 
observed in the cytokine production following NH4Cl stimulation even though it was not 
in manifold increase [Figure 3.26]. 
Following ODN 2395 stimulation, IL-8 and TNF-α were significantly increased in the 
supernatants in PALF patients on day 1 (p<0.05) compared to HC which were 
unchanged [Figure 3.27]. Intracellular IL-8 expression remained unchanged in PALF 
patients on day 1 compared to HC which were significantly increased (p<0.05) [Figure 
3.28]. Baseline intracellular IL-8 expression was significantly increased in PALF patients 
on day 1 compared to HC [Figure 3.29]. These data are indicative that neutrophils in 





Figure 3.25: Changes in cytokine production in PALF patients following ex-vivo stimulation with LPS. 
IL-8 and TNF-α production was increased 200 to 600 fold following LPS stimulation (both p<0.0001) in HC and increased 40 to 60 fold in 
PALF patients with low SIRS score (0-1) (both p<0.05). There was only a maximum of a two-fold increase in IL-8 and TNF-α production in 
PALF patients with high SIRS score (2-4) on day 1 following the NH4Cl or LPS stimulation. Normality assumptions were checked; p<0.05 were 




Figure 3.26: IL-8 and TNF-α were increased following ex-vivo stimulation with NH4Cl in the neutrophil supernatants of HC and 





Figure 3.27: Changes in supernatant cytokines in PALF patients following ex-
vivo stimulation with ODN 2395. 
Following ODN 2395 stimulation, IL-8 and TNF-α remained unchanged in HC 
supernatants but were significantly increased in PALF supernatants (p<0.05). Normality 
assumptions were checked; p<0.05 were considered statistically significant..Paired t-test 






Figure 3.28: Changes in intracellular neutrophil IL-8 expression following ex-
vivo stimulation with ODN 2395. 
Following ODN 2395 stimulation, intracellular IL-8 was significantly increased 
compared to unstimulated (p<0.05) but remained unchanged in PALF patients on day 1 
compared to its unstimulated counterpart. Normality assumptions were checked; 
p<0.05 were considered statistically significant.. Paired t-test was used to analyse the 
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Figure 3.29: Increased intracellular IL-8 in PALF patients on day 1 compared 
to HC. 
Baseline intracellular IL-8 was significantly increased in PALF patients on day 1 (n=8) 
compared to HC (n=10) (p<0.05) [mean: 319; 95% C.I.: 25 to -613 and r2-0.25]. The data 
are normally distributed and p<0.05 were considered statistically significant. Student t-
test was used to analyse the difference between two groups. 
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3.9. Neutrophil function 
Neutrophil dysfunction has been previously studied in PALF patients by our group 139. 
To confirm these findings amongst the patients recruited for my study, NPA and 
oxidative burst of neutrophils were studied amongst a small cohort of PALF patients at a 
later stage in the study. NPA was significantly decreased in PALF on day 1 compared to 
HC (p<0.0001) significantly improving on days 4 and 7 compared to day 1 (p<0.005) 
(Figure 3.30). Neutrophil SOB was significantly increased in PALF on day 1 compared to 
HC (p<0.0001). There was no difference in the neutrophil SOB between PALF patients 
on days 1, 4 and 7 (Figure 3.31). Neutrophil low burst (LB) and high burst (HB) induced 
by fMLP and PMA respectively was also significantly increased in PALF on day 1 
compared to HC (p<0.05). There was no difference in the neutrophil LB and HB between 
PALF patients on days 1, 4 and 7 (Figures 3.32 – 3.33). There was no difference in the 
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Figure 3.30: Impaired neutrophil phagocytosis in patients with PALF. 
(a) NPA (percentage of neutrophils undergoing phagocytosis) was significantly 
decreased in PALF patients on day 1 (n=11) compared to HC (n=10) (p<0.0001) [mean: -
33.5; 95% C.I.: -47.5 to -19.6 and r2-0.57]. NPA increased in PALF patients on day-4  
compared to day 1 (p<0.005). Normality assumptions were checked; p<0.05 were 
considered statistically significant. Student t-test (HC Vs PALF day 1) (normal data) and 
Friedman’s with multiple Conover’s testing (PALF day 1 Vs day 4 Vs day 7) (normal 
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Figure 3.31: Impaired neutrophil spontaneous oxidative burst in patients 
with PALF. 
Neutrophil SOB was significantly increased in PALF patients on day 1 (n=11) compared 
to HC (n=10) (p<0.0001) [mean: 23.4; 95% C.I.: 11 to 35.9 and r2-0.45]. There was no 
difference in the neutrophil SOB in PALF patients on days-4 and 7 compared to day 1. 
Normality assumptions were checked; p<0.05 were considered statistically significant. 
Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s with multiple Conover’s 
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Figure 3.32: Impaired neutrophil oxidative low burst (LB) in patients with 
PALF. 
Neutrophil LB was significantly increased in PALF patients on day 1 (n=11) compared to 
HC (n=10) (p<0.05) [mean: 23.4; 95% C.I.: 11 to 35.9 and r2-0.45]. There was no 
difference in the neutrophil LB in PALF patients on days-4 and 7 compared to day 1. 
Normality assumptions were checked; p<0.05 were considered statistically significant. 
Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s with multiple Conover’s 
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Figure 3.33: Impaired neutrophil oxidative high burst (HB) in patients with 
PALF. 
Neutrophil HB was significantly increased in PALF patients on day 1 (n=11) compared to 
HC (n=10) (p<0.05) [mean: 23.4; 95% C.I.: 11 to 35.9 and r2-0.45]. There was no 
difference in the neutrophil HB in PALF patients on days 4 and 7 compared to day 1. 
Normality assumptions were checked; p<0.05 were considered statistically significant. 
Student t-test (HC Vs PALF day 1) (normal data) and Friedman’s with multiple Conover’s 





























Figure 3.34: Neutrophil phagoburst in patients with PALF and HC. 
There was no difference in neutrophil PB in PALF patients on day 1(n=11) compared to 
HC (n=10). There was no difference in the neutrophil PB in PALF patients on days 4 and 
7 compared to day 1. Normality assumptions were checked; p<0.05 were considered 
statistically significant. Student t-test (HC Vs PALF day 1) and Friedman’s with multiple 




In this study, a robust correlation between neutrophil TLR9 expression and arterial 
ammonia concentration and plasma IL-8 in PALF has been demonstrated. Neutrophil 
TLR9 expression and IL-8 were highest in those with severe SIRS and advanced HE 
which is consistent with the pro-inflammatory state observed in patients with PALF. 
Neutrophil function was impaired with reduced phagocytic activity and increased SOB.  
This led me to postulate that in addition to the release of pro-inflammatory cytokines 
such as IL-6 and IL-8 following paracetamol-induced hepatic necrosis, the resulting 
reduced hepatocyte mass (with less capacity to incorporate nitrogen species into urea) 
results in an elevation in arterial ammonia inducing neutrophil TLR9 expression. Indeed, 
it has been shown that the necrotic liver releases DNA into the systemic circulation 106, 
108 where upon exposure, TLR9 along with the Nalp3 inflammasome and caspase-1 
activates the cell signaling cascade of pro-inflammatory cytokines IL-1β and IL-18 108. 
This is supported by my observation that there was a significant increase in TLR9 
expression when healthy neutrophils were incubated with PALF plasma which was 
abrogated by pre-incubating with DNase-I. It has been shown that TLR9 receptor 
activation stimulates IL-8 production by activating the p38 – mitogen activated protein 
kinase (MAPK) and downstream NF-κB pathways in haematopoietic stem cells 177 and 
endothelial cells 178 which is reflected in our observation that TLR9 expression reflected 
neutrophil intracellular IL-8 expression. 
In this study it has been demonstrated that neutrophil TLR9 is synergistically induced 
by ammonia and IL-8. Furthermore, the pre-treatment of PALF plasma with DNAse-I 
edIt has been well established that TLR9 is mainly activated by the DNA released from 
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the necrotic liver induced by paracetamol overdose 108, 179. This led me to postulate that 
DNA could be increased in the circulation in paracetamol-induced liver injury as a result 
of hyperammonemia in addition to DNA released by apoptotic hepatocytes. However 
this warrants further investigation as there has been no direct evidence so far 
associating hyperammonemia with release of DNA into the circulation. 
It has previously been reported that astrocyte swelling is reduced in TLR4 silenced brain 
endothelium exposed to ammonia, cytokines and LPS 180 and brain oedema is abrogated 
in acute HE TLR4 knockout mice models 180. TLR4 antagonists administered to a 
paracetamol-induced mice have also been shown to be protective with a reduction in the 
brain water volume 165 implicating TLR4 as playing a major role in the development of 
HE. However the decrease in circulating neutrophil TLR4 expression observed in this 
study in the context of no detectable systemic endotoxin suggests that neutrophil TLR4 
does not play as significant a role as TLR9 in the development of SIRS in PALF. The 
distinct effects of ALF caused by paracetamol and TLR sub-type changes in mice versus 
patients could be due to the fact that mice and humans behave differently. 
The neutrophils from patients with PALF and high SIRS failed to upregulate TLR9 in 
response to LPS and NH4Cl challenge and paradoxically downregulated which may result 
from a negative feedback mechanism. They were also unable to produce the pro-
inflammatory cytokines TNF-α and IL-8 compared to those with PALF and lower SIRS 
implying that exposure to high levels of the potent neutrophil chemokine IL-8 in early 
PALF may lead to circulating neutrophil exhaustion. Furthermore, stimulation with 
oligodinucleotides failed to upregulate intracellular IL-8 expression in patients with 
PALF explaining why patients with PALF and severe SIRS are so susceptible to 
developing bacterial and fungal infections 181. 
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Upregulation of TLR9 in HC following co-stimulation with NH4Cl and IL-8 but not with 
IL-8 or NH4Cl alone suggests that inflammation and ammonia act synergistically to 
increase TLR9 expression in PALF. Moreover, increased intracellular IL-8 production in 
healthy neutrophils following stimulation with NH4Cl (or oligodinucleotides) suggests 
that ammonia and circulating DAMPs can potentially trigger production of this potent 
neutrophil attracting chemokine. LPS also activates the production of IL-8 in human 
neutrophils 182 with IL-15 inducing this process by activating the NF-κB pathway 183. The 
increased neutrophil TLR9 expression observed following ex-vivo stimulation with IL-8 
and NH4Cl in healthy neutrophils is similar in magnitude to the TLR9 expression 
observed in PALF patients on presentation and may be representative of the circulating 
inflammatory milieu which develops in PALF. However the mechanistic pathway 
through which TLR9 responds to these stimuli would require further interrogation in 
these patients. 
Although the phagocytic activity of neutrophils improved on days 4 and 7 in PALF 
patients compared to the baseline, there was no change in the production of ROS on 
days 4 and 7. The overproduction of ROS is detrimental to PALF patients as it leads to 
tissue damage and apoptosis of hepatocytes in paracetamol overdose 184. Furthermore, 
in an azoxymethane acute liver injury model it has been demonstrated that TNF-α plays 
an important role in the pathogenesis of ALF and HE. Etanercept, an antagonist of TNF-
α, neutralized TNF-α and attenuated systemic inflammation, hepatic damage, oxidative 
stress and neuroinflammation 185. Whilst it has been demonstrated that etanercept 
inhibits the cytokine production and reduces hepatocyte necrosis, the influence of 
etanercept on TLRs remains to be determined. The expression of CXCR-4 is increased in 
aged neutrophils and this receptor plays an essential role in the neutrophil homeostasis 
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in bone marrow 186, 187. Therefore measuring the CXCR4 expression would have helped 
identify exhausted neutrophils and their function in PALF patients. 
These data may put into context why studies have revealed that high arterial ammonia 
concentration is central in the development of ICH in those with advanced HE 51 and go 
some way to explaining why there is progression to more severe grades of HE in 
patients with ALF who have significant systemic inflammation 37. Indeed, we have 
demonstrated that patients with PALF and high SIRS score (2-4) and advanced HE 
(grade 3/4) had higher baseline plasma IL-8 concentration and circulating neutrophil 
TLR9 expression than those with low SIRS (score 0-1) and milder HE (grade 0-2) which 
supports the validity of this concept. These circulating neutrophils are integral in the 
development of SIRS and advanced HE but may also amplify liver injury as neutrophil 
depleted mice with paracetamol hepatotoxicity have evidence of reduced hepatocellular 
necrosis. Furthermore, blocking CXCR-2 and formyl peptides protected against the 





Neutrophil TLR9 expression in PALF is mediated both by circulating endogenous DNA as 
well as ammonia and IL-8 in a synergistic fashion inducing systemic inflammation, 
neutrophil exhaustion and exacerbating HE [Figure 3.35]. The findings of this study 
taken with the important observation by Imaeda and colleagues that paracetamol-
induced hepatotoxicity in wild type and Nalp3 deficient mice is dependent on TLR9 and 
the Nalp3 inflammasome resulting from DNA released from the apoptotic hepatocytes 
108 implies that TLR9 antagonists may be of therapeutic value in PALF, particularly in 





Figure 3.35: Illustration demonstrating the mechanism by which 
paracetamol hepatotoxicity might lead to MOF. 
Paracetamol overdose causes necrosis of the liver leading to reduced ammonia 
detoxification capability and increased IL-8 production. Ammonia and IL-8 act 
synergistically to induce increased neutrophil TLR9 expression and cytokine production 
in PALF patients with advanced grade HE (3/4) compared to lower grade HE (0-2). 
When there is an infectious stimulus, neutrophils of the patients with lower grade HE (0-
2) are more likely to be able to respond resulting in cytokine production and 
recruitment of the adaptive immune system. In patients with advanced grade HE the 
increased neutrophil TLR9 expression and cytokine production culminates in neutrophil 
exhaustion and failure to respond to an infectious stimulus resulting in sepsis and MOF. 
Patients with lower grade HE (0-2) still have a tendency towards developing sepsis and 










Chapter 4. Ammonia-induced 
brain oedema and immune 















In the previous chapter, it has been demonstrated that ammonia, IL-8 and DNA together 
contribute to upregulating neutrophil TLR9 expression with the highest values of TLR9 
being associated both with high SIRS score and advanced HE grade. Therefore the next 
question was to determine whether TLR9 plays a central role in the development of 
brain oedema in HE. However it has been previously reported in paracetamol 
hepatotoxicity that inhibition of TLR9 using genetically altered mice and neutralizing 
antibodies abrogates the inflammatory responses and protects the mice against acute 
liver injury 108. Therefore it is not possible to determine the role of TLR9 in the 
development of brain oedema in a paracetamol mouse model. Therefore to test my 
hypothesis, ammonium acetate (NH4-Ac) was used as a stimulant to induce brain 
oedema in mice deficient of TLR9 (TLR9-/- B6) and compared to WT-B6 along with 
controls (NH4-Ac untreated). 
4.1. Ammonia-induced brain oedema and changes in the liver were 
dependent on TLR9 
Ammonia is increased in the blood in PALF and it crosses the blood brain barrier 
resulting in astrocyte swelling and brain oedema thereby increasing the water content 
in the brain 51, 188. Increased ammonia also causes hepatocyte swelling and changes to 
the liver 189, 190. Since 12 mM/kg of NH4-Ac induced mortality and 7 mM of NH4-Ac 
induced cell death, a lower concentration was used after optimisation experiments to 
induce inflammation and brain oedema [Method 2.24.1]. To determine whether TLR9 
influenced the ammonia-induced brain oedema the differences in the brain water 
content of WT-B6 and TLR9-/- B6 mice was determined six hours after a single low dose 
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of NH4-Ac administration (I.P., 4 mM) and compared to controls (untreated) [Method-
2.24.4.5].  
Following NH4-Ac stimulation (4 mM), there was a significant increase in the brain water 
content in WT-B6 mice (n=11) compared to controls (n=12) (NH4-Ac untreated) 
(p<0.0001); there was no difference in the brain water content in TLR9-/- B6 mice 
(n=10) compared to controls (n=12). There was a significant decrease in the brain water 
content in TLR9-/- B6 mice compared to WT-B6 mice (p<0.01) following NH4-Ac 
stimulation (4 mM) [Figure 4.1]. These findings were consistent with the recently 
published data from Shah et al. that demonstrated the development of brain oedema in a 
paracetamol-induced mouse model 165. 
Since brain oedema was decreased in TLR9-/- B6 mice and astrocyte swelling is an 
important consequence of brain oedema in the pathogenesis of HE, 
immunohistochemistry staining was performed on the brain sections to identify 
whether there are changes in the expression of TLR9 in astrocytes following NH4-Ac 
stimulation. This technique was not successful as the TLR9 antibodies were raised from 
mouse and did not yield good results. The availability of TLR9 antibodies raised from 
other species, which are reactive with mouse and could be used for 
immunohistochemistry/immunofluorescence, were limited. 
To determine whether the water content in the brain was associated with the changes in 




4.1.1. Changes in the liver bodyweight ratio 
Following low dose of NH4-Ac stimulation (4 mM), there was a significant increase in the 
liver bodyweight ratio in WT-B6 mice (n=16) compared to controls (n=13) (p<0.0001); 
there was no difference in the liver bodyweight ratio in TLR9-/- B6 mice (n=11) 
compared to controls (n=14). There was a significant decrease in the liver bodyweight 
ratio in TLR9-/- B6 mice compared to WT-B6 mice following NH4-Ac stimulation (4 mM) 
(p<0.0001) [Figure 4.2]. 
4.1.2. Changes in the liver histology 
Following NH4-Ac stimulation (4 mM), there was hepatocyte swelling in the histology 
sections of WT-B6 mice liver compared to controls (H&E staining). Hepatocyte swelling 
was decreased in TLR9-/- B6 mice compared to WT-B6 mice following NH4-Ac 





Figure 4.1: Brain water content in WT-B6 and TLR9-/- B6 mice following NH4-
Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the brain water 
content in WT-B6 mice compared to controls (p<0.0001) [mean difference: 1.35; 95% 
C.I.: 0.9 to 1.8], which was ameliorated in TLR9-/- B6 mice compared to WT-B6 mice 
(p<0.01) [mean difference: -0.9; 95% C.I.: -1.4 to -0.39]. [WT-B6 mice (n=11) & controls 
(n=12); TLR9-/- B6 mice (n=10) & controls (n=12)]. Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the differences between 







Figure 4.2: Liver bodyweight ratio in WT-B6 and TLR9-/- B6 mice following 
NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the liver 
bodyweight ratio in WT-B6 mice compared to controls (p<0.0001) [mean difference: 
0.02; 95% C.I.: 0.013 to 0.026], which was ameliorated in TLR9-/- B6 mice compared to 
WT-B6 mice (p<0.0001) [mean difference: -0.015; 95% C.I.: -0.019 to 0.011]. [WT-B6 
mice (n=16) & controls (n=13); TLR9-/- B6 mice (n=11) & controls (n=14)]. Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. Student t-test was used to analyse the differences 





Figure 4.3: Liver histological changes in WT-B6 mice and TLR9-/- B6 mice 
following NH4-Ac stimulation. 
These light microscope images (200x magnification) are histological sections (H&E 
stained) of the liver representing four different mice groups. Following NH4-Ac 
stimulation (4 mM), hepatocyte swelling was usually identified by the clearing of 
cytoplasm was increased in the histological sections of the liver in WT-B6 mice 
compared to controls, where the cytoplasm of cells remained intact. Following NH4-Ac 
stimulation (4 mM), there was no difference in the hepatocyte morphology in TLR9-/- B6 
mice compared to controls but the hepatocyte swelling was decreased compared to WT-
B6 mice. The images in the black box inset are the same regions of the specimen 
captured at a higher magnification (400x). 
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4.2. Neutrophil function was unaltered following NH4-Ac stimulation 
Ammonia induces neutrophil dysfunction by decreasing neutrophil phagocytic activity 
and increasing the release of reactive oxygen species (ROS), which further contributes to 
the oxidative stress and systemic inflammation characteristic of PALF 139. This 
exacerbates the cerebral effects of ammonia 140. Therefore to determine whether 
ammonia altered the neutrophil phenotype and function through a TLR9-mediated 
pathway, NH4-Ac (4 mM) was administered to WT-B6 mice (n=7) and TLR9-/- B6 mice 
(n=6) and compared to controls (NH4-Ac untreated) [WT-B6 (n=10) & TLR9-/- B6 
(n=10)]. Neutrophil phagocytosis was measured by incubating the whole blood with 
FITC dextran and myeloperoxidase expression was determined as a measure of 
spontaneous ROS production in the neutrophils (Lys6G and CD11b – positive cells) 
isolated from blood. Although there are many indirect methods employed to measure 
the ROS production in mice, there is no direct method to measure the neutrophil ROS 
production in mice. Moreover, the oxidative burst kit used to measure ROS production in 
humans is not compatible for mice, therefore this method was used. 
Following NH4-Ac stimulation (4 mM), there was no difference in the phagocytic activity 
of neutrophils from whole blood in WT-B6 mice and TLR9-/- B6 mice compared to 
controls [Figure 4.4a]. Also there was no difference in the expression of 
myeloperoxidase present on the surface of neutrophils isolated from whole blood in 
WT-B6 mice and TLR9-/- B6 mice following NH4-Ac stimulation (4 mM) compared to 




(a)      
    
(b) 
Figure 4.4: Circulating neutrophil function following NH4-Ac stimulation 
Following NH4-Ac stimulation (4 mM), there was no difference in the phagocytic activity 
(a) or myeloperoxidase expression (b) of neutrophils in WT-B6 mice or TLR9-/- B6 mice 
compared to controls. Normality assumptions were checked and the data are expressed 
as mean with S.D.; p<0.05 were considered statistically significant. Student t-test was 
used to analyse the differences between parametric data sets. 
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4.3. Ammonia altered the function of T cells, macrophages and NK 
cells in a TLR9-dependent manner 
It is well known that systemic inflammation exacerbates the development of ammonia-
induced brain oedema 39, 103. Astrocyte swelling was markedly increased in cultures pre-
treated with ammonia and then exposed to the cytokines IFN-γ, TNF-α, IL-1 and IL-6 191. 
Immune cell subsets including T cells, NK cells and macrophages produce these 
cytokines and contribute to an inflammatory environment 118. 
To understand whether inflammation contributes to the ammonia-induced brain water 
content through a TLR9-mediated pathway, the cytokine production of these cell subsets 
was determined in WT-B6 mice and TLR9-/- B6 following NH4-Ac (4 mM) stimulation. 
The intracellular cytokine production of T cells, macrophages and NK cells was 
determined in those cells isolated from spleen using flow cytometry in WT-B6 mice and 
TLR9-/- B6 mice. Intracellular cytokine production of T cells was also determined in the 
immune cells isolated from liver [Method-2.13]. 
4.3.1. Decreased cytokine production in splenic T cells in TLR9-/- B6 mice 
Intracellular cytokine production was determined in the CD4pos T cells (CD3 & CD4 – 
positive cells) and CD8pos T cells (CD3 & CD8 – positive cells) in WT-B6 mice (n=13) and 
TLR9-/- B6 mice (n=14) six hours following NH4-Ac (4 mM) stimulation and compared to 
controls (NH4-Ac untreated) [WT-B6 (n=13) & TLR9-/- B6 (n=10)] [Method-2.14.4.7]. 
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4.3.1.1. Decreased cytokine production in splenic CD4pos T cells in 
TLR9-/- B6 mice 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by CD4pos T cells isolated from spleen in WT-B6 
mice compared to controls (p<0.0001); there was no difference in the intracellular 
cytokine IFN-γ produced by CD4pos T cells isolated from spleen in TLR9-/- B6 mice 
compared to controls. There was a significant decrease in the intracellular cytokine IFN-
γ produced by CD4pos T cells in TLR9-/- B6 mice compared to WT-B6 mice following NH4-
Ac stimulation (4 mM) (p<0.001) [Figure 4.5]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by CD4pos T cells isolated from spleen in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine TNF-α produced by CD4pos T cells isolated from spleen in TLR9-/- 
B6 mice compared to controls (p<0.0001). However, there was a significant decrease in 
the intracellular cytokine TNF-α produced by CD4pos T cells in TLR9-/- B6 mice compared 
to WT-B6 mice following NH4-Ac stimulation (4 mM) (p<0.0001) [Figure 4.6]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IL-6 produced by CD4pos T cells isolated from spleen in WT-B6 
mice compared to controls (p<0.0001) but there was no difference in the intracellular 
cytokine IL-6 produced by CD4pos T cells isolated from spleen in TLR9-/- B6 mice 
compared to controls. There was a significant decrease in the intracellular cytokine IL-6 
produced by CD4pos T cells in TLR9-/- B6 mice compared to WT-B6 mice following NH4-
Ac stimulation (4 mM) (p<0.01) [Figure 4.7]. 
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Following NH4-Ac stimulation (4 mM), there was no difference in the intracellular 
cytokine IL-17 produced by CD4pos T cells isolated from spleen in WT-B6 mice and TLR9-







Figure 4.5: CD4pos IFN-γ production in WT-B6 and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IFN-γ produced by splenic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [median difference: 2.2; 95% C.I.: 1.5 to 3] (non-normal data). There was no 
difference in IFN-γ produced by splenic CD4pos T cells in TLR9-/- B6 mice following NH4-
Ac stimulation (4 mM) compared to controls [median difference: 0.8; 95% C.I.: -0.1 to 
1.7] (non-normal data), but it was significantly ameliorated compared to WT-B6 mice 
(p<0.001) [median difference: –1.9; 95% C.I.: -3 to -1.2] (non-normal data). [WT-B6 mice 
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(n=13) & controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. Mann-Whitney U test was used to analyse the 
differences between non-parametric data sets. (A) Graph and (B) FACS plots 







Figure 4.6: CD4pos TNF-α production in WT-B6 and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by splenic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [median difference: 49.7; 95% C.I.: 47.4 to 51.7] (non-normal data). There 
was a significant increase in TNF-α produced by splenic CD4pos T cells in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.0001) [median 
difference: 25.2; 95% C.I.: 22.7 to 27.5] (non-normal data), but it was significantly 
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ameliorated compared to WT-B6 mice (p<0.0001) [median difference: –27.8; 95% C.I.: -
30 to -25.3] (non-normal data). [WT-B6 mice (n=13) & controls (n=13); TLR9-/- B6 mice 
(n=14) & controls (n=10)]. Normality assumptions were checked and the data are 
expressed as mean with S.D.; p<0.05 were considered statistically significant. Mann-
Whitney U test was used to analyse the differences between non-parametric data sets. 







Figure 4.7: CD4pos IL-6 production in WT-B6 and TLR9-/- B6 mice splenocytes 
following NH4-Ac stimulation. 
The intracellular cytokine IL-6 produced by splenic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 2.1; 95% C.I.: 1.3 to 3] (normal data). There was no 
difference in IL-6 produced by splenic CD4pos T cells in TLR9-/- B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls [mean difference: 0.5; 95% C.I.: 0.02 to 1.07] 
(normal data), but it was significantly ameliorated compared to WT-B6 mice (p<0.01) 
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[mean difference: –1.6; 95% C.I.: -2.6 to -0.6] (normal data). [WT-B6 mice (n=13) & 
controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the differences between 





Figure 4.8: CD4pos IL-17 production in WT-B6 mice and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
There was no difference in the intracellular cytokine IL-17 produced by splenic CD4pos T 
cells in WT-B6 mice or TLR9-/- B6 mice following NH4-Ac stimulation (4 mM) compared 
to controls. Normality assumptions were checked and the data are expressed as mean 
with S.D.; p<0.05 were considered statistically significant. Student t-test was used to 








4.3.1.2. Decreased cytokine production in splenic CD8pos T cells in 
TLR9-/- B6 mice 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by CD8pos T cells isolated from spleen in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine IFN-γ produced by CD8pos T cells isolated from spleen in TLR9-/- 
B6 mice compared to controls (p<0.05). There was however a significant decrease in the 
intracellular cytokine IFN-γ produced by CD8pos T cells in TLR9-/- B6 mice compared to 
WT-B6 mice following NH4-Ac stimulation (4 mM) (p<0.001) [Figure 4.9]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by CD8pos T cells isolated from spleen in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine TNF-α produced by CD8pos T cells isolated from spleen in TLR9-/- 
B6 mice compared to controls (p<0.05). There was a significant decrease in the 
intracellular cytokine TNF-α produced by CD8pos T cells in TLR9-/- B6 mice compared to 







Figure 4.9: CD8pos IFN-γ production in WT-B6 and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IFN-γ produced by splenic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 3.9; 95% C.I.: 2.1 to 5.8] (normal data). There was no 
difference in IFN-γ produced by splenic CD8pos T cells in TLR9-/- B6 mice following NH4-
Ac stimulation (4 mM) compared to controls [mean difference: 1.78; 95% C.I.: -0.4 to 4] 
(normal data), but it was significantly ameliorated compared to WT-B6 mice (p<0.001) 
[mean difference: –4; 95% C.I.: -6 to -2] (normal data). [WT-B6 mice (n=13) & controls 
 195 
 
(n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the differences between 







Figure 4.10: CD8pos TNF-α production in WT-B6 and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by splenic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 47.6; 95% C.I.: 44.2 to 51] (normal data). There was a 
significant increase in TNF-α produced by splenic CD8pos T cells in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.05) [mean difference: 
3; 95% C.I.: 0.8 to 5.4] (normal data), but it was significantly ameliorated compared to 
WT-B6 mice (p<0.0001) [mean difference: –46; 95% C.I.: -49.6 to -42.7] (normal data). 
[WT-B6 mice (n=13) & controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. 
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Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. Student t-test was used to analyse the 




4.3.1.3. Decreased cytokine production in hepatic CD4pos T cells in 
TLR9-/- B6 mice 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by CD4pos T cells isolated from the liver in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine IFN-γ produced by CD4pos T cells isolated from liver in TLR9-/- B6 
mice compared to controls (p<0.001). There was however a significant decrease in the 
intracellular cytokine IFN-γ produced by CD4pos T cells in TLR9-/- B6 mice compared to 
WT-B6 mice following NH4-Ac stimulation (4 mM) (p<0.0001) [Figure 4.11]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by CD4pos T cells isolated from the liver in WT-B6 
mice compared to controls (p<0.0001) but there was no difference in the intracellular 
cytokine TNF-α produced by CD4pos T cells isolated from liver in TLR9-/- B6 mice 
compared to controls. There was a significant decrease in the intracellular cytokine TNF-
α produced by CD4pos T cells in TLR9-/- B6 mice compared to WT-B6 mice following NH4-
Ac stimulation (4 mM) (p<0.0001) [Figure 4.12]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IL-6 produced by CD4pos T cells isolated from the liver in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine IL-6 produced by CD4pos T cells isolated from liver in TLR9-/- B6 
mice compared to controls (p<0.05). There was however a significant decrease in the 
intracellular cytokine IL-6 produced by CD4pos T cells in TLR9-/- B6 mice compared to 




Figure 4.11: CD4pos IFN-γ production in WT-B6 and TLR9-/- B6 mice hepatic T 
cells following NH4-Ac stimulation. 
The intracellular cytokine IFN-γ produced by hepatic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 18.3; 95% C.I.: 15 to 21.7] (normal data). There was a 
significant increase in IFN-γ produced by hepatic CD4pos T cells in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.001) [mean difference: 
3.9; 95% C.I.: 2.3 to 5.4] (normal data), but it was significantly ameliorated compared to 
WT-B6 mice (p<0.0001) [mean difference: –14.5; 95% C.I.: -18.6 to -10.4] (normal data). 
[WT-B6 mice (n=13) & controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. Student t-test was used to analyse the 




Figure 4.12: CD4pos TNF-α production in WT-B6 and TLR9-/- B6 mice hepatic T 
cells following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by hepatic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 21.4; 95% C.I.: 14.5 to 28.2] (normal data). There was no 
difference in TNF-α produced by hepatic CD4pos T cells in TLR9-/- B6 mice following NH4-
Ac stimulation (4 mM) compared to controls [mean difference: 4.9; 95% C.I.: -4.1 to 14] 
(normal data), but it was significantly ameliorated compared to WT-B6 mice (p<0.0001) 
[mean difference: –19.9; 95% C.I.: -27 to -12.6] (normal data). [WT-B6 mice (n=13) & 
controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the differences between 




Figure 4.13: CD4pos IL-6 production in WT-B6 and TLR9-/- B6 mice hepatic T 
cells following NH4-Ac stimulation. 
The intracellular cytokine IL-6 produced by hepatic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 11.9; 95% C.I.: 8.1 to 15.6] (normal data). There was a 
significant increase in IL-6 produced by hepatic CD4pos T cells in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.05) [mean difference: 
4.8; 95% C.I.: 0.4 to 9] (normal data), but it was significantly ameliorated compared to 
WT-B6 mice (p<0.01) [mean difference: –7.2; 95% C.I.: -12.4 to -2.2] (normal data). [WT-
B6 mice (n=13) & controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. Student t-test was used to analyse the 




4.3.1.4. Decreased cytokine production in hepatic CD8pos T cells in 
TLR9-/- B6 mice 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by CD8pos T cells isolated from liver in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine IFN-γ produced by CD8pos T cells isolated from liver in TLR9-/- B6 
mice compared to controls (p<0.05). There was however a significant decrease in the 
intracellular cytokine IFN-γ produced by CD8pos T cells in TLR9-/- B6 mice compared to 
WT-B6 mice following NH4-Ac stimulation (4 mM) (p<0.0001) [Figure 4.14]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by CD8pos T cells isolated from liver in WT-B6 
mice compared to controls (p<0.0001) but there was no difference in the intracellular 
cytokine TNF-α produced by CD8pos T cells isolated from liver in TLR9-/- B6 mice 
compared to controls. There was however a significant decrease in the intracellular 
cytokine TNF-α produced by CD8pos T cells in TLR9-/- B6 mice compared to WT-B6 mice 




Figure 4.14: CD8pos IFN-γ production in WT-B6 and TLR9-/- B6 mice hepatic T 
cells following NH4-Ac stimulation 
The intracellular cytokine IFN-γ produced by hepatic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 18.3; 95% C.I.: 15.8 to 20.8] (normal data). There was a 
significant increase in IFN-γ produced by hepatic CD8pos T cells in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.05) [mean difference: 
5.8; 95% C.I.: 0.3 to 11.3] (normal data), but it was significantly ameliorated compared 
to WT-B6 mice (p<0.0001) [mean difference: –12.4; 95% C.I.: -16.7 to -8.1] (normal 
data). [WT-B6 mice (n=13) & controls (n=13); TLR9-/- B6 mice (n=14) & controls 
(n=10)]. Normality assumptions were checked and the data are expressed as mean with 
S.D.; p<0.05 were considered statistically significant. Student t-test was used to analyse 




Figure 4.15: CD8pos TNF-α production in WT-B6 and TLR9-/- B6 mice hepatic T 
cells following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by hepatic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 47.3; 95% C.I.: 38.8 to 55.8] (normal data). There was no 
difference in TNF-α produced by hepatic CD8pos T cells in TLR9-/- B6 mice following NH4-
Ac stimulation (4 mM) compared to controls [mean difference: -1; 95% C.I.: -14 to 10] 
(normal data), but it was significantly ameliorated compared to WT-B6 mice (p<0.0001) 
[mean difference: –44; 95% C.I.: -55 to -32] (normal data). [WT-B6 mice (n=13) & 
controls (n=13); TLR9-/- B6 mice (n=14) & controls (n=10)]. Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the difference between 
parametric data sets. 
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4.3.2. T cell phenotype was unaltered following NH4-Ac stimulation 
To determine whether ammonia altered the T cell phenotype, the frequency of naive 
(CD44+ and CD62L-); memory T cells (CD44- and CD62L+) and activation markers 
(CD69+) were determined in the CD4pos T cells (CD3 & CD4 – positive cells) and CD8pos T 
cells (CD3 & CD8 – positive cells) isolated from the spleen using flow cytometry 
[Method- 2.14.4.7]. 
There was no difference in the naive and memory subsets of the splenic CD4pos T cells in 
WT-B6 mice and TLR9-/- B6 mice following NH4-Ac stimulation (4 mM) compared to 
controls [Figure 4.16a and b]. However, there was a significant increase in the splenic 
CD4pos CD69+ T cells in WT-B6 mice and TLR9-/- B6 mice following NH4-Ac stimulation 
(4 mM) compared to controls [Figure 4.16c]. 
There was also no difference in the naive and memory subsets of the splenic CD8pos T 
cells in WT-B6 mice and TLR9-/- B6 mice following NH4-Ac stimulation (4 mM) compared 
to controls [Figure 4.16d and e]. However, there was a significant increase in the splenic 
CD8pos CD69+ T cells in WT-B6 mice and TLR9-/- B6 mice following NH4-Ac stimulation 




                                               (a)                                                                               (b)                                                                                     (c) 
 
                                              (d)                                                                               (e)                                                                                      (f) 
Figure 4.16: Phenotype of T cells following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was no difference in the frequency of CD4pos naive and memory T cells (a & b) and CD8pos naive 
and memory T cells (d & e) isolated from spleen in WT-B6 mice or TLR9-/- B6 mice compared to controls. Following NH4-Ac stimulation (4 
mM), there was a significant increase in the CD4pos CD69+ T cells but there was no difference in the CD8pos CD69+ T cells in WT-B6 mice or 
TLR9-/- B6 mice compared to controls. Normality assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. Student t-test was used to analyse the differences between parametric data sets. 
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4.3.3. Decreased cytokine production in splenic macrophages in TLR9-/- B6 
mice 
The frequency of intracellular cytokines was determined in the macrophages (F4/80 & 
CD11b – positive cells) in WT-B6 mice (n=5) and TLR9-/- B6 mice (n=6) six hours 
following NH4-Ac (4 mM) stimulation and compared to controls (NH4-Ac untreated) 
[WT-B6 (n=5) & TLR9-/- B6 (n=7)] [Method-2.14.4.9]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by macrophages isolated from the spleen in WT-
B6 mice compared to controls (p<0.01) but there was no difference in the intracellular 
cytokine IFN-γ produced by macrophages isolated from spleen in TLR9-/- B6 mice and 
compared to controls. There was however a significant decrease in the intracellular 
cytokine IFN-γ produced by macrophages in TLR9-/- B6 mice compared to WT-B6 mice 
following NH4-Ac stimulation (4 mM) (p<0.001) [Figure 4.17]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by macrophages isolated from spleen in WT-B6 
mice compared to controls (p<0.0001). There was also a significant increase in the 
intracellular cytokine TNF-α produced by macrophages isolated from spleen in TLR9-/- 
B6 mice compared to controls (p<0.001). There was however a significant decrease in 
the intracellular cytokine TNF-α produced by macrophages in TLR9-/- B6 mice compared 
to WT-B6 mice following NH4-Ac stimulation (4 mM) (p<0.0001) [Figure 4.18]. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IL-6 produced by macrophages isolated from spleen in WT-B6 
mice compared to controls (p<0.0001) but there was no difference in the intracellular 
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cytokine IL-6 produced by macrophages isolated from spleen in TLR9-/- B6 mice 
compared to controls. There was a significant decrease in the intracellular cytokine IL-6 
produced by macrophages in TLR9-/- B6 mice compared to WT-B6 mice following NH4-








Figure 4.17: IFN-γ production by macrophages in WT-B6 and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IFN-γ produced by splenic macrophages was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.01) [median difference: 2.4; 95% C.I.: 1.3 to 3.6] (non-normal data). There was no 
difference in IFN-γ produced by splenic macrophages in TLR9-/- B6 mice following NH4-
Ac stimulation (4 mM) compared to controls [mean difference: 0.3; 95% C.I.: -0.27 to 
0.9] (normal data), but it was significantly ameliorated compared to WT-B6 mice 
(p<0.001) [mean difference: –1.6; 95% C.I.: -2.6 to -0.6] (normal data). [WT-B6 mice 
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(n=5) & controls (n=5); TLR9-/- B6 mice (n=6) & controls (n=7)]. Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the difference between 
parametric data sets and Mann-Whitney U test was used to analyse the difference 








Figure 4.18: TNF-α production by macrophages in WT-B6 and TLR9-/- B6 
mice splenocytes following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by splenic macrophages was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 25.1; 95% C.I.: 21.1 to 29.1] (normal data). There was a 
significant increase in TNF-α produced by splenic macrophages in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.001) [mean difference: 
9.3; 95% C.I.: 4.8 to 13.7] (normal data), but it was significantly ameliorated compared 
to WT-B6 mice (p<0.0001) [mean difference: –14.3; 95% C.I.: -18.3 to -10.3] (normal 
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data). [WT-B6 mice (n=5) & controls (n=5); TLR9-/- B6 mice (n=6) & controls (n=7)]. The 
data are normally distributed and expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the differences between 







Figure 4.19: IL-6 production by macrophages in WT-B6 and TLR9-/- B6 mice 
splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IL-6 produced by splenic macrophages was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 4; 95% C.I.: 3.2 to 4.7] (normal data). There was no 
difference in IL-6 produced by splenic macrophages in TLR9-/- B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls [mean difference: -0.2; 95% C.I.: -1.1 to 0.5] 
(normal data), but it was significantly ameliorated compared to WT-B6 mice (p<0.0001) 
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[mean difference: –4.1; 95% C.I.: -4.7 to -3.4] (normal data). [WT-B6 mice (n=5) & 
controls (n=5); TLR9-/- B6 mice (n=6) & controls (n=7)]. Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Student t-test was used to analyse the differences between 
parametric data sets. (A) Graph and (B) FACS plots representing each group. 
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4.3.4. Decreased cytokine production in splenic NK cells in TLR9-/- B6 mice 
The phenotype and intracellular cytokine production was determined in the NK cells 
(DX-5 & CD122 – positive cells) in WT-B6 mice (n=5) and TLR9-/- B6 mice (n=6) six 
hours following NH4-Ac (4 mM) stimulation and compared to controls (NH4-Ac 
untreated) [WT-B6 (n=7) & TLR9-/- B6 (n=7)] [Methods-2.14.4.8]. 
NK cell phenotype 
Among the controls, there was a significant decrease in the frequency of KLRG-1pos NK 
cells isolated from spleen in TLR9-/- B6 mice compared to WT-B6 mice (p0.01). 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the frequency 
of KLRG-1pos NK cells isolated from spleen in WT-B6 mice compared to controls (p<0.05) 
but there was no difference in the intracellular frequency of KLRG-1pos NK cells isolated 
from spleen in TLR9-/- B6 mice compared to controls. There was however a significant 
decrease in the frequency of KLRG-1pos NK cells in TLR9-/- B6 mice compared to WT-B6 
mice following NH4-Ac stimulation (4 mM) (p<0.0001) [Figure 4.20]. 
NK cell function 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by KLRG-1pos NK cells isolated from spleen in WT-
B6 mice compared to controls (p<0.0001),  There was also a significant increase in the 
intracellular cytokine IFN-γ produced by KLRG-1pos NK cells isolated from spleen in 
TLR9-/- B6 mice compared to controls (p<0.01). There was however a significant 
decrease in the intracellular cytokine IFN-γ produced by KLRG-1pos NK cells in TLR9-/- 




Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by KLRG-1pos NK cells isolated from spleen in 
WT-B6 mice compared to controls (p<0.001) but there was no difference in the 
intracellular cytokine TNF-α produced by KLRG-1pos NK cells isolated from spleen in 
TLR9-/- B6 mice compared to controls. There was however a significant decrease in the 
intracellular cytokine TNF-α produced by KLRG-1pos NK cells in TLR9-/- B6 mice 







Figure 4.20: KLRG-1pos NK cells in WT-B6 and TLR9-/- B6 mice splenocytes 
following NH4-Ac stimulation. 
Splenic KLRG-1pos NK cells were significantly increased in WT-B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls (p<0.05) [mean difference: 3.4; 95% C.I.: 0.4 to 
6.4] (normal data). There was no difference in splenic KLRG-1pos NK cells in TLR9-/- B6 
mice following NH4-Ac stimulation (4 mM) compared to controls [median difference: -
0.8; 95% C.I.: -6.3 to 7.6] (non-normal data), but they were significantly ameliorated 
compared to WT-B6 mice (p<0.0001) [mean difference: –18.3; 95% C.I.: -23.2 to -13.5] 
(normal data). Among the controls, there was a significant decrease in KLRG-1pos NK 
cells in TLR9-/- B6 mice compared to WT-B6 mice (p<0.01) [median difference: -15.1; 
95% C.I.: -20 to -9] (non-normal data). [WT-B6 mice (n=6) & controls (n=6); TLR9-/- B6 
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mice (n=7) & controls (n=7)]. Normality assumptions were checked and the data are 
expressed as mean with S.D.; p<0.05 were considered statistically significant. Student t-
test was used to analyse the difference between parametric data sets and Mann-Whitney 
U test was used to analyse the difference between non-parametric data sets. (A) Graph 







Figure 4.21: IFN-γ production by KLRG-1pos NK cells in WT-B6 and TLR9-/- B6 
mice splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IFN-γ produced by splenic KLRG-1pos NK cells was 
significantly increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared 
to controls (p<0.0001) [mean difference: 4; 95% C.I.: 2.6 to 5.4] (normal data). There 
was a significant increase in IFN-γ produced by splenic KLRG-1pos NK cells in TLR9-/- B6 
mice following NH4-Ac stimulation (4 mM) compared to controls (p<0.01) [mean 
difference: 2.5; 95% C.I.: 1.1 to 3.8] (normal data), but it was significantly ameliorated 
compared to WT-B6 mice (p<0.01) [median difference: –2.2; 95% C.I.: -3.6 to -0.8] (non-
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normal data). [WT-B6 mice (n=6) & controls (n=6); TLR9-/- B6 mice (n=7) & controls 
(n=7)]. Normality assumptions were checked and the data are expressed as mean with 
S.D.; p<0.05 were considered statistically significant. Student t-test was used to analyse 
the difference between parametric data sets and Mann-Whitney U test was used to 
analyse the difference between non-parametric data sets. (A) Graph and (B) FACS plots 







Figure 4.22: TNF-α production by KLRG-1pos NK cells in WT-B6 and TLR9-/- B6 
mice splenocytes following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by splenic KLRG-1pos NK cells was 
significantly increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared 
to controls (p<0.001) [mean difference: 5.9; 95% C.I.: 3.7 to 8] (normal data). There was 
no difference in TNF-α produced by splenic KLRG-1pos NK cells in TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls [median difference: 0.75; 
95% C.I.: -0.9 to 3.3] (non-normal data), but it was significantly ameliorated compared 
to WT-B6 mice (p<0.01) [median difference: –4.4; 95% C.I.: -5.7 to -0.6] (non-normal 
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data). [WT-B6 mice (n=6) & controls (n=6); TLR9-/- B6 mice (n=7) & controls (n=7)]. 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. Student t-test was used to analyse the 
difference between parametric data sets and Mann-Whitney U test was used to analyse 
the difference between non-parametric data sets. (A) Graph and (B) FACS plots 
representing each group. 
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4.4. Ammonia-induced mortality and inflammation were independent 
of acetate or pH 
A recent study shows that acetate induces inflammation in acute alcoholic hepatitis 192. 
In another study, it has been shown that the toxicity of ammonium salts was increased in 
relation to the rise in blood pH and the direct effect of pH (alkalinization) was 
responsible for promoting ammonium gas transfer across the blood brain barrier 71, 72. 
Therefore to determine whether the TLR9-mediated mortality, brain oedema and 
inflammation were solely induced by ammonia and not by the acetate or change in pH, 
sodium acetate (Na-Ac), an alternate salt of acetate was injected in WT-B6 mice after 
adjusting for pH (same as NH4-Ac). 
4.4.1. Changes in immune function after 4 mM Na-Ac stimulation 
Further, to determine whether it was acetate or pH that induced the systemic 
inflammation and subsequent brain oedema and changes in the liver in WT-B6 mice, Na-
Ac (4 mM) was injected to WT-B6 mice (n=7) and compared to controls (n=13) and WT-
B6 mice stimulated with NH4-Ac (n=13). 
4.4.1.1. Brain water content and liver bodyweight ratio after Na-Ac 
stimulation 
There was no difference in the brain water content or liver bodyweight ratio in WT-B6 
mice after Na-Ac (4 mM) stimulation compared to controls. The brain water content and 
liver bodyweight ratio was significantly decreased in WT-B6 mice treated with Na-Ac (4 
mM) compared to WT-B6 mice treated with NH4-Ac (4 mM) [Figure 4.23a and b]. 
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4.4.1.2. CD4pos T cells and CD8pos T cells after Na-Ac stimulation 
There was no difference in the intracellular cytokines (IFN-γ, TNF-α and IL-6) produced 
by splenic CD4pos T cells and CD8pos T cells in WT-B6 mice after Na-Ac stimulation (4 
mM) compared to controls. The cytokine production was significantly decreased after 
Na-Ac stimulation compared to the group stimulated with NH4-Ac (p<0.001) [Figures 
4.24 and 25]. 
There was no difference in the intracellular cytokine production by hepatic CD4pos T cells 
and CD8pos T cells in WT-B6 mice after Na-Ac stimulation (4 mM) compared to controls 
[data not shown]. 
4.4.1.3. Macrophages and NK cells after Na-Ac stimulation 
There was no difference in the intracellular cytokine production by splenic macrophages 
and KLRG-1pos NK cells in WT-B6 mice after Na-Ac stimulation (4 mM) compared to 
controls. The cytokine production was significantly decreased after Na-Ac stimulation 




                                              (a)                                                                            (b)                                                                          
Figure 4.23: Brain water content and liver bodyweight ratio in WT-B6 mice after Na-Ac stimulation. 
(a) Brain water content and (b) liver bodyweight ratio were significantly increased in WT-B6 mice following NH4-Ac stimulation (4 mM) 
compared to controls (p<0.0001) (normal data). There was no difference in brain water content (a) and liver bodyweight ratio (b)  in WT-B6 
mice after Na-Ac stimulation (4 mM) compared to controls, which were significantly ameliorated compared to those stimulated with NH4-Ac 
(p<0.001) (normal data). [NH4-Ac treated mice (n=13), controls (n=13) and Na-Ac treated mice (n=7)]. Normality assumptions were checked 
and the data are expressed as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA with Tukey’s multiple 
comparisons test was used to analyse the differences between parametric data sets. 
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(a)                                                                                    (b)                                                                                         (c)   
 
                                                                                                 (d)                                                                                   (e) 
Figure 4.24: Intracellular cytokine production in splenic T cells after Na-Ac stimulation. 
There was no difference in the intracellular cytokines (a) CD4pos IFN-γ, (b) CD4pos TNF-α, (c) CD4pos IL-6, (d) CD8pos IFN-γ and (e) CD8pos TNF-α  
in WT-B6 mice after Na-Ac stimulation (4 mM) compared to controls, which were significantly decreased compared to the NH4-Ac stimulated 
group (p<0.001) (normal data). [NH4-Ac treated mice (n=13), controls (n=13) and Na-Ac treated mice (n=7)]. Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA with Tukey’s multiple 




Figure 4.25: FACS plots of T cell cytokines after Na-Ac stimulation. 
FACS plots of intracellular cytokines produced by CD4pos and CD8pos T cells in WT-B6 




                                                                                        (a)                                                                                                      (b) 
 
                                                                                        (c)                                                                                                      (d) 
Figure 4.26: Cytokine production in macrophages and NK cells in WT-B6 mice after Na-Ac stimulation. 
There was no difference in the intracellular cytokines produced by macrophages (a, b and c) and KLRG-1pos NK cells (d) in WT-B6 mice after 
Na-Ac stimulation compared to controls, which were significantly ameliorated compared the NH4-Ac stimulated group(normal data). [NH4-Ac 
treated mice (n=13), controls (n=13) and Na-Ac treated mice (n=7)]. Normality assumptions were checked and the data are expressed as mean 
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with S.D.; p<0.05 were considered statistically significant. One-way ANOVA with Tukey’s multiple comparison test was used to analyse the 
differences between parametric data sets. 
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4.5. Ammonia-induced TLR9 changes are activated by DNA 
Since TLR9 is mainly activated by the CpG motif of the bacterial DNA and also as my 
human studies have shown that ammonia along with DNA activated neutrophil TLR9 
expression, I sought to determine whether the ammonia-induced TLR9 changes were 
also mediated through DNA. To understand this mechanism, total dsDNA levels (pg/ml) 
were measured from plasma samples stored in -80°C from WT-B6 mice following NH4-
Ac (4 mM) stimulation (n=13) and controls (n=13); TLR9-/- B6 mice following NH4-Ac (4 
mM) stimulation (n=19) and controls (n=16); and WT-B6 mice after Na-Ac (4 mM) 
stimulation (n=7) [Method – 2.25]. 
Plasma dsDNA levels were significantly increased in WT-B6 mice and TLR9-/- B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls (p<0.05). There was no 
difference in plasma dsDNA level in TLR9-/- B6 mice compared to WT-B6 mice following 
NH4-Ac stimulation (4 mM) [Figure 4.27]. 
Plasma dsDNA level was significantly increased in WT-B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls (p<0.001). There was no difference in plasma 
dsDNA level in WT-B6 mice after Na-Ac stimulation (4 mM) compared to controls, but it 






Figure 4.27: Plasma dsDNA level in WT-B6 and TLR9-/- B6 mice following 
NH4-Ac stimulation. 
Plasma dsDNA level was significantly increased in WT-B6 mice [median difference: 3.5; 
95% C.I.: 0.3 to 5.7] (non-normal data) and TLR9-/- B6 mice [median difference: 1.9; 95% 
C.I.: 0.2 to 3.4] (non-normal data) following NH4-Ac stimulation (4 mM) compared to 
controls (p<0.05). There was no difference in plasma dsDNA level in TLR9-/- B6 mice 
compared to WT-B6 mice following NH4-Ac stimulation (4 mM) [median difference: –
1.5; 95% C.I.: -3.2 to 0.1]. [WT-B6 mice (n=13) & controls (n=13); TLR9-/- B6 mice 





Figure 4.28: Plasma dsDNA level in WT-B6 mice after Na-Ac stimulation. 
Plasma dsDNA level was significantly increased in WT-B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls (p<0.001) [mean difference: 3.5; 95% C.I.: 1.4 
to 5.5] (normal data). There was no difference in plasma dsDNA level in WT-B6 mice 
after Na-Ac stimulation (4 mM) compared to controls [mean difference: 1.2; 95% C.I.: -
1.8 to 3.6] (normal data), but it was significantly ameliorated compared to the NH4-Ac 
stimulated group (p<0.05) [mean difference: –2.5; 95% C.I.: -4.8 to -0.11] (normal data). 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. One-way ANOVA with Tukey’s multiple 





The decreased survival rate in TLR9 deficient (TLR9-/-) B6 mice following a high dose of 
NH4-Ac stimulation indicates that TLR9 plays an important role in ammonia-induced 
mortality. The decreased cytokine production and brain water content in TLR9-/- B6 
mice, following the stimulation of NH4-Ac suggests that TLR9 plays an important role in 
the pathogenesis of inflammation and subsequent brain oedema in a DNA dependent 
fashion. 
4.6.1. Ammonia-induced inflammation and brain oedema 
In this study ammonia stimulation upregulated the production of the cytokines IFN-γ, 
TNF-α and IL-6. The observation of increased cytokine production from the hepatic 
infiltrated T cells indicates that the immune response originates from the liver. The 
cytokines IFN-γ, TNF-α and IL-6 produced by TH1/TH2 cells are predominantly 
responsible for mediating inflammation within the liver 193-195. The cytokines IFN-γ and 
TNF-α play an important role in inducing the systemic inflammatory response in 
paracetamol toxicity 196-198, and NK cells play a particularly  important role in this 
process by secreting IFN-γ 199 which induces the production of the chemokines that 
recruit neutrophils and macrophages to the site of injury which further propagates the 
inflammatory response 200, 201. In this study ammonia also activated cytokine production 
in NK cells and macrophages indicating that those cells, along with effector and cytotoxic 
T cells, are responsible for inducing the proinflammatory environment. Together, 
ammonia and systemic inflammation induce brain oedema by inducing astrocyte 
swelling. This supports the previously published observation that astrocyte swelling can 
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be induced when astrocytes are exposed to pro-inflammatory cytokines after being 
exposed to ammonia 191. 
4.6.2. Role of TLR9 in the inflammation and brain oedema 
Activation of TLR9 results in the upregulation of cytokine production and increase in the 
brain water content, and the critical role of TLR9 in this mechanism have been 
demonstrated by using genetically modified mice. Furthermore, TLR9 is essential for the 
cytokines TNF-α and IL-6 to be produced by macrophages in response to CpG DNA, 158 
and IFN-γ produced by CD4pos T cells in response to CpG DNA and Mycobacteria 158, 202.  
Although the T cell cytokine production was reduced in TLR9-/- mice following ammonia 
stimulation, there was an increase in the production of TNF-α and an increasing trend in 
other pro-inflammatory cytokines was observed compared to the controls. However this 
was not observed in the macrophages isolated from spleen after ammonia stimulation. It 
is well known that stimulation of TLR4 induces the production of TNF-α in macrophages 
203. These findings taken together indicate that apart from TLR9 activation, other factors 
are also involved in stimulating the production of cytokines following ammonia-
exposure. 
4.6.3. Activation of TLR9 by ammonia is mediated by DNA 
The increase in the liver weight could be due to the combined effect of hepatocyte 
swelling caused by ammonia 189 and the inflammation within the liver. DNA released by 
the swollen hepatocytes likely binds to TLR9 thereby activating the innate immune 
system. In paracetamol toxicity, DNA fragments released by apoptotic hepatocytes have 
been shown to be responsible for the activation of TLR9, inducing pro-inflammation 108, 
179 and resulting in MOF by damaging the lungs 106. These findings taken together with 
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the observations in my human studies that neutrophil TLR9 activated by ammonia, IL-8 
and DNA induced SIRS and progression to HE in PALF 204 suggest that TLR9 mediates 












Chapter 5. TLR9 antagonism 
abrogates ammonia-induced 
inflammation and brain oedema 
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In the previous chapter, by using TLR9-/- B6 mice it has been established that TLR9 plays 
an important role inducing the cytokine production of T cells, NK cells and macrophages, 
increasing brain water content following ammonia stimulation and driving mortality. 
Since TLR9-/- B6 mice were protected against NH4-Ac stimulation, the next aim was to 
determine whether an antagonist of TLR9 would inhibit the ammonia-induced pro-
inflammatory changes and brain oedema seen in the WT-B6 mice [Method – 2.26]. 
5.1. Decreased brain water content and liver bodyweight ratio in WT-
B6 mice after TLR9 inhibition 
Following administration of the TLR9 antagonist, ODN2088 (50 µg) along with NH4-Ac 
(4 mM), there was a significant decrease in the brain water content in WT-B6 mice 
(n=10) compared to the NH4-Ac alone treated group (p<0.001) whereas there was a 
significant increase in the brain water content in WT- B6 mice treated with NH4-Ac alone 
(n=11) compared to controls (n=12) (p<0.0001). There was no difference in the brain 
water content in WT-B6 mice treated with ODN2088 and NH4-Ac (4 mM) compared to 
controls [Figure 5.1]. 
Administration of ODN2088 along with NH4-Ac (4 mM), significantly decreased the liver 
bodyweight ratio in WT-B6 mice (n=15) compared to the NH4-Ac alone treated group 
(p<0.0001) whereas there was a significant increase in the liver bodyweight ratio in WT- 
B6 mice treated with NH4-Ac alone (n=16) compared to controls (n=13) (p<0.0001). 
There was no difference in the liver bodyweight ratio in WT-B6 mice treated with 
ODN2088 and NH4-Ac (4 mM) compared to controls [Figure 5.2]. 
Administration of ODN2088 along with NH4-Ac (4 mM), reduced the hepatocyte swelling 
observed in WT-B6 mice compared to the NH4-Ac alone treated group whereas there 
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was an increase in the liver bodyweight ratio in WT- B6 mice treated with NH4-Ac alone 
compared to controls. There was no difference in the liver bodyweight ratio in WT-B6 





Figure 5.1: Decreased brain water content in WT-B6 mice after TLR9 
inhibition. 
Brain water content was significantly increased in WT-B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls (p<0.0001) [mean difference: 1.2; 95% C.I.: 
0.64 to 1.7]. This was significantly inhibited when the TLR9 antagonist (ODN2088) was 
administered to WT-B6 mice along with NH4-Ac (4 mM) (p<0.001) [mean difference: –
1.1; 95% C.I.: -1.71 to -0.48] and there was no difference compared to controls [mean 
difference: 0.1; 95% C.I.: -0.46 to 0.68]. [NH4-Ac (n=11); controls (n=12) & ODN2088 
(n=10)] (normal data). Normality assumptions were checked and the data are expressed 
as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA was 





Figure 5.2: Decreased liver bodyweight ratio in WT-B6 mice after TLR9 
inhibition. 
Liver bodyweight ratio was significantly increased in WT-B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls (p<0.0001) [median difference: 0.018; 95% 
C.I.: 0.012 to 0.024]. The liver bodyweight ratio was significantly inhibited when TLR9 
was inhibited using ODN2088 in WT-B6 mice following NH4-Ac stimulation (4 mM) 
(p<0.0001) [median difference: –0.02; 95% C.I.: -0.025 to -0.016] and there was no 
difference compared to controls [median difference: -0.002; 95% C.I.: -0.008 to 0.004]. 
[NH4-Ac (n=16); controls (n=13) & ODN2088 (n=15)] (non-normal data). Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. Kruskal-Wallis with Dunn’s multiple comparison test 






Figure 5.3: Liver histological changes in WT-B6 mice liver following NH4-Ac stimulation after TLR9 inhibition. 
These light microscope images (200x magnification) are histological sections (H&E stained) of the liver representing three different 
mice groups. Administration of ODN2088 along with NH4-Ac (4 mM) inhibited the hepatocyte swelling in WT-B6 mice. The images in the 
black box inset are the same regions of the specimen captured at a higher magnification (400x). 
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5.2. Cytokine production of T cells, macrophages and NK cells function 
were reduced after using ODN2088 
To determine whether the TLR9 antagonist inhibited the function of splenic or hepatic T 
cells, ODN2088 (50 µg) was administered to WT-B6 mice along with NH4-Ac (4 mM) for 
6 hours (n=14) and compared to controls (n=13) and WT-B6 mice stimulated with NH4-
Ac alone (n=13). 
5.2.1. Decreased cytokine production in splenic CD4pos T cells 
Following NH4-Ac (4 mM) stimulation, intracellular cytokine IFN-γ produced by splenic 
CD4pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), intracellular cytokine IFN-γ produced by splenic CD4pos T cells in WT-B6 mice 
was significantly decreased compared to NH4-Ac alone treated group (p<0.01) and was 
not different compared to controls [Figure 5.4]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine TNF-α produced by 
splenic CD4pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine TNF-α produced by splenic CD4pos T cells in WT-B6 
mice was significantly decreased compared to the NH4-Ac alone treated group (p<0.05) 
and significantly increased compared to controls (p<0.001) [Figure 5.5]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IL-6 produced by 
splenic CD4pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
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(4 mM), the intracellular cytokine IL-6 produced by splenic CD4pos T cells in WT-B6 mice 
was significantly decreased compared to the NH4-Ac alone treated group (p<0.0001) 







Figure 5.4: Decreased CD4pos IFN-γ production in WT-B6 mice splenocytes 
after TLR9 inhibition. 
The intracellular cytokine IFN-γ produced by splenic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [median difference: 2.2; 95% C.I.: 1.5 to 3]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.01) [median difference: –1.8; 95% C.I.: -2.5 to -1.1]; there was no 
difference compared to controls [median difference: 0.5; 95% C.I.: -0.3 to 1.1]. [NH4-Ac 
(n=13); controls (n=13) & ODN2088 (n=14)] (non-normal data). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Kruskal-Wallis with Dunn’s multiple comparisons test was used 
to analyse the differences between non-parametric data sets. (A) Graph and (B) FACS 







Figure 5.5: Decreased CD4pos TNF-α production in WT-B6 mice splenocytes 
after TLR9 inhibition. 
The intracellular cytokine TNF-α produced by splenic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [median difference: 49.7; 95% C.I.: 47.4 to 51.7]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.05) [median difference: –25.4; 95% C.I.: -28.8 to -22.2] 
although was significantly increased compared to controls [median difference: 24.1; 
95% C.I.: 20.8 to 27.1]. [NH4-Ac (n=13); controls (n=13) & ODN2088 (n=14)] (non-
normal data). Normality assumptions were checked and the data are expressed as mean 
with S.D.; p<0.05 were considered statistically significant. Kruskal-Wallis with Dunn’s 
multiple comparison test was used to analyse the differences between non-parametric 







Figure 5.6: Decreased CD4pos IL-6 production in WT-B6 mice splenocytes 
after TLR9 inhibition. 
The intracellular cytokine IL-6 produced by splenic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 2.1; 95% C.I.: 1.3 to 3]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.0001) [mean difference: –2; 95% C.I.: -2.8 to -1.3] and there was no 
difference compared to controls [mean difference: 0.09; 95% C.I.: -0.6 to 0.8]. [NH4-Ac 
(n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. (A) Graph and (B) FACS 
plots representing each group. 
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5.2.2. Decreased cytokine production in splenic CD8pos T cells  
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IFN-γ produced by 
splenic CD8pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine IFN-γ produced by splenic CD8pos T cells in WT-B6 
mice was significantly decreased compared to the NH4-Ac alone treated group 
(p<0.0001) and was not different compared to controls [Figure 5.7]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine TNF-α produced by 
splenic CD8pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine TNF-α produced by splenic CD8pos T cells in WT-B6 
mice was significantly decreased compared to NH4-Ac alone treated group (p<0.0001) 








Figure 5.7: Decreased CD8pos IFN-γ production in WT-B6 mice splenocytes 
after TLR9 inhibition. 
The intracellular cytokine IFN-γ produced by splenic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 3.9; 95% C.I.: 2 to 5.9]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.0001) [mean difference: –3.9; 95% C.I.: -5.8 to -2]; there was no 
difference compared to controls [mean difference: 0.03; 95% C.I.: -1.7 to 1.8]. [NH4-Ac 
(n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. (A) Graph and (B) FACS 







Figure 5.8: Decreased CD8pos TNF-α production in WT-B6 mice splenocytes 
after TLR9 inhibition. 
The intracellular cytokine TNF-α produced by splenic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 47.6; 95% C.I.: 44.2 to 51]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.0001) [mean difference: –44; 95% C.I.: -47.8 to -40.1]; there was no 
difference compared to controls [mean difference: 3.5; 95% C.I.: -0.2 to 7.4]. [NH4-Ac 
(n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. (A) Graph and (B) FACS 
plots representing each group. 
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5.2.3. Decreased cytokine production in hepatic CD4pos T cells 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IFN-γ produced by 
hepatic CD4pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine IFN-γ produced by hepatic CD4pos T cells in WT-B6 
mice was significantly decreased compared to the NH4-Ac alone treated group 
(p<0.0001) and was not different compared to controls [Figure 5.9]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine TNF-α produced by 
hepatic CD4pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM),the intracellular cytokine TNF-α produced by hepatic CD4pos T cells in WT-B6 
mice was significantly decreased compared to the NH4-Ac alone treated group (p<0.001) 
and was not different compared to controls [Figure 5.10]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IL-6 produced by 
hepatic CD4pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine IL-6 produced by hepatic CD4pos T cells in WT-B6 mice 
was significantly decreased compared to the NH4-Ac alone treated group (p<0.0001) 




Figure 5.9: Decreased CD4pos IFN-γ production in WT-B6 mice hepatic T cells 
after TLR9 inhibition. 
The intracellular cytokine IFN-γ produced by hepatic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 18.3; 95% C.I.: 15.1 to 21.6]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.0001) [mean difference: –18.4; 95% C.I.: -21.54 to -15.2]; 
there was no difference compared to controls [mean difference: -0.05; 95% C.I.: -3.2 to 
3.1]. [NH4-Ac (n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. One-way ANOVA with Tukey’s multiple comparisons 






Figure 5.10: Decreased CD4pos TNF-α production in WT-B6 mice hepatic T 
cells after TLR9 inhibition. 
The intracellular cytokine TNF-α produced by hepatic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [median difference: 21.4; 95% C.I.: 13.8 to 28.9]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.001) [median difference: –14.3; 95% C.I.: -22.3 to -6.3]; there 
was no difference compared to controls [median difference: 7; 95% C.I.: -0.7 to 14.8]. 
[NH4-Ac (n=13); controls (n=13) & ODN2088 (n=14)] (non-normal data). Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. Kruskal-Wallis with Dunn’s multiple comparisons 






Figure 5.11: Decreased CD4pos IL-6 production in WT-B6 mice hepatic T cells 
after TLR9 inhibition. 
The intracellular cytokine IL-6 produced by hepatic CD4pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 11.9; 95% C.I.: 18.2 to 15.6]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.0001) [mean difference: –11.7; 95% C.I.: -15.3 to -8.1]; there 
was no difference compared to controls [mean difference: 0.1; 95% C.I.: -3.4 to 3.7]. 
[NH4-Ac (n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. One-way ANOVA with Tukey’s multiple comparisons 





5.2.4. Decreased cytokine production in hepatic CD8pos T cells  
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IFN-γ produced by 
hepatic CD8pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine IFN-γ produced by hepatic CD8pos T cells in WT-B6 
mice was significantly decreased compared to the NH4-Ac alone treated group 
(p<0.0001); there was no difference compared to controls [Figure 5.12]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine TNF-α produced by 
hepatic CD8pos T cells in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine TNF-α produced by hepatic CD8pos T cells in WT-B6 
mice was significantly decreased compared to the NH4-Ac alone treated group 




Figure 5.12: Decreased CD8pos IFN-γ production in WT-B6 mice hepatic T cells 
after TLR9 inhibition. 
The intracellular cytokine IFN-γ produced by hepatic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 18.3; 95% C.I.: 15.1 to 21.5]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.0001) [mean difference: –16.4; 95% C.I.: -19.58 to -13.3]; 
there was no difference compared to controls [mean difference: 4.9; 95% C.I.: -1.1 to 
4.9]. [NH4-Ac (n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. One-way ANOVA with Tukey’s multiple comparisons 






Figure 5.13: Decreased CD8pos TNF-α production in WT-B6 mice hepatic T 
cells after TLR9 inhibition. 
The intracellular cytokine TNF-α produced by hepatic CD8pos T cells was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 47.3; 95% C.I.: 35.6 to 59]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.0001) [mean difference: –38.5; 95% C.I.: -50 to -27]; there was no 
difference compared to controls [mean difference: 8.8; 95% C.I.: -2.3 to 19.9]. [NH4-Ac 
(n=13); controls (n=13) & ODN2088 (n=14)] (normal data). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. 
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5.2.5. Decreased cytokine production in macrophages 
To determine whether the TLR9 antagonist inhibited the function of macrophages, 
ODN2088 (50 µg) was administered to WT-B6 mice along with NH4-Ac (4 mM) for 6 
hours (n=13) and compared to controls (n=5) and WT-B6 mice stimulated with NH4-Ac 
alone (n=6). 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IFN-γ produced by 
macrophages in WT-B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine IFN-γ produced by macrophages in WT-B6 mice was 
significantly decreased compared to the NH4-Ac alone treated group (p<0.01) and was 
not different compared to controls [Figure 5.14]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine TNF-α produced by 
macrophages in WT-B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine TNF-α produced by macrophages in WT-B6 mice was 
significantly decreased compared to the NH4-Ac alone treated group (p<0.05) and was 
not different compared to controls [Figure 5.15]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IL-6 produced by 
macrophages in WT- B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine IL-6 produced by macrophages in WT-B6 mice was 
significantly decreased compared to the NH4-Ac alone treated group (p<0.0001) and 







Figure 5.14: Decreased IFN-γ production by macrophages in WT-B6 mice 
splenocytes after TLR9 inhibition. 
The intracellular cytokine IFN-γ produced by splenic macrophages was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.05) [median difference: 2.4; 95% C.I.: 1.3 to 3.6]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.01) [median difference: -2.4; 95% C.I.: -3.4 to -1.6]; there was no 
difference compared to controls [median difference: –0.1; 95% C.I.: -0.7 to 0.3]. [NH4-Ac 
(n=6); controls (n=5) & ODN2088 (n=13)] (non-normal data). Normality assumptions 
were checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. Kruskal-Wallis with Dunn’s multiple comparisons test was used 
to analyse the differences between non-parametric data sets. (A) Graph and (B) FACS 







Figure 5.15: Decreased TNF-α production by macrophages in WT-B6 mice 
splenocytes after TLR9 inhibition. 
The intracellular cytokine TNF-α produced by splenic macrophages was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 25.1; 95% C.I.: 20.49 to 29.76]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.0001) [mean difference: -28.4; 95% C.I.: -32.2 to -24.7]; there 
was no difference compared to controls [mean difference: –3.3; 95% C.I.: -7.3 to 0.6]. 
[NH4-Ac (n=6); controls (n=5) & ODN2088 (n=13)] (normal data).  Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were 
considered statistically significant. One-way ANOVA with Tukey’s multiple comparisons 
test was used to analyse the differences between parametric data sets. (A) Graph and (B) 







Figure 5.16: Decreased IL-6 production by macrophages in WT-B6 mice 
splenocytes after TLR9 inhibition. 
The intracellular cytokine IL-6 produced by splenic macrophages was significantly 
increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared to controls 
(p<0.0001) [mean difference: 3.9; 95% C.I.: 3.2 to 4.7]. This was significantly inhibited 
when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along with 
NH4-Ac (4 mM) (p<0.0001) [mean difference: -4.9; 95% C.I.: -5.5 to -4.3]; there was no 
difference compared to controls [mean difference: –1; 95% C.I.: -1.6 to -0.3]. [NH4-Ac 
(n=6); controls (n=5) & ODN2088 (n=13)] (normal data). Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. (A) Graph and (B) FACS 
plots representing each group. 
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5.2.6. Decreased cytokine production in KLRG-1pos NK cells 
To determine whether the TLR9 antagonist inhibited the phenotype and function of 
KLRG-1pos NK cells, ODN2088 (50 µg) was administered to WT-B6 mice along with NH4-
Ac (4 mM) for 6 hours (n=10) and compared to controls (n=7) and WT-B6 mice 
stimulated with NH4-Ac alone (n=5). 
Following NH4-Ac (4 mM) stimulation, the frequency of KLRG-1pos NK cells in WT-B6 
mice was significantly increased compared to controls (p<0.05). When theTLR9 
antagonist, ODN2088 was administered along with NH4-Ac (4 mM), the frequency of 
KLRG-1high NK cells in WT-B6 mice was significantly decreased compared to the NH4-Ac 
alone treated group (p<0.0001) and was not different compared to controls [Figure 
5.17]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine IFN-γ produced by 
KLRG-1pos NK cells in WT-B6 mice was significantly increased compared to controls 
(p<0.001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac (4 
mM), the intracellular cytokine IFN-γ produced by KLRG-1pos NK cells in WT-B6 mice 
was significantly decreased compared to the NH4-Ac alone treated group (p<0.0001) 
and was not different compared to controls [Figure 5.18]. 
Following NH4-Ac (4 mM) stimulation, the intracellular cytokine TNF-α produced by 
KLRG-1pos NK cells in WT-B6 mice was significantly increased compared to controls 
(p<0.0001). When the TLR9 antagonist, ODN2088 was administered along with NH4-Ac 
(4 mM), the intracellular cytokine TNF-α produced by KLRG-1pos NK cells in WT-B6 mice 
was significantly decreased compared to the NH4-Ac alone treated group (p<0.0001) 







Figure 5.17: Decreased KLRG-1pos NK cells in WT-B6 mice splenocytes after 
TLR9 inhibition. 
Splenic KLRG-1pos NK cells were significantly increased in WT-B6 mice following NH4-Ac 
stimulation (4 mM) compared to controls (p<0.05) [mean difference: 5; 95% C.I.: 0.37 to 
9.7]. This was significantly inhibited when the TLR9 antagonist (ODN2088) was 
administered in WT-B6 mice along with NH4-Ac (4 mM) (p<0.0001) [mean difference: -
12; 95% C.I.: -16.3 to -7.7]; there was no difference compared to controls [mean 
difference: –7; 95% C.I.: -11.6 to -2.3]. [NH4-Ac (n=5); controls (n=7) & ODN2088 
(n=10)] (normal data). Normality assumptions were checked and the data are expressed 
as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA 
with Tukey’s multiple comparisons test was used to analyse the differences between 







Figure 5.18: Decreased IFN-γ production by KLRG-1pos NK cells in WT-B6 
mice splenocytes after TLR9 inhibition. 
The intracellular cytokine IFN-γ produced by splenic KLRG-1pos NK cells was 
significantly increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared 
to controls (p<0.001) [mean difference: 4; 95% C.I.: 2.1 to 5.9]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.0001) [mean difference: -4.8; 95% C.I.: -6.5 to -3]; there was 
no difference compared to controls [mean difference: –0.7; 95% C.I.: -2.3 to 0.8]. [NH4-Ac 
(n=5); controls (n=7) & ODN2088 (n=10)] (normal data). Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. (A) Graph and (B) FACS 







Figure 5.19: Decreased TNF-α produced by KLRG-1pos NK cells in WT-B6 mice 
splenocytes after TLR9 inhibition. 
The intracellular cytokine TNF-α produced by splenic KLRG-1pos NK cells was 
significantly increased in WT-B6 mice following NH4-Ac stimulation (4 mM) compared 
to controls (p<0.0001) [mean difference: 5.9; 95% C.I.: 4 to 7.8]. This was significantly 
inhibited when the TLR9 antagonist (ODN2088) was administered in WT-B6 mice along 
with NH4-Ac (4 mM) (p<0.0001) [mean difference: -6.5; 95% C.I.: -8.3 to -4.8]; there was 
no difference compared to controls [mean difference: –0.6; 95% C.I.: -2.2 to 0.9]. [NH4-Ac 
(n=5); controls (n=7) & ODN2088 (n=10)] (normal data). Normality assumptions were 
checked and the data are expressed as mean with S.D.; p<0.05 were considered 
statistically significant. One-way ANOVA with Tukey’s multiple comparisons test was 
used to analyse the differences between parametric data sets. (A) Graph and (B) FACS 
plots representing each group. 
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To determine whether the TLR9 antagonist inhibited the dsDNA released into the 
circulation, ODN2088 (50 µg) was administered to WT-B6 mice along with NH4-Ac (4 
mM) for 6 hours (n=15) and compared to controls (n=13) and WT-B6 mice stimulated 
with NH4-Ac alone (n=13). 
Following NH4-Ac (4 mM) stimulation, the plasma dsDNA level in WT-B6 mice was 
significantly increased compared to controls (p<0.001). When the TLR9 antagonist, 
ODN2088 was administered along with NH4-Ac (4 mM), the plasma dsDNA level in WT-
B6 mice was not different compared to NH4-Ac alone treated group but was significantly 





Figure 5.20: Unchanged plasma dsDNA level in WT-B6 mice after TLR9 
inhibition. 
Plasma dsDNA level was significantly increased in WT-B6 mice following NH4-Ac (4 mM) 
stimulation compared to controls (p<0.001) [mean difference: 3.5; 95% C.I.: 1.3 to 5.6]. 
This was unchanged when the TLR9 antagonist (ODN2088) was administered in WT-B6 
mice along with NH4-Ac (4 mM) [mean difference: 3.5; 95% C.I.: 1.3 to 5.6] and remained 
significantly increased compared to controls (p<0.01) [mean difference: -0.4; 95% C.I.: -





In this chapter, it has been demonstrated that the TLR9 antagonist ODN2088 abrogates 
the cytokine production of T cells, macrophages and NK cells in WT-B6 mice and 
protects against the development of brain oedema in WT-B6 mice induced by 4 mM 
ammonia challenge. These data are well supported by the findings of Imaeda et al who in 
a paracetamol toxicity model, established that inhibition of TLR9 using ODN2088 and 
IRS954, a TLR7/9 antagonist, protected against the development of pro-inflammation 
and mortality 108. Furthermore it has been shown that inhibition of TLR9 reduced the 
resultant inflammation induced by Legionella pneumophila, 205 and is an effective anti-
hypertensive in rats 206. 
Usually the TLR9 antagonist, ODN2088, acts by disrupting the co-localization of the CpG 
motif of the ODN with TLR9 without affecting cellular binding and uptake 207, therefore 
it could be assumed a similar mechanism would have been involved in this study as the 
TLR9 activated by ammonia-induced inflammation is dependent on DNA. The reactivity 
of the compound ODN2088 is specific for murine TLR9, but a study on systemic lupus 
erythematosus, an autoimmune disease, demonstrated that IRS954, a similar compound, 
inhibited both TLR7 and 9 208, therefore it is unclear whether this compound cross 
reacts with other TLRs. Although ammonia was not measured in the brain or in other 
regions in the animals, the upregulation of TLR9 expression was reversed at the 8 hour-
time point after the injection of ammonia, therefore it could be assumed that ammonia 
starts clearing from the body 6 hours after the injection. 
There was no change in the DNA release when the TLR9 antagonist was injected along 
with NH4-Ac. This is mainly because the ODN2088 disrupts the co-localization of the 
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DNA with TLR9 and as discussed previously the DNA release could be a result of 
ammonia stimulation 189. There is no clear information about the duration it takes for 
this compound to get activated or whether it is able to cross the blood brain barrier. 
It is clearly evident from this study that administration of ODN2088 prevents the 
ammonia-induced brain oedema in WT mice. However, the current  understanding of 
ammonia-induced brain oedema in relation to ALF is that it is mainly caused by 
accumulation of glutamine in the astrocytes and the possible mechanisms for this 
include increased synthesis of glutamine and decreased clearance of glutamine from the 
astrocyte as a result of impaired transport 88, 89. This raises the question as to whether 
the TLR9 antagonist might have influenced the glutamine system in the brain, but there 
is no existing literature that supports or validates the impact of TLR9 antagonism on the 
brain and/or the glutamine system. This also leads us to postulate that the ammonia-
induced brain oedema in ALF is mainly driven by systemic inflammation mediated by 







Chapter 6. Neutrophil and/or 
Kupffer cell TLR9 expression 
mediates the ammonia-induced 
inflammation and brain oedema 
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In chapters 4 and 5, it has been shown that TLR9-/- B6 mice were protected against the 
deleterious effects of ammonia on the immune system and brain. The use of a TLR9 
antagonist tempered the pro-inflammatory state and abrogated the development of 
brain oedema following ammonia stimulation. Furthermore, it has also been shown that 
T cells, macrophages and NK cells were the immune cell sub-sets involved in this 
ammonia-induced TLR9-mediated systemic inflammatory response. However, it 
remains unclear as to which innate immune cell type(s) were activated by the ammonia 
and triggered the adaptive immune response. Although there was no difference in the 
neutrophil function between WT-B6 mice and TLR9-/- B6 mice following NH4-Ac 
stimulation, neutrophil TLR9 expression was synergistically upregulated by ammonia, 
IL-8 and DNA in the human study. 
Therefore to determine whether neutrophils play an important role in the ammonia-
induced inflammatory response, NH4-Ac was injected into another transgenic mouse 
model, TLR9fl/fl LysCre B6 mice whereby TLR9 is only deficient in neutrophils and 
Kupffer cells, and compared to controls and TLR9fl/fl B6 mice. The TLR9fl/fl LysCre B6 
mice results were also compared to WT-B6 mice and TLR9-/- B6 mice [Method – 2.24.1].  
6.1. Ammonia-induced brain oedema and changes in the liver were 
dependent on neutrophils and/or Kupffer cell TLR9 
6.1.1. Brain water content 
To determine whether neutrophils and/or Kupffer cell TLR9 expression influenced the 
ammonia-induced brain oedema, the differences in the brain water content of TLR9fl/fl 
B6 mice and TLR9fl/fl LysCre B6 mice was determined six hours after a single low dose of 
NH4-Ac administration (I.P., 4 mM) and compared to controls (untreated).  
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Following NH4-Ac stimulation (4 mM), there was a significant increase in the brain water 
content in TLR9fl/fl B6 mice (n=11) compared to controls (n=8) (NH4-Ac untreated) 
(p<0.001); there was no difference in the brain water content in TLR9fl/fl LysCre B6 mice 
(n=9) compared to controls (n=9). There was a significant decrease in the brain water 
content in TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice (p<0.05) following 
NH4-Ac stimulation (4 mM) [Figure 6.1]. 
When compared between three groups, brain water content was significantly decreased 
in TLR9-/- B6 mice (n=8) (p<0.05) and TLR9fl/fl LysCre B6 mice (n=9) (p<0.001) 
compared to WT-B6 mice (n=9) following NH4-Ac stimulation (4 mM). There was no 
difference in the brain water content between TLR9-/- B6 mice and TLR9fl/fl LysCre B6 
mice [Figure 6.2]. 
6.1.2. Changes in the liver bodyweight ratio 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the liver 
bodyweight ratio in TLR9fl/fl B6 mice (n=15) compared to controls (n=8) (NH4-Ac 
untreated) (p<0.05); there was no difference in the liver bodyweight ratio in TLR9fl/fl 
LysCre B6 mice (n=10) compared to controls (n=10). There was a significant decrease in 
the liver bodyweight ratio in TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice 
(p<0.05) following NH4-Ac stimulation (4 mM) [Figure 6.3]. 
When compared between three groups, liver bodyweight ratio was significantly 
decreased in TLR9-/- B6 mice (n=11) (p<0.0001) and TLR9fl/fl LysCre B6 mice (n=10) 
(p<0.0001) compared to WT-B6 mice (n=16) following NH4-Ac stimulation (4 mM). 
There was no difference in the liver bodyweight ratio between TLR9-/- B6 mice and 
TLR9fl/fl LysCre B6 mice [Figure 6.4]. 
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6.1.3. Changes in the liver histology 
Hepatocyte swelling was decreased in TLR9-/- B6 mice and TLR9fl/fl LysCre B6 mice 
compared to WT-B6 mice following NH4-Ac stimulation (4 mM). There was no difference 
in the hepatocyte morphology between TLR9-/- B6 mice and TLR9fl/fl LysCre B6 mice 





Figure 6.1: Brain water content in TLR9fl/fl B6 mice and TLR9fl/fl LysCre B6 
mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the brain water 
content in TLR9fl/fl B6 mice compared to controls (p<0.001) [mean difference: 1.1; 95% 
C.I.: 0.5 to 1.6] (normal data). The increase in brain water was significantly ameliorated 
in TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice (p<0.05) [mean difference: -
0.7; 95% C.I.: -1.2 to -0.15] (normal data). [TLR9fl/fl B6 mice (n=11) & controls (n=8); 
TLR9fl/fl LysCre B6 mice (n=9) & controls (n=9)]. Normality assumptions were checked 
and the data are expressed as mean with S.D.; p<0.05 were considered statistically 






Figure 6.2: Brain water content in WT-B6 mice, TLR9-/- B6 mice and TLR9fl/fl 
LysCre B6 mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant decrease in the brain 
water content in TLR9-/- B6 mice (p<0.05) [mean difference: -0.91; 95% C.I.: -1.6 to -
0.17] and TLR9fl/fl LysCre B6 mice (p<0.001) [mean difference: -1.4; 95% C.I.: -2.1 to -
0.7] compared to WT-B6 mice. There was no difference between the brain water content 
in TLR9fl/fl LysCre B6 mice and TLR9-/- B6 mice [mean difference: -0.5; 95% C.I.: -1.2 to 
0.2]. [WT-B6 mice (n=9); TLR9-/- B6 mice (n=8) and TLR9fl/fl LysCre B6 mice (n=9)] 
(normal data). Normality assumptions were checked and the data are expressed as 
mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA with 
Tukey’s multiple comparisons test was used to analyse the differences between 





Figure 6.3: Liver bodyweight ratio in TLR9fl/fl B6 mice and TLR9fl/fl LysCre B6 
mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the brain water 
content in TLR9fl/fl B6 mice compared to controls (p<0.05) [median difference: 0.007; 
95% C.I.: 0.001 to 0.01] (non-normal data), which was abrogated in the TLR9fl/fl LysCre 
B6 mice (p<0.05) [mean difference: -0.006; 95% C.I.: -0.015 to -0.001] (normal data). 
[TLR9fl/fl B6 mice (n=11) & controls (n=8); TLR9fl/fl LysCre B6 mice (n=9) & controls 
(n=9)]. Normality assumptions were checked and the data are expressed as mean with 
S.D.; p<0.05 were considered statistically significant. Student t-test was used to analyse 
the difference between parametric data sets and Mann-Whitney U test was used to 




Figure 6.4: Liver bodyweight ratio in WT-B6 mice, TLR9-/- B6 mice and 
TLR9fl/fl LysCre B6 mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant decrease in the liver 
bodyweight ratio in TLR9-/- B6 mice (p<0.0001) [mean difference: -0.015; 95% C.I.: -0.02 
to -0.008] and TLR9fl/fl LysCre B6 mice (p<0.0001) [mean difference: -0.019; 95% C.I.: -
026 to -0.013] compared to WT-B6 mice. There was no difference between TLR9fl/fl 
LysCre B6 mice compared to TLR9-/- B6 mice [mean difference: -0.005; 95% C.I.: -0.01 to 
-0.002]. [WT-B6 mice (n=16); TLR9-/- B6 mice (n=11) and TLR9fl/fl LysCre B6 mice 
(n=10)] (normal data). Normality assumptions were checked and the data are expressed 
as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA 
with Tukey’s multiple comparisons test was used to analyse the differences between 





Figure 6.5: Liver histological changes following NH4-Ac stimulation. 
These light microscope images (200x magnification) are sections (H&E stained) of the liver representing three different mice groups. 
Following NH4-Ac stimulation (4 mM), hepatocyte swelling was increased in the sections of the liver in WT-B6 mice compared to TLR9-/- B6 
mice and TLR9fl/fl LysCre B6 mice. There was no difference in the hepatocyte morphology between TLR9-/- B6 mice and TLR9fl/fl LysCre B6 




6.2. Ammonia-induced macrophage dysfunction was mediated by 
TLR9 expressed on neutrophils and/or Kupffer cells 
To determine whether TLR9 expressed on neutrophils and Kupffer cells influenced the 
ammonia-induced inflammation, the differences in the intracellular cytokine production 
of macrophages in TLR9fl/fl B6 mice (n=13) and TLR9fl/fl LysCre B6 mice (n=9) was 
determined six hours after the administration of a single low dose of NH4-Ac (I.P., 4 mM) 
and compared to controls (untreated) [TLR9fl/fl B6 mice (n=8) and TLR9fl/fl LysCre B6 
mice (n=10)] (Method-2).  
6.2.1. IFN-γ produced by macrophages 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IFN-γ produced by macrophages in TLR9fl/fl B6 mice compared to 
controls (NH4-Ac untreated) (p<0.0001); there was no difference in the intracellular 
cytokine IFN-γ produced by macrophages in TLR9fl/fl LysCre B6 mice compared to 
controls. There was a significant decrease in the intracellular cytokine IFN-γ produced 
by macrophages in TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice (p<0.0001) 
following NH4-Ac stimulation (4 mM) [Figure 6.6]. 
When compared between three groups, the intracellular cytokine IFN-γ produced by 
macrophages was significantly decreased in TLR9-/- B6 mice (n=7) (p<0.01) and TLR9fl/fl 
LysCre B6 mice (n=9) (p<0.05) compared to WT-B6 mice (n=5) following NH4-Ac 
stimulation (4 mM). There was no difference in the intracellular cytokine IFN-γ 
produced by macrophages of TLR9-/- B6 mice and TLR9fl/fl LysCre B6 mice [Figure 6.7]. 
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6.2.2. TNF-α produced by macrophages  
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine TNF-α produced by macrophages in TLR9fl/fl B6 mice compared to 
controls (NH4-Ac untreated) (p<0.0001); there was also a significant increase in the 
intracellular cytokine TNF-α produced by macrophages in TLR9fl/fl LysCre B6 mice 
compared to controls (p<0.05). There was however, a significant decrease in the 
intracellular cytokine TNF-α produced by macrophages in TLR9fl/fl LysCre B6 mice 
compared to TLR9fl/fl B6 mice (p<0.0001) following NH4-Ac stimulation (4 mM) [Figure 
6.8]. 
When compared between three groups, the intracellular cytokine TNF-α produced by 
macrophages was significantly decreased in TLR9-/- B6 mice (n=7) (p<0.01) and TLR9fl/fl 
LysCre B6 mice (n=9) (p<0.01) compared to WT-B6 mice (n=5) following NH4-Ac 
stimulation (4 mM). There was no difference in the production of the intracellular 
cytokine TNF-α by macrophages between TLR9-/- B6 mice and TLR9fl/fl LysCre B6 mice 
[Figure 6.9]. 
6.2.3. IL-6 produced by macrophages 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the 
intracellular cytokine IL-6 produced by macrophages in TLR9fl/fl B6 mice compared to 
controls (NH4-Ac untreated) (p<0.0001); there was no difference in the intracellular 
cytokine IL-6 produced by macrophages in TLR9fl/fl LysCre B6 mice compared to 
controls. There was however a significant decrease in the intracellular cytokine IL-6 
produced by macrophages in TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice 
(p<0.0001) following NH4-Ac stimulation (4 mM) [Figure 6.10]. 
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When compared between three groups, the intracellular cytokine IL-6 produced by 
macrophages was significantly decreased in TLR9-/- B6 mice (n=7) (p<0.0001) and 
TLR9fl/fl LysCre B6 mice (n=10) (p<0.0001) compared to WT-B6 mice (n=5) following 
NH4-Ac stimulation (4 mM). There was no difference in the production of the 
intracellular cytokine IFN-γ by macrophages between TLR9-/- B6 mice and TLR9fl/fl 





Figure 6.6: IFN-γ production by macrophages in TLR9fl/fl B6 mice and TLR9fl/fl 
LysCre B6 mice splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IFN-γ produced by splenic macrophages was significantly 
increased in TLR9fl/fl B6 mice following NH4-Ac stimulation (4 mM) compared to 
controls (p<0.0001) [mean difference: 3.1; 95% C.I.: 2 to 4.2] (normal data). There was 
no difference in IFN-γ produced by splenic macrophages in TLR9fl/fl LysCre B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls [mean difference: -0.04; 
95% C.I.: -0.4 to 0.3] (normal data), but it was significantly decreased compared to 
TLR9fl/fl B6 mice (p<0.0001) [mean difference: –3.1; 95% C.I.: -4.1 to -2.2] (normal data). 
[TLR9fl/fl B6 mice (n=13) & controls (n=9); TLR9fl/fl LysCre B6 mice (n=8) & controls 
(n=10)]. Normality assumptions were checked and the data are expressed as mean with 
S.D.; p<0.05 were considered statistically significant. Student t-test was used to analyse 







Figure 6.7: IFN-γ production by macrophages in WT-B6 mice, TLR9-/- B6 mice 
and TLR9fl/fl LysCre B6 mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant decrease in the IFN-γ 
production by macrophages in TLR9-/- B6 mice (p<0.01) [mean difference: -1.5; 95% C.I.: 
-2.6 to -0.6] and TLR9fl/fl LysCre B6 mice (p<0.05) [mean difference: -1.1; 95% C.I.: -2 to -
0.12] compared to WT-B6 mice. There was no difference between TLR9fl/fl LysCre B6 
mice compared to TLR9-/- B6 mice [mean difference: 0.5; 95% C.I.: -0.3 to 1.3]. [WT-B6 
mice (n=5); TLR9-/- B6 mice (n=7) and TLR9fl/fl LysCre B6 mice (n=9)] (normal data). 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. One-way ANOVA with Tukey’s multiple 
comparisons test was used to analyse the differences between parametric data. (A) 





Figure 6.8: TNF-α production by macrophages in TLR9fl/fl B6 mice and 
TLR9fl/fl LysCre B6 mice following NH4-Ac stimulation. 
The intracellular cytokine TNF-α produced by splenic macrophages was significantly 
increased in TLR9fl/fl B6 mice following NH4-Ac stimulation (4 mM) compared to 
controls (p<0.0001) [mean difference: 14.3; 95% C.I.: 10.2 to 18.3] (normal data). There 
was a significant increase in the TNF-α produced by splenic macrophages in TLR9fl/fl 
LysCre B6 mice following NH4-Ac stimulation (4 mM) compared to controls (p<0.05) 
[median difference: 2.9; 95% C.I.: 0.5 to 4.5] (normal data), but it was significantly 
decreased compared to TLR9fl/fl B6 mice (p<0.0001) [mean difference: –13; 95% C.I.: -
16.3 to -9.7] (normal data). [TLR9fl/fl B6 mice (n=13) & controls (n=9); TLR9fl/fl LysCre 
B6 mice (n=8) & controls (n=10)]. Normality assumptions were checked and the data 
are expressed as mean with S.D.; p<0.05 were considered statistically significant. 







Figure 6.9: TNF-α production by macrophages in WT-B6 mice, TLR9-/- B6 
mice and TLR9fl/fl LysCre B6 mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant decrease in the TNF-α 
production by macrophages in TLR9-/- B6 mice (p<0.01) [median difference: -15.9; 95% 
C.I.: -20.6 to -9.3] and TLR9fl/fl LysCre B6 mice (p<0.01) [median difference: -13.5; 95% 
C.I.: -15 to -10.8] compared to WT-B6 mice. There was no difference between TLR9fl/fl 
LysCre B6 mice compared to TLR9-/- B6 mice [median difference: 3.7; 95% C.I.: -4.4 to 
6.9]. [WT-B6 mice (n=5); TLR9-/- B6 mice (n=7) and TLR9fl/fl LysCre B6 mice (n=9)] 
(non-normal data). Normality assumptions were checked and the data are expressed as 
mean with S.D.; p<0.05 were considered statistically significant. Kruskal-Wallis with 
Dunn’s multiple comparisons test was used to analyse the differences between non-






Figure 6.10: IL-6 production by macrophages in TLR9fl/fl B6 mice and TLR9fl/fl 
LysCre B6 mice splenocytes following NH4-Ac stimulation. 
The intracellular cytokine IL-6 produced by splenic macrophages was significantly 
increased in TLR9fl/fl B6 mice following NH4-Ac stimulation (4 mM) compared to 
controls (p<0.0001) [mean difference: 2.7; 95% C.I.: 2.2 to 3.4] (normal data). There was 
no difference in the IL-6 produced by splenic macrophages in TLR9fl/fl LysCre B6 mice 
following NH4-Ac stimulation (4 mM) compared to controls [mean difference: 0.17; 95% 
C.I.: -0.25 to 0.6] (normal data), but it was significantly decreased compared to TLR9fl/fl 
B6 mice (p<0.0001) [mean difference: –2.3; 95% C.I.: -2.8 to -1.8] (normal data). 
[TLR9fl/fl B6 mice (n=13) & controls (n=9); TLR9fl/fl LysCre B6 mice (n=8) & controls 
(n=10)]. Normality assumptions were checked and the data are expressed as mean with 
S.D.; p<0.05 were considered statistically significant. Student t-test was used to analyse 







Figure 6.11: IL-6 production by macrophages in WT-B6 mice, TLR9-/- B6 mice 
and TLR9fl/fl LysCre B6 mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), there was a significant decrease in the IL-6 
production by macrophages in TLR9-/- B6 mice (p<0.0001) [mean difference: -4; 95% 
C.I.: -4.7 to -3.2] and TLR9fl/fl LysCre B6 mice (p<0.0001) [mean difference: -3.5; 95% 
C.I.: -4.1 to -2.7] compared to WT-B6 mice. There was no difference between TLR9fl/fl 
LysCre B6 mice compared to TLR9-/- B6 mice [mean difference: 0.5; 95% C.I.: -0.13 to 
1.1]. [WT-B6 mice (n=5); TLR9-/- B6 mice (n=7) and TLR9fl/fl LysCre B6 mice (n=9)] 
(normal data). Normality assumptions were checked and the data are expressed as 
mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA with 
Tukey’s multiple comparisons test was used to analyse the differences between 
parametric data sets. (A) Graph and (B) FACS plots representing each group. 
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6.3. Ammonia-induced T cell dysfunction was independent of TLR9 
expressed on neutrophils and/or Kupffer cells 
To determine whether TLR9 expression on neutrophils and Kupffer cells influenced the 
ammonia-induced inflammatory response, the differences in the intracellular cytokine 
production of T cells in TLR9fl/fl B6 mice (n=13) and TLR9fl/fl LysCre B6 mice (n=9) was 
determined six hours after a single low dose of NH4-Ac administration (I.P., 4 mM) and 
compared to controls (untreated) [TLR9fl/fl B6 mice (n=8) and TLR9fl/fl LysCre B6 mice 
(n=10)] (Method-2).  
Intracellular cytokine production by T cells 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the production 
of the intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD4pos T cells and CD8pos T cells 
in TLR9fl/fl B6 mice compared to controls (NH4-Ac untreated) (p<0.0001). In contrast, 
there was a significant increase in the production of the intracellular cytokines (IFN-γ, 
TNF-α and IL-6) by CD4pos T cells and CD8pos T cells in TLR9fl/fl LysCre B6 mice 
compared to controls (p<0.0001). There was no difference in the production of the 
intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD4pos T cells and CD8pos T cells in 
TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice following NH4-Ac stimulation (4 
mM) [data not shown]. 
When compared between three groups, the production of the intracellular cytokines 
(IFN-γ, TNF-α and IL-6) by CD4pos T cells and CD8pos T cells was significantly decreased 
in TLR9-/- B6 mice (n=10) compared to WT-B6 mice (n=11) (p<0.05) and TLR9fl/fl LysCre 
B6 mice (n=7) (p<0.01) following NH4-Ac stimulation (4 mM). There was no difference 
in the production of the intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD4pos T cells 
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Figure 6.12: Intracellular cytokine production by CD4pos T cells in WT-B6 mice, TLR9-/- B6 mice and TLR9fl/fl LysCre B6 mice 
following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), the production of the intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD4pos T cells in TLR9-/- B6 
mice was significantly decreased compared to WT-B6 mice (p<0.05) and TLR9fl/fl LysCre B6 mice (p<0.01). There was no difference in the 
production of the intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD4pos T cells of WT-B6 mice and TLR9fl/fl LysCre B6 mice. Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA 
with Tukey’s multiple comparisons test was used to analyse the differences between parametric data sets and Kruskal-Wallis with Dunn’s 







Figure 6.13: Intracellular cytokine production by CD8pos T cells in WT-B6 mice, TLR9-/- B6 mice and TLR9fl/fl LysCre B6 mice 
following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), the production of the intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD8pos T cells in TLR9-/- B6 
mice was significantly decreased compared to WT-B6 mice (p<0.001) and TLR9fl/fl LysCre B6 mice (p<0.001). There was no difference in the 
production of the intracellular cytokines (IFN-γ, TNF-α and IL-6) by CD8pos T cells of WT-B6 mice and TLR9fl/fl LysCre B6 mice. Normality 
assumptions were checked and the data are expressed as mean with S.D.; p<0.05 were considered statistically significant. One-way ANOVA 
with Tukey’s multiple comparisons test was used to analyse the differences between parametric data sets and Kruskal-Wallis with Dunn’s 
multiple comparisons test was used to analyse the differences between non-parametric data sets. 
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6.4. Ammonia-induced NK cell dysfunction was independent of TLR9 
expressed on neutrophils and/or Kupffer cells 
To determine whether TLR9 expressed on neutrophils and Kupffer cells influenced the 
ammonia-induced inflammation, the differences in the phenotype of NK cells in TLR9fl/fl 
B6 mice (n=13) and TLR9fl/fl LysCre B6 mice (n=9) was determined six hours after a 
single low dose of NH4-Ac administration (I.P., 4 mM) and compared to controls 
(untreated) [TLR9fl/fl B6 mice (n=8) and TLR9fl/fl LysCre B6 mice (n=10)] (Method-2). 
Intracellular cytokine production by NK cells 
Following NH4-Ac stimulation (4 mM), there was a significant increase in the KLRG-1pos 
NK cells in TLR9fl/fl B6 mice compared to controls (NH4-Ac untreated) (p<0.01); there 
was also a significant increase in the KLRG-1pos NK cells in TLR9fl/fl LysCre B6 mice 
compared to controls (p<0.01). There was no difference however in the KLRG-1pos NK 
cells in TLR9fl/fl LysCre B6 mice compared to TLR9fl/fl B6 mice following NH4-Ac 
stimulation (4 mM) [data not shown]. 
When compared between three groups, the frequency of KLRG-1pos NK cells was 
significantly decreased in TLR9-/- B6 mice (n=10) compared to WT-B6 mice (n=11) 
(p<0.0001) and TLR9fl/fl LysCre B6 mice (n=7) (p<0.01) following NH4-Ac stimulation (4 
mM). There was also a significant decrease in the frequency of KLRG-1pos NK cells in 






Figure 6.14: KLRG-1pos NK cells in WT-B6 mice, TLR9-/- B6 mice and TLR9fl/fl 
LysCre B6 mice following NH4-Ac stimulation. 
Following NH4-Ac stimulation (4 mM), the frequency of KLRG-1pos NK cells in TLR9-/- B6 
mice was significantly decreased compared to WT-B6 mice (p<0.0001) and TLR9fl/fl 
LysCre B6 mice (p<0.01). There was also a significant decrease in the frequency of 
KLRG-1pos NK cells in TLR9fl/fl LysCre B6 mice compared to WT-B6 mice (p<0.01). 
Normality assumptions were checked and the data are expressed as mean with S.D.; 
p<0.05 were considered statistically significant. One-way ANOVA with Tukey’s multiple 
comparisons test was used to analyse the differences between parametric data sets and 
Kruskal-Wallis with Dunn’s multiple comparisons test was used to analyse the 





In this chapter the most important finding is that there was decreased cytokine 
production from macrophages and a reduction in liver bodyweight ratio and brain water 
content in TLR9fl/fl LysCre B6 mice following NH4-Ac stimulation; and surprisingly, they 
exhibited no difference compared to TLR9-/- B6 mice. 
Macrophages are liver resident Kupffer cells and infiltrating monocytes, and are one of 
the important proinflammatory cell subsets that were induced by ammonia stimulation. 
Neutrophil function although seemingly unaffected by ammonia in mice has been 
reported to be abnormal in hyperammonemic conditions in rats 140 and ALF patients 139. 
Although neutrophils have a definitive role in amplifying the liver injury in paracetamol 
and cholestasis mice models 106, 107, 209, 210, the phenotype and function of neutrophils in 
normal mice has not been characterised so far. Thus neutrophils may behave differently 
in mice and humans in response to ammonia. Moreover the ratio of neutrophils in mice 
is reduced compared to the humans 199. 
In this study, deletion of TLR9 in Kupffer cells and neutrophils reduced macrophage-
induced inflammation and prevented an increase in brain water content following 
ammonia stimulation indicating that TLR9 expressed in those cells plays an important 
role in sensing the DNA released by the hepatocytes in the circulation. Marques et al 
recently demonstrated that neutrophils are the key innate immune cells, but not the 
Kupffer cells, that sense DNA through the TLR9/NF-κB pathway and induce 
proinflammation in paracetamol toxicity 107. These data are well supported by the 
strong correlation demonstrated between neutrophil TLR9, ammonia and IL-8 in PALF 
and the abrogation of neutrophil TLR9 upregulation and cytokine production to PALF 
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plasma by DNAse-I. Taken together these data suggest that although neutrophil function 
remains unaffected by ammonia in this mouse model, neutrophils may still play an 
important role in the development of brain oedema as suggested by the human PALF 
study by  sensing DNA released by ammonia and the necrotic liver mediated  through 
TLR9. The downstream consequences of neutrophil TLR9 activation then results in the 
recruitment of other adaptive immune cell sub-sets, to produce a pro-inflammatory 
milieu. However, this postulated mechanism can only be tested in the future by 














Chapter 7. General discussion 
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Hypothesis 1: Circulating neutrophil TLR9 expression is increased in PALF patients with 
advanced hepatic encephalopathy and SIRS resulting from the release of necrotic 
hepatocyte products, ammonia, DNA and IL-8 into the circulation [Chapter 3]. 
The importance of neutrophil TLR9 expression in human PALF has been demonstrated 
by characterising neutrophil phenotype and function, although the role of neutrophils in 
the development of liver injury and importance of TLR4 and -9 have been previously 
studied extensively in paracetamol-induced murine models. Ex-vivo studies revealing 
robust correlations demonstrate that ammonia and IL-8 synergistically upregulate 
neutrophil TLR9 and induce systemic inflammation. Incubation of healthy neutrophils 
with and without DNAse-I demonstrates that necrotic hepatocyte products upregulate 
neutrophil TLR9 expression. Moreover, following stimulation with various stimuli and 
undertaking further functional studies it has been demonstrated that neutrophil 
function varied in PALF. Neutrophils were pre-primed in patients with low SIRS scores 
and HE grade, but exhausted in patients with high SIRS scores and advanced HE. Taken 
together these data demonstrate that circulating neutrophil TLR9 expression is 
increased in PALF as a result of necrotic hepatocyte products released in the circulation 
and thereby induces systemic inflammation and advanced coma grades . 
Hypothesis 2: TLR9 is central in the development of ammonia-induced cerebral 
oedema [Chapters 4 and 5]. 
Brain water content, a measure of brain oedema was increased in WT-B6 mice six hours 
following stimulation with NH4-Ac (4mM). The importance of TLR9 in the development 
of ammonia-induced brain oedema was demonstrated by the observation that any 
 297 
 
increase in ammonia-induced brain water content could be abrogated using a mouse 
model deficient of TLR9 or by inhibiting TLR9 using the antagonist ODN2035. 
Hypothesis 3: Ammonia induces inflammation by activating neutrophils and adaptive 
immune cell sub-sets through a TLR9-mediated mechanism [chapters 3, 4 and 5]. 
In the human PALF study, ex-vivo stimulation with NH4Cl resulted in the upregulation of 
TLR9 and cytokine production in neutrophils in HC and PALF patients. In the animal 
study, intraperitoneal injection of NH4-Ac resulted in the upregulation of pro-
inflammatory cytokine production by T cells, NK cells and macrophages which was 
abrogated in mice deficient of TLR9 or by inhibiting TLR9 using the antagonist 
ODN2035. Taken together these results indicate that ammonia induces inflammation by 
activating circulating neutrophils and adaptive immune cells through a TLR9 mediated 
mechanism. 
Hypothesis 4: Activation of TLR9 is a DNA dependent mechanism [Chapters 3 and 4]. 
In the human study, TLR9 and intracellular IL-8 expression was upregulated in healthy 
neutrophils following the exposure to PALF plasma, which could be decreased when the 
plasma was pre-treated with DNAse-I.  In the animal study, total DNA was increased in 
the plasma samples of WT-B6 mice and TLR9-/- B6 mice following NH4-Ac stimulation 
but not after Na-Ac stimulation indicating that ammonia influenced the release of DNA 
into the circulation in both the groups. Taken together these results indicate that 
ammonia activates TLR9 through a DNA dependent mechanism. 
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In this thesis, a novel link between ammonia-induced inflammation and the subsequent 
development of hepatic encephalopathy in PALF mediated by neutrophil TLR9 
activation has been demonstrated using two different models, human and mouse. In 
patients with PALF, a strong correlation between neutrophil TLR9 expression and 
ammonia and IL-8 was observed with the highest values of neutrophil TLR9 expression 
and IL-8 production observed in PALF patients with severe SIRS and advanced HE. 
Moreover, it was observed that necrotic by products such as ammonia, IL-8 and DNA 
released into the circulation upregulate neutrophil TLR9 expression in PALF. In the 
mouse model, a low dose of ammonia induced systemic inflammation and subsequent 
brain oedema through a TLR9-mediated mechanism in a DNA dependent manner with 
the importance of TLR9 being unequivocally demonstrated by using antagonists and 
genetically modified mice. In concordance with the human study, neutrophil and/or 
Kupffer cell TLR9 expression played an important role in inducing brain oedema and 
this was observed in the mouse model by deleting the TLR9 gene only in lysozyme 
expressing cells. Furthermore, the improved survival following a high dose of ammonia 
in the absence of TLR9 demonstrates the central role of TLR9 in the pathophysiology of 
ammonia-induced death. In addition to the existing literature base that demonstrates 
the importance of TLR9 in binding to DNA and inducing inflammation in PALF, I have 
demonstrated that TLR9 also plays an important role in the development of brain 
oedema in PALF 106-108. 
This novel observation that activation of TLR9 by ammonia induces systemic 
inflammation and subsequently leads to the development of brain oedema is well 
supported by recently published studies that show TLR9 induces inflammation in 
paracetamol overdose and non-alcoholic steatohepatitis 108, 211. This study further 
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expands our understanding of the role of TLR9 in liver failure by demonstrating that it 
plays an important role in the development of brain oedema. It has been already been 
established that pre-treatment with ammonia and then incubation with a mixture of 
pro-inflammatory cytokines exacerbates astrocyte swelling through the NF-κB pathway 
191. Furthermore, it has been demonstrated that mitochondrial permeability transition 
induces astrocyte swelling when cultured astrocytes were exposed to ammonia 212, 213 or 
a mixture of cytokines IFN-γ, TNF-α, IL-6 and IL-1β 214. Consistent with these published 
findings, increased cytokine production and brain water content in response to 
ammonia stimulation were observed in the animal study. The abrogation of cytokine 
production and protection against the development of brain oedema following 
administration of a specific TLR9 antagonist and in mice deficient of TLR9 indicates that 
TLR9 has an important role in the development of HE. This finding also supports the 
observation that increased cerebral hyperemia and systemic inflammation are 
responsible for inducing ICH 215.  
In this study, TLR9 has been shown to have a central role in the development of brain 
oedema in HE. It has also been previously reported that reduced astrocyte swelling can 
be seen in TLR4 silenced brain endothelium exposed to ammonia, cytokines and LPS 180 
and an increase in brain water content can be prevented following the administration of 
a TLR4 antagonist or in mice deficient of TLR4 in paracetamol hepatotoxicity 165 
implicating TLR4 as also playing a major role in the development of brain oedema. In 
spite of these data, the mechanism behind the activation of TLR4 remains unclear in the 
pathogenesis of HE. The observation of decreased circulating neutrophil TLR4 
expression in PALF in the context of no detectable systemic endotoxin in my human 
study suggests that neutrophil TLR4 does not play as significant a role as TLR9 in the 
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development of systemic inflammation or HE in PALF. These findings are corroborated 
by the animal study as neutrophil TLR4 expression was showing a trend towards 
downregulation during the optimization of ammonia in contrast to the upregulation of 
TLR9. The observation of increased necrotic byproducts such as high mobility group box 
– 1 (HMGB-1), a ligand of TLR4, in paracetamol overdose 216 and its role in the activation 
of TLR4 and guiding the neutrophils towards the liver 217 supports my postulation that 
TLR4 is not responsible for the ammonia-induced inflammation and subsequent brain 
oedema, rather other factors could be responsible for the activation of TLR4. 
Another important point to consider would be the route by which paracetamol is 
administered in human and mouse. In an animal model of paracetamol overdose, it has 
been demonstrated that oral administration of paracetamol developed clinical features 
similar to that of humans, but those administered paracetamol through the 
intraperitoneal route developed respiratory distress which was associated with a 
reduction in the arterial partial pressure of oxygen 218. These findings taken together 
suggest that the route of administration plays an important role in determining the 
mechanism by which paracetamol causes acute liver injury and subsequent 
development of multiple organ failure in those animals. 
In this study, deletion of TLR9 in Kupffer cells and neutrophils abrogated the 
inflammation induced by macrophages and increase in brain water content following 
ammonia stimulation. The decrease in the liver weight, brain water content and 
macrophage cytokine production after ammonia stimulation in TLR9fl/fl LysCre mice 
indicates that Kupffer cells and neutrophils sense the DNA induced by ammonia via a 
TLR9 mediated pathway. Recently it has been demonstrated that neutrophils, but not 
Kupffer cells, mainly sense the DNA through the TLR9 and NF-κB pathways in 
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paracetamol toxicity 107 supporting my earlier finding in human PALF that ammonia, IL-
8 and DNA upregulate neutrophil TLR9 expression, induce inflammation and exacerbate 
the severity of hepatic encephalopathy. Although neutrophil function remains 
unaffected by ammonia in the mouse model, it has been demonstrated that ammonia 
impairs neutrophil phagocytosis and increases the production of ROS in patients with 
liver cirrhosis 140. Furthermore, it has been demonstrated that neutrophil TLR9 
collaborates with chemokines and mitochondrial products to amplify the liver injury 
and systemic inflammation in paracetamol toxicity 106. These data taken together with 
the human study suggest that neutrophils may still play an important role in the 
development of brain oedema by sensing DNA released by ammonia and the necrotic 
liver mediated through TLR9. The downstream signalling of neutrophil TLR9 activation 
then results in the recruitment of other adaptive immune cell sub-sets, which then leads 
to the production of pro-inflammatory cytokines. However, this postulated mechanism 
can only be tested in the future by performing an adoptive transfer in neutrophil 
depleted mice. 
It has been previously reported that acetylation induces inflammation in acute alcoholic 
hepatitis 192 and the toxicity of ammonium salts was due to the rise in blood pH and 
alkalinization was responsible for the transfer of ammonium gas across the blood brain 
barrier 71, 72. Since the pH of mice is different compared to humans, infusion of fluids 
might affect the buffer reserve in the system. In the animal study, stimulation with 4 mM 
of Na-Ac did not alter the cytokine production of the immune cells or change the water 
content in the brain. Furthermore, the volume of NH4-Ac injected in this experiment was 
less than 5% of the total volume of blood. Taken together these results suggest that 
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inflammation and brain oedema was not influenced by acetate or change in the pH and 
this effect was solely induced by ammonia. 
This study for the first time demonstrates the central role of innate immunity as a driver 
of acute ammonia toxicity. When TLR9 gets activated by DNA, pro-inflammatory 
cytokines are produced by a number of innate immune cell sub-sets 158 and this 
normally takes about 5 hours. In a model of paracetamol hepatotoxicity, after sensing 
the DNA through TLR9, neutrophil infiltration was increased in the DNA-rich areas of 
the necrotic liver 6 hours after the administration of paracetamol and increased the 
production of proinflammatory cytokines 107. Based on these findings it can be assumed 
that ammonia-induced systemic inflammation within 5 hours and the subsequent 
development of brain oedema occurred shortly thereafter. This concept is supported by 
the acute ammonia toxicity model, where it has been demonstrated that animals develop 
brain oedema within minutes rather than hours 73. Taken together with the optimisation 
experiments, these results indicate that ammonia induces systemic inflammation and 
brain oedema within a span of 6 hours. 
The compensatory anti-inflammatory response syndrome (CARS) is a pattern of 
immunological responses that are responsible for deactivation of an over-exuberant 
SIRS restoring homeostasis 219. It has been previously reported that early changes in the 
anti-inflammatory cytokine IL-10 can predict outcomes thereby highlighting the 
importance of CARS in the pathophysiology of PALF 220. In this study, although the 
production of the anti-inflammatory cytokine, IL-10 was observed in PALF patients, the 
levels of the pro-inflammatory cytokines, IL-6 and IL-8 were markedly increased in 




Ammonia plays a central role in the pathogenesis of HE and brain oedema in ALF, with 
up to 25% of patients developing ICH and succumbing to brain herniation 32, 33, 51, 62. 
Infection and systemic inflammation are common in ALF, drive the development of HE 
and are major prognosticators 37, 38. Experimental models have unequivocally associated 
ammonia exposure with astrocyte swelling in the brain, an important finding of ALF, 
where ammonia is converted to glutamine and exerts an osmotic effect and induces 
oedema 47, 49, 191. This study provides new insights into ammonia, inflammation and 
brain oedema in PALF. In the animal study, I have demonstrated that ammonia-induced 
brain oedema is mediated through TLR9, dependent on DNA and is driven by the innate 
immune system. These findings taken along with the important observations in the 
human study that neutrophil TLR9 expression in PALF is mediated both by circulating 
endogenous DNA as well as ammonia and IL-8 in a synergistic manner inducing systemic 
inflammation and exacerbating HE implies that neutrophil TLR9 plays an important role 
in the development of HE. These data are well supported by the recently published 
observation that DNA deposition within the hepatocytes triggers inflammation in PALF 
through neutrophil TLR9 107. The amelioration of brain oedema and cytokine production 
by ODN2088 supports exploration of TLR9 antagonism as a therapeutic modality in 










Chapter 8. Drawbacks and 
perspectives for the future 
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In this thesis, the role that TLR9 plays in the development of ammonia-induced 
inflammation and HE in the context of PALF has been explored. The importance of the 
role of ammonia has been highlighted previously with respect to both inflammation and 
on brain swelling through its detoxification in the astrocyte, the cell most often 
associated with the pathogenesis of HE. This thesis still represents just the tip of the 
iceberg in terms of understanding the mechanisms involved in the pathogenesis of HE, 
however it was not possible for me to answer or demonstrate certain aspects due to the 
limitations of time and funding inherent in undertaking a PhD. Therefore I will 
summarise the drawbacks and briefly outline the future directions of travel for this 
study on which I look forward to continuing to work on over the coming years.  
One of the most important observations in this thesis is the role of TLR9 in the 
development of brain oedema following ammonia challenge, with astrocyte swelling 
most often associated with HE and quantified by measuring the brain water content. The 
observation of astrocyte swelling under an electron microscope remains the best 
method in terms of analysing it qualitatively. However this was not possible in the 
animal study due to the restriction in funding. Alternatively, immunofluorescence was 
tried on the brain sections by staining them for TLR9 expressed by astrocytes. This was 
not successful since most of the commercially available TLR9 antibodies were raised 
from mouse and had high background when they were tested on my samples. The 
availability of TLR9 antibodies raised from other species, which are reactive with mouse 
and could be used for immunohistochemistry/immunofluorescence, were limited. The 
mouse-on-mouse protocol provided by Abcam, for which the Fc region of the antigen 
was blocked, also yielded negative results. 
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Future studies which could include immunohistochemistry and electron microscopy 
techniques with specific labels to detect astrocytes, TLR9 and other brain organelles 
such as mitochondria in WT-B6 mice and TLR9-/- B6 mice brain sections would allow the 
investigation of TLR9 expressed within those cells and the effect of ammonia on brain 
energy metabolism. 
The influence of gut bacteria on TLR9 and the ammonia-induced inflammation and 
subsequent brain oedema has not yet been examined. It is well established that TLR9 
has ligands to bacterial DNA 158 and intestinal bacteria produce ammonia by splitting 
urea and other amino acids 77, while PAG present in the enterocytes of germ-free mice 
breaks down glutamine to produce ammonia 78. Furthermore, it has also been observed 
that engineering the gut microbes decreased the urease activity, thereby reducing the 
morbidity and mortality in a murine model of hepatic injury 81. Therefore it can also be 
argued/postulated that the ammonia produced by the intestines along with the injected 
ammonia could have exacerbated the inflammation and brain oedema.  
Future studies involving the alteration of gut microbiota by inoculation of bacteria 
and/or treatment with antibiotics would allow investigation of the influence intestinal 
bacteria have on ammonia and TLR9. In fact, I have also measured the cytokine 
production from mesenteric lymph nodes and Peyer’s patches and have stored the gut 
flush samples of all the mice studied. Analysis of these samples in the future with 
RNAseq would allow me to determine the influence of gut bacteria on ammonia and 
TLR9.  
Neutrophil TLR9 expression has been shown to play an important role in inducing brain 
oedema in this study. Future studies involving neutrophil depletion and adoptive 
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transfer of neutrophils from TLR9-/- B6 mice to WT-B6 mice and vice versa would allow 
us to investigate the role of neutrophils in ammonia-induced inflammation. 
Furthermore, inflammasomes such as Nalp3 and Caspase-1, along with TLR9 induce 
pro-inflammation. Therefore future studies involving mouse models deficient of these 
inflammasomes would allow us to identify whether they are involved and essential in 
this process. 
In this thesis it has been shown that neutrophils are the key innate cells that amplify the 
acute liver injury and induce inflammation and brain oedema. However, the mechanism 
by which neutrophils interplay with the adaptive immune cells and induce systemic 
inflammation is unknown. NK cells promote the activation and recruitment of 
macrophages and T cells to the injury site thereby inducing inflammation. Preliminary 
experiments on PALF samples in our lab indicate that NK cells become effector cells and 
produce cytokines on interaction with activated neutrophils. Therefore further studies 
in PALF patients that could involve co-culture of neutrophils with effector T cells in the 
presence and absence of NK cells, along with methods or molecules that can inhibit the 
interaction of neutrophils with lymphocytes would allow us to investigate the 
mechanism behind the activation of the adaptive immune system and also identify 
whether NK cells serve as the bridging cells between the innate and adaptive immune 
systems.  
Another main drawback to the human study is that we were only first able to analyze 
plasma arterial ammonia and IL-8 concentrations on day 1 of the ICU admission. We 
therefore were unable to determine how these variables might influence neutrophil 
TLR9 expression and the severity of SIRS and HE during the early onset of PALF 
preceding ICU admission. Furthermore, we were unable to interrogate how neutrophil 
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TLR9 expression and intracellular cytokine production in response to LPS, ammonia or 
oligodinucleotides related to the eventual development (or not) of sepsis due to the 
limited number of patients that could be studied and due to the fact that the sickest 
patients with advanced HE were transplanted early on during their admission, died 
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Table – 1: Antibodies used for characterisation of neutrophil phenotype at baseline 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD16 (PE) 3G8 Human BD Biosciences, UK 100 Tests 1:500 
CD11b (APC-Cy7) ICRF44 Human BD Biosciences, UK 100 Tests 1:500 
CD282 (Alexafluor 488) 11G7 Human BD Biosciences, UK 100 Tests 1:500 
TLR4 (Biotin-conjugated) HTA125 Human BD Biosciences, UK 100 Tests 1:500 
Streptavidin (PE-Cy7) -- Human BD Biosciences, UK 0.2 mg/mL 1:500 




Table – 2: Antibodies used for characterisation of neutrophil phenotype and IL-8 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD16 (PerCP-Cy5.5) 3G8 Human BD Biosciences, UK 50 Tests 1:500 
CD11b (APC-Cy7) ICRF44 Human BD Biosciences, UK 100 Tests 1:500 
CD62L (FITC) DREG-56 Human BD Biosciences, UK 100 Tests 1:500 
TLR9 (APC) eB72-1665 Human BD Biosciences, UK 100 Tests 1:500 




Table – 3: Antibodies used for characterisation of neutrophil phenotype in mice 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD11b (PerCP-Cy5.5) M1/70 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
MPO (Biotin) -- Mouse Hycult, USA 0.2 mg/mL 1:1000 
Streptavidin (PE) 11-26C.2a Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table – 4: Antibodies used for characterisation of T cells phenotype 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD4 (APC-Cy7) GK1.5 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
CD8 (PE-Cy7) 53-6.7 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
CD44 (PE) IM7 Mouse Biolegend, USA 0.2 mg/mL 1:8000 
CD62L (FITC) MEL-14 Mouse Biolegend, USA 0.5 mg/mL 1:1000 
CD69 (PerCP-Cy5.5) 7E9 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




 Table – 5: Antibodies used for characterisation of T cells cytokine - 1 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD3 (FITC) 17A2 Mouse Biolegend, USA 0.5 mg/mL 1:1000 
CD4 (APC-Cy7) GK1.5 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
CD8 (PE-Cy7) 53-6.7 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
TNF-α (APC) MP6-XT22 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
IFN-γ (PerCP-Cy5.5) XMG1.2 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table – 6: Antibodies used for characterisation of T cells cytokine - 2 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD3 (FITC) 17A2 Mouse Biolegend, USA 0.5 mg/mL 1:1000 
CD4 (APC-Cy7) GK1.5 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
CD8 (PE-Cy7) 53-6.7 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table – 7: Antibodies used for characterisation of NK cell phenotype 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD122 (PE) TM-b1 Mouse ebioscience, USA 0.2 mg/mL 1:1000 
DX-5 (FITC) DX-5 Mouse Biolegend, USA 0.5 mg/mL 1:1000 
KLRG-1(APC) 2F2/KLRG-1 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table – 8: Antibodies used for characterisation of NK-cells cytokine 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD122 (PE) TM-b1 Mouse ebioscience, USA 0.2 mg/mL 1:1000 
DX-5 (FITC) DX-5 Mouse Biolegend, USA 0.5 mg/mL 1:1000 
KLRG-1 (APC) 2F2/KLRG-1 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table – 9: Antibodies used for characterisation of NK cells cytokine 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
CD122 (PE) TM-b1 Mouse ebioscience, USA 0.2 mg/mL 1:1000 
DX-5 (FITC) DX-5 Mouse Biolegend, USA 0.5 mg/mL 1:1000 
KLRG-1 (APC) 2F2/KLRG-1 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table – 10: Antibodies used for characterisation of Macrophages cytokine 
Antibody (Fluorochromes) Clone Reactivity Supplier Concentration Dilution 
F4/80 (FITC) BM8 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
CD11b (PE-Cy7) M1/70 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
TNF-α (APC) MP6-XT22 Mouse Biolegend, USA 0.2 mg/mL 1:1000 
IFN-γ (PerCP-Cy5.5) XMG1.2 Mouse Biolegend, USA 0.2 mg/mL 1:1000 




Table –11: Preparation of in-house reagents 
Reagent Name Contents 
Ammonium acetate solution (1M) Dissolved 0.77 gm of ammonium acetate in 10 mL of de-ionised water 
Anaesthesia solution Mixed 1 part of iso-fluorane with 3 parts of 1, 2 – Propanediol 
Complete media Freshly prepared by adding Foetal bovine serum (FBS) [10%] and antibiotics [1%] in RPMI 
1640 and stored in 4°C 
Cytofix solution Dissolved 5 g of p-formaldehyde in 100 mL of de-ionised water 
Phosphate Buffered Saline (PBS) (1x) Dissolved five PBS tablets in one litre of de-ionised water 
Phosphate Buffered Saline (PBS) (10x) Dissolved five PBS tablets in 100 mL of de-ionised water 
30% Polymorphprep™ solution Mixed 3 parts of Polymorphprep™ solution with 7 parts of RPMI 1640 
70% Polymorphprep™ solution Mixed 7 parts of Polymorphprep™ solution was mixed with 3 parts of 10x PBS 
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